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In this thesis, the role of PARP-l and XRCCl in camptothecin (CPT) induced 
homologous recombination (HR) has been elucidated. The aims of this study were to 
investigate the role of PARP-l and XRCCl in the repair of CPT-induced damage, to 
find out if P ARP-l was involved in single strand break (SSB) repair, and to investigate 
the role ofPARP inhibitors in the repair ofCPT-induced damage. 
Cells lacking P ARP-1, and wildtype cells treated with P ARP inhibitors, were found to 
have increased sensitive to CPT. This increased sensitivity was found to correlate to an 
increased amount of DNA double-strand breaks (DSBs), and an increased number of 
cells containing RADSl foci. This is an indication ofan increased amount of HR in 
these cells. 
Cells deficient in XRCC 1 were also found to have an increased sensitivity to CPT, 
increased levels ofDSBs and an increased number of cells containing RADS1 foci. A 
mutant XRCC 1 cell line containing a disrupted BRCT I motif showed even further 
sensitivity to CPT. This motif interacts with PARP- I, and when disrupted, seems to 
inhibit the protein in some way. 
We have concluded that in the absence ofPARP-l or XRCCI, the repair ofSSBs is 
slower. These breaks are therefore more likely to encounter the replication machjnery, 
where they become DSBs. These breaks are repaired by HR. Cells that lack both P ARP-
1 and XRCC 1 may have even slower SSB repair, as they have an increased amount of 
cells containing RADSl foci, which indicates increased HR. P ARP inhibitors used in 
conjunction with CPT increases the cytotoxicity of CPT, which could help in 
chemotherapy. In the future, maybe inhibiting XRCCl as well could further enbance 
this affect. 
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CHAPTER 1: INTRODUCTION 
1.1 General Introduction 
Our DNA is constantly bombarded by a combination of exogenous and endogenous 
DNA damaging agents (Friedberg et aI, 1995). There are a number of different DNA 
lesions each resulting from one of three main causes. These are environmental agents, 
such as ultraviolet (UV) light (Tomaletti & Pfeiffer, 1996), by-products of nonnal 
cellular metabolism, like reactive oxygen species (hydroxyl radicals, hydrogen peroxide 
and superoxide anions) (Clopton & Saltman, 1995), and spontaneous lesions, like the 
dearnination and hydrolysis of nucleotide residues (Cadet, 1994). Eukaryotic cells have 
evolved highly conserved repair pathways to deal with all three types of damage. 
1.1.1 DNA damage 
During a human lifetime, the body's cells undergo approximately 10,000 trillion cell 
divisions. Even in an environment free of mutagens, there will be an estimated rate of 
106 mutations per gene, per cell division. This is due to inaccuracies during DNA 
replication and repair. Therefore, during that lifetime, it is likely that every single gene 
will have undergone mutation on about ] 0 billion separate occasions. Among the 
resulting mutant cells, it could be expected that many would show defects in genes that 
regulate cell division, and could therefore become cancerous. The fact that 100% of the 
population does not have cancer seems to be evidence that a single mutation is not 
enough to make a healthy cell into a cancerous one. A series of sequential mutational 
17 
In titutc for ancer tudie 
Univer ity of heffield 
events have to occur in order for normal cells to alter to a state of uncontrolled 
proliferation, which leads to tumour formation. 
The human cell cycle can be divided into four stages, Gl, S, G2 and M. In order for 
cells to produce exact copies of themselves, this process is strictly regulated by 
checkpoints. Therefore, there is a checkpoint just before DNA replication (the G 1 IS 
checkpoint), during replication (the intra-S checkpoint) and before entering mitosis (the 
G2/Mcheckpoint). If damage to the DNA is discovered during one of these checkpoints, 
the cell cycle is arrested while repair is carried out. When the damage is repaired, the 
cell cycle continues. If the damage is too extensive, the cell goes through programmed 
cell death (apoptosis) (van Gent et aI, 2001). 
DNA damage initiates a chain of phosphorylation events to activate downstream 
effectors. Double-stranded breaks in the DNA are processed by the MRN complex 
which cause ATM to become phosphorylated (Uziel et ai, 2003). The ATM protein then 
phosphorylates p53 (Nakagawa et ai, 1999). The p53 protein then activates p21 which 
binds to a cyclin-cdk heterodimer and inhibits the CDK protein kinase activity. This 
blocks the cell cycle from progressing. If the DNA damage occurs in during G 1, it is 
the cylinE-cdk2 heterodimer that is inhibited (Koff et aI, 1992). If the DNA damage 
occurs in the G2 phase of the cell cycle, it is the cyclin AlB-cdkl heterodimer that is 
inhibited (Draetta et ai, 1989). A TM can also phosphorylate Chkl and Chk2, two 
proteins involved in cell cycle arrest at the G2/M checkpoint. 
18 
In titut for Cancer tudies 
University of Sheftield 
A TM is not only responsible for downstream arrest of the cell cycle. A TM also 
phosphorylates BRCA1 in response to DNA double-strand breaks (Cortez et ai, 1999). 
BRCA fonns foci with Rad51 and has a role in repair of DNA double strand breaks 
(DSBs). ATM also has a role in apoptosis. By phosphorylating pS3, it prevents the 
binding of Mdm2, the negative inhibitor of p53. This increases the transcriptional 
activation of p53 for pro-apoptotic factors, F AS, PUMA and BAX which lead to the 
death of the cell. 
1.2 Factors that lead to DNA damage 
There are many factors both intrinsic to the human body and in the environment that 
surrounds us, which could lead to a mutation within a cell. Mutations can be inherited 
that either cause cancer or predispose a person ~to developing cancer: Endogenous 
factors, such as mistakes during DNA synthesis, also play a role, as do exogenous 
factors, such as radiation or genotoxic chemicals, which can enter the body and cause 
mutations. 
1.2.1 Endogenous factors 
The vast majority of mutations in the body are of endogenous origin (De Bont & van 
Larebeke, 2004; lackson & Loeb, 2001). These are caused by processes such as 
hydrolysis, exposure to reactive oxygen species, free radical production by oestrogens, 
methylation, deamination, poor proofreading by DNA polyrnerases, and carboxyl stress. 
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1.2.2.1 Hydrolysis 
The glycosidic bond between DNA bases and the deoxyribose sugar is labile under 
certain conditions, such as heating, alkylation of the bases, or activation of N-
glycosylases (Lindahl & Barnes, 1992). The cleavage of these bonds leads to the 
formation of abasic sites, or apurinic-apyrimidinic (AP) sites, which are among the most 
common lesion found in DNA. There are an estimated 10,000 AP sites formed, per 
human cell, per day (LindahJ, 1993). 
Typical AP sites induce base pair substitutions, usually an AP site is converted to 
thymine, but can also sometimes induce a frameshift mutation. AP sites are mutagenic 
due to the preferential incorporation of adenine opposite abasic sites by DNA 
polymerase during replication. 
1.2.1.2 Oxidative DNA damage 
Reactive oxygen species (ROS) are generated constantly by the body as a consequence 
of metabolic and biochemical reactions, and cause the majority of the DNA damage in a 
cell (Jackson & Loeb, 2001). ROS are produced through a variety of endogenous 
processes, such as mitochondrial respiration, and neutrophil and macrophage activation. 
ROS include superoxide (02-), hydrogen peroxide (H202), hydroxyl radicals (OH), and 
singlet oxygen (1 02). Neutrophils produce oxygen bursts of superoxide and hydrogen 
peroxide, which interact to form hydroxyl radicals, whilst macrophages produce 
superoxide and nitric oxide. These ROS oxidise DNA, which can lead to oxidised bases 
and single- and double strand breaks. In fact, many studies have found a relationship 
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between inflammatory diseases, where these white blood cells are activated, and cancer. 
The oxidation of bases by ROS can lead to mispairing during replication., For example, 
one oxidative DNA adduct, 8-oxodeoxyguanine, pairs preferentially with cytosine 
instead of guanine and causes GC to TA transversions. 
1.2.1.3 Lipid oxidation 
The polyunsaturated fatty acids of phospholipids are very sensitive to oxidation, and 
form lipid hydroperoxides. These are quickly reduced to unreactive fatty acid alcohols 
or react with metals to produce aldehydes, such as 4-hydroxynoenal (HNE) and 
malondialdehyde (MDA). These can then form exocyclic adducts, which damage DNA 
by blocking the base-pairing region. For example, HNE reacts with DNA and modulates 
the expression of genes that are involved in cell cy£le control and apoptosis. 
1.2.1.4 Endogenous oestrogens 
Several oestrogen metabolites can cause DNA damage directly or indirectly, through 
redox recycling processes that generate reactive radical species (Yager & Liehr, 1996). 
Oestrogen metabolites, particularly catechol oestrogens (CEs), are involved in the 
initiation process through oxidative DNA damage, and also enhance cell proliferation, 
which leads to tumour promotion. Oestrogen-induced direct or indirect DNA damage 
includes single-strand breaks, 8-hydroxylation of guanine bases, bulky DNA adducts, 
estradiol-induced MDA adducts and oestrogen-DNA adducts (Liehr. 2000). 
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Direct DNA damage is caused by CEs that have been oxidised to semiquinones (CE-
SQ) or quinones (CE-Q) by redox cycling. CEs are formed by the oxidation of 
oestrogens, and are inactivated by specific enzymes. If this process is incomplete the 
CEs may be oxidised to CE-SQ or CE-Q. CE-Q is inactivated by conjunction with 
glutathione, or reduction to CE. If either of these inactivation processes are incomplete, 
the CE-2,3-Q can interact with DNA and form adducts, that remain in the DNA unless 
repaired. These adducts are lost from the DNA by cleavage of the glycosidic bond, 
which leaves an AP site. 
Indirect DNA damage can be caused by redox cycling generated by the enzyrnatic 
reduction of CE-Q to CE-SQ, and subsequent autoxidation back to CE-Q by oxygen, as 
this leads to the formation of superoxide and hydroxyl radicals. Oestrogens also cause 
the proliferation and activation of macrophages, which produce superoxide and nitric 
oxide. 
1.2.1.5 Endogenous alkylating agents 
Endogenous methylating agents, such as S-adenosylmethionine (SAM) betaine and 
choline, have a role in the regulation of gene expression by contributing to enzyrnatic 
DNA methylation (Holliday & Ho, 1998). However, non-enzyrnatic methylation can 
also occur, which can generate mutagenic adducts such as 7-methylguanine, 3-
methyladenine and 06-methylguanine. These adducts can lead to the formation of 
mutagenic abasic sites (7-methylguanine) or block replication (3-methyladenine). 06_ 
methylguanine causes GC to AT transitions during replication. 
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1.2.1.6 Hydrolytic deamination 
DNA bases, particularly cytosine and 5-methylcytosine, are susceptible to hydrolytic 
deamination (Lindahl, 1993), which is when the exocyclic amino group of the base is 
lost. The deaminated form of cytosine is uracil , and this is rapidly excised by uracil-
DNA glycohydrolase to generate a base-free site, which is then repaired. The 
dearninated form of 5-methylcytosine is thymidine, and forms a GT base pair, which is 
corrected by mismatch repair. However, this is a slow process, and often causes a GC to 
AT transition. 
Figure 1.2.1.6 Deamination o/DNA bases 
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Guanine and adenine are deaminated to xanthine and hypoxanthine respectively, but at a 
much lower frequency than cytosine (Karran & Lindahl, 1980). Hypoxanthine pairs 
with C rather than T and as hypoxanthine can cause a mutagenic lesion. Xanthine pairs 
with C, so is less mutagenic; however the xanthine-deoxyribose bond can be easily 
hydrolysed, generating an AP site. 
1.2.1.7 Carbonyl stress 
Reactive carbonyl species (RCS) are fonned by endogenous chemical processes, such as 
lipid peroxidation and glycation (Roberts et aI., 2003), and mediate cellular carbonyl 
stress. RCS include glyoxal and methylglyoxal, which are reactive aldehydes formed as 
the result of glucose metabolism. These form DNA adducts such as glyoxalated 
deoxycytidine, which are mutagenic. 
1.2.1.8 DNA polymerases 
If a cell fails to repair endogenous lesions prior to replication, DNA synthesis proceeds 
in the presence of DNA damage - translesion synthesis (TLS). This process allows 
replication to progress past the site of damage by switching DNA polymerases. 
There are several families of DNA polymerases - A, B and Y. Polymerases of the A 
and B family, such as polymerase 8 and E replicate the bulk of genomic DNA and have 
been streamlined for processivity and accuracy - they have a proofreading ability of 
< 20 errors per million bases. These polymerases fit the DNA substrate tightly into 
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their active site, where the replicating base pair is enclosed by the finger domain. They 
use a system called the induced-fit mechanism to check the fidelity of replication - the 
fmgers can only close when the correct base is incorporated into the DNA. If the wrong 
base is incorporated, the polymerase undergoes confonnational distortion of its active 
site, which causes it to pause replicating. The polymerase then proofreads the wrong 
base and removes it so that synthesis can resume. 
Polymerases from the Y family, such as polymerases t and 11, have less good 
proofreading than NB family DNA polymerases and have a high error rate when 
replicated non-damaged DNA. They can also synthesise DNA across and past a variety 
of template lesions (Eckert & Opresko, 1999). V-family DNA polymerases have a 
unique carboxyterminal domain which fonns a spacious active site, allowing the DNA 
substrate through a few largely non-specific contacts. Therefore they can tolerate DNA 
substrate distortions. 
During translesion synthesis, the NB family polymerase comes across an impassable 
lesion, such as an abasic site, and pauses. It then switches with a V-family polymerase, 
which simply bypasses the lesion, inserting a base opposite, which is the Watson-Crick 
partner to the base 5' to the abasic site. This usually results in -1 frameshift mutation or 
a base substitution. The AIB family polymerase then switches place with the V-family 
polymerase to resume replication (Lehmann, 2002). 
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1.2.2 Exogenous factors 
1.2.2.1 Ionising radiation 
Ionising radiation involves high energies and as electrons are ejected from molecules 
charged particles - ion pairs - are formed. These often break down to form highly 
reactive free radicals. There are two classes of ionising radiation - particulate 
(involving p particles, neutrons and a. particles), and electromagnetic (involving x-rays 
and y rays). Both classes produce ionisation, but the way in which it is produced, and 
the patterns are different. 
ets of ion pairs can be spaced close together or far apart, and the average energy 
released p r unit distance is called linear energy transfer (LET). The LET depends on 
the energy and charge of a particle - the greater the charge and lower the velocity, the 
greater the LET. High L T radiation (a. particles or neutrons) produces dense sets of ion 
pairs, and is more potent than low LET radiation (P particles, x-rays or y rays) because 
of its more disruptive effects on proteins, RNA and DNA. 
The free radicals produced by ionising radiation can cause single and double strand 
breaks in the DNA. These radicals can oxidise guanine to 8-hydroxyguanjne, and 
generate abasic sites or strand breaks in the DNA, which result in miscoding if left 
unrepaired. Radiation is very effective at producing breaks in chromosomes (Carrano 
and W Iff 1975). These breaks often lead to chromosome translocations which can , 
lead t the activation of certain oncogenes. 
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1.2.2.2 Non-ionising radiation 
Non-ionising radiation, which includes ultraviolet light (UV), microwaves and radio 
waves, does not produce ions, but causes molecular excitations such as vibrations and 
electron movement. Thjs form of radiation is not as potent as iomsing radiation but UV 
light can still cause damage to DNA. When DNA absorbs a UV photon it forms an 
extra chemical bond between two adjacent pyrimidines, resulting in thymidine-
thymidine, cytosine-cytosine, or thymidine-cytosine dimers. These can be in the form 
of cyclobutane pyrimidines dimers, where bonds are formed between the C5 and C6 
carbons of the two bases, or a 6-4 photoproduct, where a single bond is formed between 
the C6 carbon of one base, and the C4 carbon of the other. 
Figure 1.2.2.2 Theformation o/pyrimidine dimers and 6-4 photo products. 
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C-T transitions are fonned if a cytosine is a component of the dimer, as it is read as a 
thymidine, and an adenine is matched with a cytosine dim er, instead of a guanine. If 
this mutation occurs inside a gene that regulates cell division, the cell could become 
prone to malignancy. 
1.2.2.3 Genotoxic compounds 
The genotoxic compounds can be grouped into four major classes, polycyclic aromatic 
hydrocarbons, aromatic amines, nitrosamines and alkylating agents. These all act by 
fonning covalent adducts with DNA bases, which distort the DNA structure and disrupt 
DNA replication. 
1.2.2.3.1 Polycyclic aromatic hydrocarbons 
Polycyclic aromatic hydrocarbons (P AH) are a group of over 100 carcinogenic 
chemicals, derived from the incomplete combustion of organic matter, such as coal, oil 
and gas, or other organic substances such as tobacco or cooked meat. One extensively 
studied PAH benzo(a)pyrene (BaP) is found in cigarettes and is a potent lung 
carcinogen. These compounds are metabolical1y activated in cells by drug-metabolising 
enzymes such as cytochrome p450 and epoxide hydrolase, fonning electrophilic 
dihydrodiol epoxide derivatives, which react with DNA to form bulky adducts. The 
DNA adducts with a bulky aromatic ring attached to the base, block replication and 
transcription. If unrepaired, these can cause mutations during replication, most 
commonly causing GC to TA transversions. 
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1.2.2.3.2 Aromatic amines 
Aromatic amines include phenols, hydroquinones, and catechols, which are found in 
hair dye, fungicides, rubber, food and cigarette smoke. These can be converted to 
quinones by N-oxidation catalyzed by monooxygenase or peroxidase enzymes, such as 
hepatic cytochrome P450 or nonhepatic peroxidases, and in some cases molecular 
oxygen. Aromatic amine N-cation radicals formed by peroxidases were found to co-
oxidise GSH or NADH and form reactive oxygen specie, which leads to DNA adduct 
formation. 
1.2.3.3.3 Nitrosamines 
Nitrosamines are commonly occurring agents, formed from their chemical precursors, 
amines and nitrosating agents via a simple chemical reaction. Nitrosamines are used as 
preservatives in processed foods to prevent the growth of toxic bacteria, and are also 
found in cigarette smoke. Nitrosamines, nitrite and nitrate salts all metabolise to form 
nitrous acid, which is a deaminating agent that accelerates the rate of base deamination 
in the cell. 
1.2.2.3.4 Alkylating agents 
Alkylating agents, such as N-methyl-N-nitro-nitrosoguanidine (MNNG) and 
methylmethanesulfonate (MMS), interfere with DNA by adding methyl groups onto 
DNA bases. MNNG and MMS add methyl groups to guanine to fonn 0 6 
methylguanine, causing G-C to A-T transitions. Alkylating agents belong to a family of 
anticancer drugs that inhibit cancer cell growth. 
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1.3 DNA damage-inducible cell signalling 
1.4 DNA repair mechanisms 
The DNA damage encountered by the genome does not go unchecked. The DNA in the 
cells is constantly monitored by DNA damage recognition proteins, which trigger a 
number of repair pathways to eliminate damage. When DNA lesions are detected, a 
cascade of events occurs in order to respond to and repair DNA lesions. Sensor proteins 
detect any damage and activate transducer proteins, which amplify and branch out the 
DNA-damage signals to trigger the proper response. 
Dividing cells respond to DNA damage in the Gl or S-phase of the cell cycle stopping 
the advance of the cell cycle, preventing entry and progression in the S-phase. This 
provides time for DNA repair before the arrival of the DNA replication machinery. If 
DNA damage takes place in the G2-phase, progression into the M-phase is stopped in 
order to prevent mis-segregation of chromosome fragments (Zhou & ElIedge, 2000; 
Khanna & Jackson, 2001). These points in the cell cycle are called checkpoints and are 
regulated by proteins such as p53 (Kuerbitz et al., 1992). If the damage is too great to 
repair the cell enters into an apoptotic cascade (Martin & Schwartz, 1997). 
A single repair process cannot cope with all types of DNA damage, so mammalian cells 
have several overlapping DNA repair pathways, evolved to repair different types of 
damage. These are translesion synthesis (TLS), mismatch repair (MMR), base excision 
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repair (BER), nucleotide excision repair (NER), non-homologous end joining (NHEJ) 
and homologous recombination (HR). 
1.3.1 Translesion synthesis 
Translation synthesis (TLS) is a way for the cell to bypass mutations, such as 
cyclobutane pyrimidine dimers, and then either correct them or incorporate them into 
the daughter strands (Eckert & Opresko, 1999). In this process, replication is stalled by 
a mutated base, activating a second set of DNA polymerases known as the V-family 
polymerases. These special polymerases can bypass the mutation but can cause errors in 
the new daughter strand, which can be either non-mutagenic or mutagenic. However, 
using the error prone polymerases can be a potential benefit to the cell because they 
allow replication to continue (Cox et al., 2000) and sometimes tolerance of the DNA 
damage is preferable to cell death .. 
TLS occurs in two stages, first a nucleotide is inserted opposite the damaged base or 
bases, and then the DNA strand is extended beyond the lesion (Lehmann, 2002). The Y-
family group lack exonuclease proofreading activity which is why they tend to be error-
prone. These polymerases are able to bypass UV -induced cyclo-butane pyrimidine 
dimers (6-4) photodimers, 8-oxoguanine and 0-6-methylguanine (Lehmann, 2002). One 
of the Y polymerases, DNA polymerase " (pol,,) is encoded by the XPV gene in 
humans and its mutation induces a variant form of Xeroderma pigmentosum (Xp-V). 
XP-V patients are UV sensitive and susceptible to a high incidence of skin cancer 
(Yamada et al., 2000). 
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1.3.2 Mis-match repair 
When mismatched bases are incorporated into the DNA, they will lead to mutations in 
the cell, and potentially lead to the formation of a mutant cell. Therefore such errors 
have to be repaired. Errors can be repaired via MMR, which recognises and corrects 
mispairs and insertions that have occurred during DNA replication and recombination. 
MMR can correct non-Watson-Crick base pairing and small distortions produced by the 
incorrect alignment of DNA strands. There are two forms of MMR, long patch MMR 
and short patch MMR. Excision and resynthesis of more than I kb of DNA occurs in 
long patch MMR (O'Driscoll & Jeggo, 2002), whilst short patch MMR mechanism 
removes single base mismatches. 
MMR happens in three stages. First the mismatch must be recognised, and in 
mammalian cells this is done by the hMutSa. or hMutSB proteins (O'Driscoll & Jeggo, 
2002). The hMutSa. heterodimer is made up of hMsh2 and hMsh6 and is preferentially 
involved in single base repair mismatches. The hMutSB complex includes hMsh6 and 
hMsh3 and deals with two or more mismatched bases. Secondly, the mismatched base, 
or bases must be excised. Single base mismatches are probably excised by hExo 1 and 
an unknown helicase removes the sequences containing two or more mismatch bases. 
Thirdly the produced gap must be filled and religated. In humans, DNA ploymerase 8 
possibly fills the gap and DNA ligase I seals the generated nicks (Bennett et al., 1997). 
Other proteins implicated in the MMR pathway are proliferating cell nuclear antigen 
(P NA), which serves as cofactor for DNA polymerase 8, and replicating protein A 
(RPA) mar et al. ] 996). 
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1.3.3 Base excision repair 
Base excision repair (BER) repairs nucleotides damaged by free radical oxidation, 
methylation, or hydroxylation, incorrect bases, and single strand breaks (SSBs). Left 
unrepaired, this damage may result in miscoding and mutations. Two of the most 
frequent spontaneous lesions are depurination and deamination. Depurination interferes 
with the glycosidic bond between the adenine or guanine and the deoxyribose sugar, 
resulting in the loss of the bases from the DNA. The deamination of cytosine results in 
the formation of uracil and the deamination of 5-methylcytosine forms thymine (Blount 
et al. , 1989). 
The incorrect base is initially removed from the DNA backbone by an appropriate 
glycosyJase, producing an abasic AP site. The deoxyribose phosphate 5' to the damaged 
base is then cleaved by AP endonuclease (APE 1) creating a 3' -OH terminus. In the 
short-patch BER pathway, which is dominant in mammalian cells, the polP enzyme 
removes the sugar residue and fills the one-nucleotide gap (Hoeijmakers, 2001). In 
long-patch BER, poJp, and pol3 or POlE, as well as PCNA, synthesise 2-10 base pairs 
and FEN1 removes the displacing DNA flap. Finally, the remaining nick is sealed by 
DNA ligase III or DNA ligase I in short-patch BER and long-patch BER, respectively. 
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1.3.4 Nucleotide excision repair 
Nucleotide excision repair (NER) involves a large number of enzymes and removes any 
mismatched bases, UV -induced pyrimidine dimers, and bulky adducts. These forms of 
damage generally obstruct transcription and the normal replication progress, and 
interfere with base pairing. NER recognises damaged regions based on their abnormal 
structure and excises the DNA strand containing the damage, filling the gap by 
replication. In mammals, XPC (together with hRAD23aJP) recognises the lesion. Then, 
the XPB and XPD helicase subunits in the transcription factor TFIIH open up the base 
pairs around the lesion (Hoeijmakers, 2001) to create an open region of 20-30 
nuc1eotides. This is then excised on the 3' side by the exonuclease, XPG and on the 5' 
side by another endonuclease, XPF, aided by ECCRl (excision repair control 
component). After excision, the gap is filled by DNA polymerase 8 or E, DNA ligase 
and proliferation control nuclear antigen (PCNA). In the case ofUV damage, XPE aids 
TFUH in the repair process. 
1.3.5 Recombinational repair 
There are several types of lesions thought to induce recombinational repair, one-ended 
DNA strand breaks (DSBs), two-ended DSBs, and stalled replication forks (RFS) 
(Figure 1.3.5). The ways in which they are produced and the pathways that are triggered 
by each are discussed below in detail, but briefly these lesions are repaired by 
homologous recombination (HR) or non-homologous end-joining (NHEJ). These are 
two different and complementary mechanisms with overlapping roles in DNA repair. 
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The contribution of each pathway in DNA repair depends on the type of damage, and 
the phase of cell cycle. There is competition between the two pathways, for example, 
cells defective for NHEJ enzymes such as Ku protein had increased HR (pierce et al., 
2001). Also if NHEJ fails, HR may take over and compensate for the repair (Frank-
Vaillant & Marcand 2002). 
During late S and G2 phase both HR and NHEJ are active, while in other phases NHEJ 
predominates. Compared to wildtype cells, cells defective in HR proteins, such as 
RAD54 and XRCC2, show relatively unchanged levels of sensitivity to ionising 
radiation as they pass through the cell cycle as compared to wild type cells (Takata et 
al. 1998). DNA damage caused by ionising radiation is mostly repaired by NHEJ, 
implying that NHEJ remains intact in all phases of the cell cycle. Late S and G2-phase 
are the only phases in which HR can be used because it is only then that sister 
chromatids are available to serve as donor templates (Arnaudeau et aI, 2001). 
Two-ended DSBs are caused by ionising radiation (X-rays and gamma rays) (Figure 
J.3.5a). Free radicals during normal cellular metabolism may also cause two-ended 
DSBs. About 1 % of the oxygen we breathe is converted into oxidative free radicals 
( hance et al., 1979). The DNA double helix breaks and the chromatin structure cannot 
keep the two DNA ends together. This particular lesion is deadly to the cell and must be 
repaired immediately. A single unrepaired chromosomal break is enough to kill a cell 
(Huang et al., 1996). 
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Figure i.3.5. Three possible substrates for recombination in mammalian cells 
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(a) DNA damage causes a break in both strands of D A and leaves a classical DSB 
with two free ends. (b) Following the stall of the replica ·on fork, the newly synthesized 
DNA strands reverse and fonn a chicken foot structure. (c) When replication machinery 
j • 
collides with a SSB, it causes the RF to collapse and creates a DSB with a single free 
end. 
HR has been suggested to be associated with the repair of stalled RFs (Lundin et al. 
2002) (Figure1.3.5b) . When a RP staUs, the newly synthesized DNA strands reverse 
and generate a structure called a chicken foot. This may serve as a substrate for HR 
(McGlynn and Lloyd 2002). As the DNA replication machinery encounters damage in 
the DNA template it may stall the RP (Kogoma et al., 1996). A collision between the 
RP and a SSB can collapse the RF and change the lesion to a one-end DSB, which is 
also a substrate for HR (Figure i.3.5c). Following the detection of a DSB, a cascade of 
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events is triggered resulting to cell cycle arrest and the activation of the repair 
machinery. 
1.3.5.1 DSB repair by non-homologous end joining 
NHEJ is a fast repair mechanism, as does not require a copy of the missing part of the 
sequence in order to repair it. The repair of two-ended DSBs can be difficult, as the cell 
has to know which ends belong together. In NHEJ, this is simplified by linking the two 
ends together (Figure 1.3.5.1a). This repair mechanism can be an error-prone repair 
pathway as it sometimes deletes or add a few nucleotides at the sealing site. During the 
repair process, the DNA bases at the DSB ends become damaged, and must be removed. 
The MRN (Mre11IRADSOlNbsl) protein complex removes the damaged bases by 
endonuclease and exonuclease activity (D'Amours and Jackson 2002). The DSB ends 
must be held in proximity to each other (synapsis) to al10w repair. In order to do this, 
two flexible colloid coils of RADSO protein dimerise using a Zn2+ ion (Lieber et al., 
1988; Agrawal & Schatz, 1997) and act as arms to bring the two broken ends together. 
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Figure 1.3.5. 1 DSB repair pathways. 
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(a) The 2-ended DSB can simply be sealed by the NHEJ mechanism, (b) The DNA 
ends may be resected and generate 3' ssDNA overhangs. (c) Homologous sequences 
flanking the DSB ends can be uncovered and used for the SSA repair pathway, (d) One 
of the 3' overhangs may invade an intact homologous DNA duplex and elongate past 
the break site, (e) The produced Holliday junction (HJ) may migrate and release the 
extended 3' overhang (t) sharing homology for synthesis-dependent SSA repair. (g) 
Synthesis-dependent NHEJ can rejoin the wandered 3'overhang and leave tandem 
duplications, (h) If the second DNA end migrates, it forms another HJ, These HJs are 
dissolved either by crossing over (i) or non-crossing over 0). 
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The DNA ends at the DSB are then bound by the Ku protein, which is a heterodimer of 
Ku70 and Ku80. The hole in the Ku protein surrounds the broken DNA ends like a ring 
(Walker et al., 2001). Ku then binds to the catalytic subunit of DNA dependent protein 
kinase (DNA-PK) bringing the two ends together (Hanakahi & West, 2002). The DSB 
ends are then sealed by a complex made up of DNA ligase IV and XRCC4 (Grawunder 
et al. , 1997). 
1.3.5.2 DSB repair by HR 
HR is well conserved in higher multicellular organisms (van Gent et al., 2001) and is 
defined as recombination occurring between identical or near identical DNA sequences 
either by exchanging or copying the genetic information. HR is a relatively slow repair 
mechanism, but is error-free. Disruption of the key protein in HR (RAD51) is lethal in 
mice at the embryonic stage (Sonoda et a/. , 1998), which suggests that intact HR is 
requir d in mammalian cells. 
The first model for HR was suggested in fungi (Holliday 1964) and developed later to 
describe meiotic recombination in yeast (Szostak et al., 1983). In Saccharomyces 
cerevi iae most DSBs are repaired by HR (Game & Mortimer, 1974). The first model 
for HR in mammalian somatic cells was not proposed until later (Kanaar et al., 1998). 
There are three main sub-groups of HR, single strand annealing (SSA), gene conversion 
(G ) and break-induced replication (BIR). All three processes start in the same way. 
Once DNA surveillance proteins detect a DSB, the MREIIINBSl/XRS2 complex 
resects the end, to generate long 3'-ended single strand DNA tails (Figure J.3.5.1b). 
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1.3.5.2.1 Single strand annealing 
Single-strand annealing (SSA) takes place between homologous sequences flanking 
both of the DSB-ends and was first reported to explain the results of intramolecular 
recombination in plasmid substrates (Lin et al., 1990; Maryon & Carroll, 1991). SSA 
requires a number of enzymes that are also required for other types of recombinational 
repair. After the MRN complex resects the ends, the newly exposed single strands load 
recombination proteins that promote annealing. The RAD52 and RP A proteins then 
anneal the compatible single stranded sequences together (Figure 1.3.5. le). The regions 
flipped out in between the repeats are removed by the XPFIERCCI complex (Sargent et 
al., 2000). In this pathway, a lot of the sequence between the regions of homology is 
lost, making SSA a non-conservative pathway. SSA can occur in competition with gene 
conversion, which is a conservative HRR pathway. 
1.3.5.2.2 Gene conversion 
Gene conversion (GC) is the most accurate repair process, utilising the complementary 
sequence on the sister chromatid, to accurately copy the missing bases. This is not the 
same as sister chromatid exchange (SCE). This is reciprocal exchange of DNA 
sequences between a damaged and an intact chromatid within a single chromosome, 
whereas GC is simply copying DNA sequence information from the sister chromatid 
without any exchange. When sister chromatids are not available as GC templates, 
homologous chromosomes or sequence repeats, such as the Alu elements can be used. 
These elements are short (300 bp) and are spread throughout the genome (Schmid 
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1996). Because they are often far apart, a lot of the DNA sequence could potentially be 
lost. Therefore, using Alu sequences as a recombination template may compromise the 
integrity ofthe genome and predispose cells to cancer. 
During GC, DNA ends are bound by RAD52, which protects them from endonucleases, 
and interacts with RAD51 (Van Dyck et ai, 1999; Lundin et ai, 2003). The RAD51 
protein forms filaments, which bind along the unwound DNA, and facilitate strand 
invasion of a homologous sequence. Once the homologous sequence has been found, 
one strand is displaced to form a D-Ioop and new DNA synthesis can be initiated to fill 
in the missing sequence (Meselson & Weigle, 1961). DNA polymerase ~ then copies 
information from the undamaged partner, extending the 3' terminus of the damaged 
DNA strand. The ends are then ligated by DNA ligase I. The migration of one strand 
across the other causes the formation of a DNA crossover, or Holliday junction that is 
resolved by cleavage and ligation to create two intact molecules. A HJ may move 
(branch migration) and if it moves in the direction of RF, it can reverse the strand 
invasion and leaves a larger single stranded DNA (Figure 1.3.5.1e). This DNA end may 
be repaired through SSA sharing sequence homology with the other end (Figure 
1.3.5. If). This will result in gene conversion. Alternatively, the extended DNA end can 
be repair via NHEJ (Figure 1.3.5.1g), which will produce a tandem duplication 
(Helleday et al. 2003). 
It is possible that the second DNA strand could move toward the same homologous 
strand and forms a second HJ (Figure 1.3.5. 1 h). This structure, with two HJ, may 
resolve itself either by a crossing over (Figure 1.3. 5.li) or a non-crossing over (Figure 
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1.3.5.1j) repair pathway. Crossovers are frequent in meiotic recombination, but the 
association of this event is less frequent in somatic mammalian cells. This could be due 
to the fact that organisms containing large numbers of repetitive elements may have 
developed a stronger crossover suppression in order to maintain the integrity of the 
genome (Richardson et al., 1998). 
1.3.5.2.3 Break-induced replication 
At the site of a difficult DNA lesion, the replication machinery may arrest causing the 
RF to stall. This may lead to complete separation of one branch of the fork end, which is 
called a one-ended DSB or a collapsed RP (Hanawalt, 1966) (Figure 1.3.5.2.3b). 
Collapsed RFs occur in most of the cells and the consequences of this event are 
catastrophic if not repaired. It has been estimated about 10 replication forks collapse or 
arrest per human cell replication cycle (Haber, 1999). This type of DSB can be a 
substrate for recombinational repair pathways (Marians et al., 2000 and Cox et al. , 
2001). 
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Figure 1.3.5.2.3 HR at stalled and collapsed replication/orks 
(a) stalled replication fork (b)half chicken foot (c) chicken foot (d) four-way DNA junction 
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(a) HR at stalled and collapsed RFs. (b) One of the newly synthesized DNA strands has 
reversed and formed a half chicken foot. (i) This structure may be cleaved by 
J 
endonucleases causing a collapsed RF. (c) If the second newly synthesized DNA strand 
reverses as well, a complete chicken foot will be generated. (d) This structure is the 
same as four-way HJ and its resolution results in a (e) DSB which can re-establish (g) 
RFs and leave a HJ. Cleavage of this HJ results in (h) gene conversion. Alternatively, 
(g) a second HJ may form at the chicken foot substrate avoiding the DSB. (h) Non-
crossing over resolution of the two HJ results in gene conversion. G) Endonucleases 
may resect the I-end DSB from 5' to 3' to produce a 3' overhang and the single strand 
nick will be filled by polymerase activity. (k) Invasion of the 3' overhang forms a HJ 
and restores the RF. The HJ can be resolved either through (m) crossing over or (I) non-
crossing over. Open arrowheads show non-crossing over and filled arrowheads 
designate crossing over. Arrows indicate the direction of DNA synthesis. Blue lines 
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demonstrate newly synthesized DNA strands and black lines designate template DNA 
strands. 
It has been suggested that HR is the preferred pathway for the repair of one-ended DSBs 
(Aroaudeau et al., 2001). However, others have proposed the partial involvement of 
NHEJ for the repair ofDSBs associated with RFs (Saintigny et al., 2001). The repair of 
lesions during replication often involves recombination between sister chromatids 
(Kadyk and Hartwell 1992). In mammalian cells, this is known as break-induced 
replication (BIR) (Haber 1999; Kraus et al. ,2001). 
In BIR, the nick at the DNA template fills and the end of the DSB processes to produce 
a 3' end. This end then invades the intact DNA duplex template (Figure 1. 3. 5. 2. 3d) and 
establishes a RP (Figure 1.3.5.2.3c). Tills RF can progress all way to the end of the 
chromosome. The HJ left behind can be resolved through a crossing over or a non 
crossing over pathway (Figure 1.3.5.2.3/). 
1.3.5.3 Repair of stalled RPs 
RP damage can arise spontaneously or when it encounters damage in the DNA. For 
example, collisions between replication and transcription proteins might present 
obstacles to replication, which pauses the RF and causes it to stall (McGlynn & Lloyd 
2000). RP arrest occurs in all organisms, and a lot of work has been done on the 
relationsillp between replication and recombination in bacteria. However, but very little 
is known about this relationship in mammalian cells (Rothstein et al., 2000). There is 
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strong evidence that HR is the prominent pathway for RP repair in E-coli (Kogoma 
1996; Cox et al. , 1999) and it has also been reported that HR has a significant role in the 
repair of stalled replication forks in mammalian cells (Lundin et al., 2002). 
At stalled RPs, a nascent strand may reverse and make a half chicken foot (Figure 
1.3.5.2.3b), which, in human cells, can be cleaved by the Mus81-Eml endonuclease 
(Ciccia, et al. 2003) and form a one-end DSB. This substrate is similar to the DSBs 
formed at collapsed RPs (Figure 1.3.5.2.3c) and may be repaired through SCE (Figure 
1.3.5.3.3d). If the second newly synthesized strand reverses, it makes a complete 
chicken foot with the first reversed-strand and forms a HJ at the four-way junction 
(Figure 1.3.5.3.3e) (Cox, 2001; McGlynn & Lloyd 2002). The stalled replication fork 
may reverse and form an intermediate chicken foot structure. Following DNA synthesis, 
both nascent strands can reverse and resume RP progression without recombination. 
However, it is also possible that HR could form two HJs before HJ cleavage and resume 
the RP (Figure 1.3.5.3.3h). The HJs may also be resolved through non-crossing over 
(Richardson et al., 1998). The outcome following recombination involving a chicken 
foot structure is always gene conversion (Helleday et al., 2003). 
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1.4 Poly(ADP-ribose) polymerase-l (PARP-l) 
Poly(ADP-ribose) polymerase (PARP) is a DNA damage detection protein. It is an 
abundant nuclear protein (10,000,000 molecules per cell), which is very well conserved 
in most mammalian cells (Herceg & Wang, 2001). PARP acts by attaching to DNA 
breaks, and catalysing a number of different events by the action of poly(ADP-
ribosyl)ation. This is the addition of poly (ADP-ribosyl), (pADPr), subunits onto a 
protein substrate (D' Amours & Desnoyers, 1999). 
1.4.1 The structure ofPARP-l 
P ARP is made up of three domains, the DNA- binding domain, the automodification 
domain, and the catalytic domain (Figure 1.4.1). The PARP-l protein has an N-terminal 
46kDa DNA binding domain containing two large zinc fingers that bind to both DNA 
single-strand breaks (SSB) and DNA double-strand breaks (DSBs) (d'Adda di Fagagna, 
1999; Lindabl, 1995). The DNA-binding domain has a high affinity with DNA because 
it contains a high proportion of basic residues. This domain also has a nuclear 
localisation signal (NLS). The catalytic domain is 54 kDa, and is responsible for 
catalysing the production of poly(ADP-ribose) polymers (pADPr) from nicotinamide 
adenine dinucleotide (NAD). pADPr subunits can be from a few, to 200 residues. After 
activation, P ARP adds these to its substrates. The automodification domain is 22 kDa in 
size, and is the site upon which P ARP regulates itself. During poly(ADP-ribosyl)ation, 
pADPr subunits bind here, and cause P ARP to dissociate from the DNA. This is 
because pADPr subunits carry a negative charge, and P ARP pulls away from negative 
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DNA because of electrostatic repulsion. Poly(ADP-ribose) glycohydrolase (pARG) then 
breaks the bonds between the pADPr polymers, allowing P ARP to bind to DNA once 
again. The automodification domain also contains a BRCT module that allows P ARP to 
bind to other proteins containing the same module. The zinc fingers , NLS and catalytic 
domain ar the most highly conserved portions of the PARP protein. Of these, there are 
50 amino acids that are 100% conserved in vertebrates (92% amongst all species). 
These are known as the P ARP signature. 
Figure 1.4.1 Structure ofPARP-1 
DNA-binding 
domain 
y 
DNA-binding Nuclear 
zinc fingers localisation 
signal 
Automodification 
domain 
BRCT 
motif 
Catalytic domain 
Minimum catalytic 
domain 
The activity of PARP-l is triggered by its DNA binding activity and it adds pADPr to 
glutamine residues of itself and to surrounding histones (Smith et aI., 2001). The 
biochemical role for the pADPr modification of histones is unknown; however it is 
believed that the negative charge caused by the modification would change the local 
chromatin structure to allow access by DNA repair proteins. 
P ARP has b en reported to regulate many cellular processes such as DNA repair, 
genomic stability, cell cycle progression, cell death and gene transcription (D'Amours 
et al. 1999; Shall & de Murcia, 2000) through the addition of pADPr polymers onto 
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acceptor proteins involved in these pathways. This pADPr modification affects their 
activity, possibly because of the negative charge of the pADPr polymers .. 
1.4.2 The function of P ARP-l and its mechanism of catalysis 
P ARP has a role in many processes including chromatin structure, DNA replication, 
transcription, BER, DNA synthesis, and maintenance of telomere length (Dantzer et aI. , 
1998; Muiras & Burkle, 2000; Herceg and Wang, 2001; d' Adda di Fagagna et aI., 1999; 
D' Amours et aI., 1999), through pADPr modification of acceptor proteins in these 
pathways. 
It has been shown that the pADPr modification of the chromatin induces structural 
changes in the nucleosomes, causing the polynucleosomes to decondense (D' Amours, 
1999) and allowing the repair and transcription proteins to access the DNA. PARP acts 
on several chromatin proteins, including histones, HI, H2A, H2B, H3, H4,H5, and the 
HMG proteins. Upon activation, PARP first shows preference for itself as a substrate, 
however, preference gradually changes in favour of the chromatin proteins, especially 
H1 and H2B. The chromatin remains decondensed until the DNA is repaired. PARP 
also has a role in transcription. It has an enzymatically inactive role through interaction 
with RNA polymerase n, by acting as a transcription factor and can also form part of 
the pre-initiation complex. P ARP also, regulates transcription when the DNA is 
damaged, by decreasing RNA polymerase II activity. Proteins involved in transcription 
are modified by pADPr polymers and cannot bind to the DNA. Therefore, P ARP can be 
a positive and negative regulator of transcription. 
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1.4.3 The role ofPARP in homologous recombination 
Although, P ARP-l binds to DSBs, it is not required for the repair of DSBs via 
homologous recombination (HR), as RAD51 foci form in response to hydroxyurea in 
P ARP-1 -l- cells. Also, P ARP-l does not co-localise to RAD51 foci and HR repair of a 
DSB is not defective in PARP-l inhibited cells (Schultz et al., 2003; Yang et al., 2004). 
However P ARP-l appears important in maintaining genetic stability, since cells 
lacking or with inhibited P ARP-l have an increase in HR, sister chromatid exchange 
(SCE) and micronuclei formation {Lindahl et ai, 1995; Molinete et al., 1993; de Murcia 
etal" 1997;Wang etal., 1997). 
As PARP-l is not required for HR, the reason for increased HR may be explained by an 
accumulation of recombinogenic substrates in PARP-l deficient cells. Therefore, HR 
could have an important role in repairing lesions that occur in the absence of P ARP-l. 
1.4.4 The role ofPARP-l in HER 
The BER complex repairs damage caused by x-rays, oxygen radicals, and alkylating 
agents. It does this by cutting out the damage, producing abasic sites that are recognised 
by APEt (Dizdaroglu, 2003). This endonuclease cleaves the phosphodiester backbone 
to form a SSB in the DNA (Dianov et al., 2003). PARP-l can bind and recognise these 
SSBs (Satoh & LindahI, 1994), and also binds to XRCCl, a scaffold protein that brings 
SSB repair proteins DNA polymerase p and DNA ligase Ill, to the site of damage 
(Kubota, et al. , 1996; Masson et al., 1998; Dantzer et al., 1999). PARP has been shown 
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to poly(ADP-ribosyl)ate the proteins of the complex, and also has physical interaction 
with XRCCl and DNA ligase III via their BRCT module (Masson et al., 1998). The 
purpose of this interaction could be to recruit the repair proteins to the site of the DNA 
lesion. P ARP-l is not required for the repair of the SSB itself (V odenicharov et aI., 
2000), however it may be that the hypersensitivity of P ARP depleted cells, or P ARP 
inhibited cells reflects a reduced ability to attract the proteins required for complete 
BER. Therefore, P ARP inhibitors may be used to enhance the cytotoxic effect of DNA 
damaging agents that cause lesions nonnally repaired by BER. 
1.4.5 PARP-l inhibitors 
Almost all PARP inhibitors are competitive inhibitors of NAD+. The first were 
analogues of nicotinamide, for example, 3-aminobenzamide (3-AB). These were useful 
for in vitro studies of P ARP activity (Wedge et al., 1996). However, there were of little 
clinical use as they had low potency, were difficult to dissolve, and lacked specificity. 
The next generation of rationally designed inhibitors were much more potent. These 
included benzirnidazole-carboxamides, quinazolin-4-[3H]-ones and isoquinoline 
derivatives, for example 2-( 4-hydroxyphenyl)benzimidazole-4-carboxamide (NUl 085), 
8-hydroxy-2-methylquinazolin-4-(3H)one (NUl 025) and dihydroisoquinalone 
(PD 128763) and demonstrated an increased amount of chemosensatisation in vitro 
(Boulton et al., 1995; Tentori et al., 1997; Tentori et al., 1998). 
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Figure 1.4.5.1 1,5-dihydroisoquinoline 
OH 
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For example, NUI025 enhanced the cytotoxicity of the monofunctional DNA-
alkylating agent temozolomide, the topoisomerase I inhibitor camptothecin and "(-
irradiation in L1210 cells and in 12 human tumour cell lines (Bowman & White, 1998; 
Bowman et al. 2001). 
Figure 1.4.5.2 NU1025 
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Unfortunately these were still not potent or specific enough for extensive pre-clinical 
trials. Recently a PARP inhibitor more than 1000 times more potent than 3-AB has been 
developed. AG14361 has been used in vivo at non-toxic doses to augment the effect of 
the DNA damaging agents irinotecan and temozolomide (Calabrese & Almassy, 2004). 
AG14361 treatment in conjunction with temozolomide caused complete remission of 
SW620 xenograft tumours (Wedge & Newlands, 1996; Tentori et al. , 2001; Curtin et 
al. 2004). The suppression ofPARP-l activity increases the sensitivity of cells to DNA 
damaging agents. The understanding of how this happens may help us to understand 
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how this increased sensitivity occurs and design even more potent therapies in the 
future. 
1.5 X-ray cross-complementing group -1 (XRCCl) 
The first XRCC 1 mutated cell line was the EM9 cell line that was isolated as clone 
sensitivity to ethyl methanesulphonate (EMS). It was found that this cell line was also 
sensitive to agents such as ionising radiation (Thompson, 1982). Several other X-ray 
sensitive cell lines were isolated and cross complementation was determined in cell 
fusion experiments (Thompson, 1991). The EM9 cell line belong to the first X-ray cross 
complementation group (XRCC1) and the gene was cloned (Thompson, 1990). 
Tt was found that the XRCC 1 protein is involved in DNA single-strand break (SSB) 
repair as well as in suppressing levels of sister chromatid exchange (SCE) (Thompson, 
1990). Further evidence that the XRCC 1 protein caused the defect in SSB repair and in 
abnormal SCE levels came from suppression of the phenotype through expression of a 
XRCC I minigene (CaJdecott, 1992). The XRCC 1 protein was found to bind to the DNA 
ligase III protein (Caldecott, ] 994) suggesting the protein had direct implication in 
repair of SSBs. It was early suggested that the XRCCl protein also was involved in the 
base excision (BER) pathway as loss of XRCCI protein resulted in sensitivity to EMS 
and other alkylating agents (Thompson, 1982). 
The interaction between XRCCI and other proteins such as DNA ligase III and DNA 
polymerase P have been further studied in detail. It was found that the XRCCl binds 
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directly with DNA ligase III and DNA polymerase ~. XRCCl binds DNA ligase III 
through a breast cancer protein 1 carboxyl terminus (BRCT) motif (Taylor 1998). 
These are folding units of about 90-100 amino acids, and so called because they were 
first identified in breast cancer cells. These BRCT motifs consist of four ~-strands 
forming a core sheet structure and two a-helices, and are important in specific protein-
protein interactions (Caldecott, 2003) (Figure /.5). In fact, BRCT motifs have been 
found in DNA-damage responsive and cell cycle check-point proteins. DNA ligase III 
contains a BRCI motif in its C-terminal domain, amino acids 841 to 922, and XRCC 1 
contains two BRCT motifs, one at amino acids 314 to 402, and another in the C-
terminal at amino acids 538 to 622. XRCCl binds DNA ligase III through its C-terminal 
BRCT motif. 
Figure 1.5. Crystal structure of a typical BRCT motjf 
From Caldecott 2003 
XRCCl bind DNA polymerase ~ through its N-terminal domain, amino acids 1 t0183. 
This ection of the XRCCl protein also binds to SSBs in the DNA (Marintchev et al., 
2000). Th thre -dimensional Structure of the N-terminal domain of XRCCl has been 
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reported, and has been shown to be well-suited to the inside curvature of 90° bent DNA 
(Marintchev et al., 1999). When PARP-l binds to SSBs in the DNA, it induces a V-
shape bend in the DNA. PARP-l eventually moves away from the DNA, leaving room 
for the repair proteins to access the break. It may be that XRCCl then binds the site 
recently vacated by P ARP-l, bringing DNA polymerase ~ and DNA ligase III to the 
site. XRCCl binds DNA polymerase ~ via its N-terminal region, but this domain has a 
much higher affinity for SSBs in the DNA, approximately 100 times greater. It could be 
that XRCCl binds DNA polymerase ~ via the N-terminal, which is then possibly 
released upon binding to a SSB. 
XRCCl binds DNA ligase III through its C-tenninal BRCT Il motif and PARP-l 
through its central BRCT I motif which binds directly with a BRCT motif within 
P ARP-l 's automodification domain (AMD) (Masson, 1998). Thjs is the domain where 
P ARP-l automodifies itself by adding ADP-ribose polymers and XRCCl preferentially 
binds to automodified PARP-l. PARP-l binds XRCCl through its BRCT motif, and 
also with the zinc-fingers found within the N-tenninal region. 
The disruption of the BRCT II motif has been shown to inhibit SSB repair in the G 1-
phase of the cell cycle (Taylor, 2000), but not in the S-phase. In contrast, a mutation in 
the BRCT J domain inhibits all SSB repair regardless of the cell cycle (Taylor, 2002). 
XRCC 1 itself is not required for SSB repair, however, the presence of XRCCl 
stimulates the poly nucleotide kinase which increases the speed of SSB repair 
(Whitehouse et ai, 2001). 
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1.6 Camptothecin (CPT) 
Camptothecin (CPT) is a chemotherapy drug, discovered by Dr. Monroe E Wall and 
Jonathon Hartwell in 1958. It is found in the bark of Camptotheca accuminta, or Xi Shu. 
This tree is also known in China as the ' happy tree' or ' cancer tree '. 
Camptothecin inhibits topoisomerase I (Top!), an enzyme that relaxes DNA 
supercoiling ahead of replication and transcription complexes. Top 1 induces a transient 
break in the DNA, so that the flanking segments of DNA can rotate freely around it. 
Camptothecin stabilises this break (Hsiang, 1985), by binding intercalating between 
upstream (-1) and downstream (+1) base pairs, displacing the downstream DNA and 
preventing relegation of the cleaved DNA, which in turn 1 av sTop 1 covalently bound 
to the DNA (Pommier et al., 2003). This leaves an unrepaired SSB in the DNA which 
must be repaired before it coJlides with oncoming r plication machinery, ~d resulting 
in a DSB, through a run off mechanism leaving a free 5' phosphate DNA end 
(Strurnberg, 2000) (Figure 1.6.1). Tt is well established replication is needed for CPT 
toxicity, which is explained by the collapse of replication forks (Avemann, 1988; Ryan, 
1991; Tsao, 1993;Strurnberg, 2000) 
Figure 1.6. 1 A SSB becomes a DSB after collision with an oncoming replicationfork 
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D B ar I thal to the cell if left unrepaired. The repair pathways involved in repairing 
PT homologous recombination and non-homologous end joining 
(Amaudeau et al. 2001) or SSB repair involving the XRCCl protein (Barrows et aI., 
1998). Th r fJ r drug that inhibit the repair of CPT -induced DSBs can enhance the 
f camptothecin. This has been shown, both in vitro and in vivo, by co-
treatm nt wi th inhibitor of DNA-dependent protein kinase (DNA-PK) or with PARP-1 
inhibi t t af 1999) but the mechanism is still unknown. 
PT ha fi nng tructure, and exists naturally in equilibrium with a similar 
tructur with an ' open ring. This equilibrium is governed by the pH of the 
urr unding . 
Figure 1.6.2 amptothecin ('closed ' ring) 
o 
OH 0 
hi gh pH will fa our the open ring, and a low pH will favour the closed ring. The 
clo d ring la t ne has the most catalytic activity, but is not soluble, whereas the open 
ring arb lic acid i oluble. 
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Figure 1.6.3 amptothecin ('open ' ring) 
OH 0 
In the early 1970s, camptothecin sodium was used to treat gastro-intestinal cancer 
patients, but thjs was discontinued to severe side ffects. Camptothecin sodium 
irreversibly opens the lactone ring, so a very high dose was needed to have any c1injcal 
effect. However, the low pH of the bladder, pushed th quil ibrium in favour of the 
closed ring structure causing a huge toxic dose of the drug. 
Figure 1.6.4 amptothecin sodium 
o 
OH 0 
The toxic side effects of CPT are neutroperua (abnormally low levels of neutrophils) 
anaemia vomiting, fever and pain (Verschraegen, et aI, 2000). Since the 1970s, many 
analogue of CPT have been created, such as topotecan and irinotecan. These are less 
to ic and are u ed today in the treatment of several cancers. 
57 
Institute for Cancer Studic: 
Uni\ ersity of SheHield 
Figure 1.5.5 Topotecan 
ethyldimethylamino 
OH 0 
Topotecan (9-[( dimethylamino )methyl]-l O-hydroxycamptothecin) is water-soluble due 
to the ethyldimethylamino side-chain at carbon nine of th A ring. This drug was 
approved for use in 1996, and is currently used to treat ovarian and small cell lung 
J 
cancer. 
lrinotecan (7 -ethyl-l 0-[ 4-(1-piperidino-l-piperidino] carbonyloxycamptothecin) is 
water-soluble due to the bulky dipiperidjno side-chain linked to the A ring via a 
carboxyl ester bond. 
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Figure 1.5.6 Irinote/an 
o carboxyl ester ( Nu 1( 
piperidine 
OH 0 
This side-chain decreases the anticancer activity of the drug, but is cleaved by 
carboxylesterases in the liver and gastro-intestinal tract to form SN-38 (7-ethyl-lO-
hydroxycamptothecin). This metabolite has 2-3-fold more activity than irinotecan. 
Currently, irinotecan is used to treat lung, cervical and ovarian cancers, but is mostly 
used to treat advanced colorectal cancers. Recently, it has been discovered that co-
treatment of cancers with CPT and P ARP-l inhibitors increases the cytotoxicity of the 
CPT. 
59 
Institute for Cancer Studies 
ni\t~rsity of. hetlield 
1. 7 Aims of this thesis 
The aim of my research is to examine the role ofPARP-1 and XRCCl in CPT-induced 
homologous recombination. I am interested to know what the role of P ARP-l is in CPT-
induced DNA damage, and why the inhibition of PARP-I increases the cytotoxicity of 
PT. Do PARP-l inhibitors increase the cytotoxicity of CPT? 
Since PARP-l -1- cells are have a hyper-recombination phenotype, I am interested to find 
out the r le f homologous recombination (HR) in the repair of CPT-induced damage 
and to know if there is more CPT-induced damage in PARP-r'- cells. CPT stabilises the 
transi nt single-strand break (SSB) induced by Top 1. Is PARP-l involved in SSB 
repair? If how is it involved? HR repairs DNA double-strand breaks (DSBs). Are 
there m re D Bs in P ARP·/- cells after CPT treatment? 
B are usually repaired by DNA ligase III and DNA polymerase 13. They are brought 
to the ite f the SSB by the scaffold protein, XRCCI. XRCCI is thought to interact 
with PARP-1. In cells lacking XRCCI, is CPT more toxic? Is CPT more toxic to cells 
lacking a functional PARP-I or XRCC 1? Do these cells have an increase in DSBs? 
his re earch i imp rtant because it will tell us why PARP-I inhibitors increase the 
cyt t xicity f P and may provide insights for future clinical work. P ARP-I 
inhibit rs may be de eI ped for clinical use which will help in the treatment of cancers 
and decrease th amount of toxic side effects seen with CPT derivatives. 
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CHAPTER 2: MATERIALS & METHODS 
2.1 Materials 
2.1.1 General lab equipment and reagents 
2.1.1.1 hemical reagents 
Unless otherwise stated, all of the chemicals used in the preparation of solutions and 
buffers were of high purity. 
Chemical Supplier 
2-mercapto-ethanol Sigma 
Acrylamide BioRad 
Ammonium persuJphate BDH 
Ampicillin Sigma 
Aquaclean ConTaFree liquids 
Bovine serum albumin (BSA) Sigma 
Boric acid BDH 
Coomassie brilliant blue BioRad 
Dextran sulphate Sigma 
Dimethyl sulphoxide (DMSO) Sigma-Aldrich 
Ethylene diamine tetra acetic acid (EDT A) BDH 
Ethanol BDH 
Ethidium bromide Sigma 
Fico1l400 BDH 
Glycerol BDH 
Hydrex® HS disinfectant spray Adams Healthcare 
Hydrochloric acid Fisher Scientific 
Industrial methylated spirit Adams Healthcare 
Isopropanol BDH 
Low fat milk powder Marvel 
Methanol BDH 
Methylene blue Sigma 
N-laurylsarcosine Sigma 
Paraformaldehyde Fisher Scientific 
Phenol BDH 
Phenyl methyl sulphonyl fluoride (PMSF) Sigma 
Polyvinylpyrolidone Sigma 
Presept (sodium dichloroisocyanurate) Johnson & lohnson Medical Limited 
RBS detergent Pierce 
-SeaKem agarose FMC Bioproducts 
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Chemical Supplier 
Sodium acetate BDH 
Sodium chloride BDH 
Sodium citrate BDH 
Sodium hydroxide BDH 
Sodium hydroxide BDH 
Sodium lauryl sulphate (SDS) Sigma 
Sodium phosphate BDH 
Tris base BDH 
Triton-X 100 Sigma 
Tween-20 BDH 
Virusolve II Amity U.K. Limited 
2.1.1.2 Glassware 
All glassware was washed with RBS detergent (Chemical concentrates), rinsed several 
times with tap water and washed with de-ionised water. Glassware was dried in a hot 
air oven and all items requiring sterilisation were autoclaved for 15 minutes at 15 p.s.i. 
Item Supplier 
Bottle 100 ml Schott Duran 
Bottle 200 ml Schott Duran 
Bottle 500 ml Schott Duran 
Bottle 1 L Schott Duran 
2.1.1.2 Plastic and disposable equipment 
Item Supplier 
25 ml vented Nunclon™ flasks Nunc 
75 ml vented Nunclon™ flasks Nunc 
175 ml vented Nunc1on™ flasks Nunc 
1 00 mm cell culture plates Greiner Bio-one 
6-well cell culture plates Greiner Bio-one 
5 ml Stripette® disposable pipette Coming Incorporated 
10 ml Stripette® disposable pipette Coming Incorporated 
20 ml Stripette® disposable pipette Coming Incorporated 
Pasteur pipettes (glass) Fisher Scientific 
400 ml beaker Azlon 
1000 ml beaker Azlon 
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Item Supplier 
2000 ml beaker Azlon 
Measuring cylinder 25 ml Azlon 
Measuring cylinder 100 ml Azlon 
Measuring cylinder 250 ml Azlon 
Measuring cylinder 500 ml Azlon 
Measuring cylinder 1000 ml Plastibrand 
Universals Bibby Sterilin 
15 ml centrifuge tubes Sarstedt 
50 ml centrifuge tubes Coming Incorporated 
Sterile needles BDUKLtd 
Syringes BD UKLtd 
UVette Eppendorf 
Cryovials Sarstedt 
Eppendorfs 0.5 ml Sarstedt 
Eppendorfs 1.5 ml Sarstedt 
Eppendorfs 2 ml Sarstedt 
Neptune barrier tips 1 0 ~l CLP 
Neptune barrier tips 20 ~l CLP 
Neptune barrier tips 1 00 ~l CLP 
Neptune barrier tips 1 000 ~l CLP 
Plastic tips < 200 ml Sarstedt 
Plastic tips < 1000 ml Sarstedt 
Filtered tips plO Starlab 
Filtered tips p20 Starlab 
Filtered tips p200 Starlab 
Filtered tips pl000 Starlab 
Super premium microscope slides BDH 
Coverslips BDH 
2.1 .1.4 Miscellaneous disposable lab equipment 
Item Supplier 
Parafilm Pechiney Plastic Packaging 
ComplyTM Indicator tape 3M 
Aluchef® Foil Terinex 
Clingfilm Caterwrap 
Surgical mask Kimberley Clark 
Disposable scalpel Swann-Morton 
Weigh boats 50 ml Scientific Laboratory Supplies 
Weigh boats 100 ml Scientific Laboratory Supplies 
Latex gloves (small) Bodyguards® 
Paper towels Kimberley Clark 
Tissues Lotus Professional 
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2.1.1.5 General lab equipment 
Item Supplier 
4°C fridge Labcold 
4°C fridge Derby 
4°C Medicool fridge Sanyo 
-20°C freezer Labcold 
-20°C freezer Ezta 
Ice machine Scotsman 
Microwave Panasonic 
Unitemp 37°C incubator HarvardJL TE 
Plus 11 oven Gallenkamp 
Unitemp drying cabinet HarvardJL TE 
MP24 control autoclave oven Rodwell Scientific Instruments 
Model G25 incubator shaker New Brunswick Scientific Co. Inc. 
CK2 microscope Olympus 
SM-LUX microscope Leitz Wetzler 
Mistral 2000R centrifuge MSE 
Microcentaur microcentrifuge MSE 
PM 4000 balance Mettler 
Fine balance Gallenkamp 
Biophotometer Eppendorf 
DPU-414 thermal printer Seiko Instruments Inc 
Min-spin plus Eppendorf 
Orbital shaker SO 3 Stuart Scientific 
Vortex-Genie 2 Scientific Industries 
Dryblock DB 2A Techne 
Heating block Grant Boeial 
[Zip] Color squid magnetic stirrer IKA 
SM-l magnetic stirrer Stuart Scientific 
SS 3H Hotplate stirrer Chemlab 
Model 200/20 power supply BioRad 
Model 1000/500 power supply BioRad 
Power P AC 300 BioRad 
pH meter Denver Instruments 
Water bath Grant 
Water bath Laboratory Thermal Equipment Ltd 
PipetAid Drummond Scientific 
plO Pipetrnan Gilson 
p20 Pipetman Gilson 
p200 Pipetman Gilson 
plOOO Pipetman Gilson 
Pipetman stand Gilson 
Cell counter Neubauer 
Counter ENM 
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2.1.1.6 De-ionised water 
Tap water passed through a reverse osmosis unit (Fi-streem, Fisons) to produce de-
ionised water with a resistance of 10 MO. The water was sterilised by autoclaving for 
15 minutes at 15 p.s.i. All references to water within this thesis should be assumed to 
mean de-ionised water unless otherwise stated. Water of ultra-pure quality (> 18 MO) 
was used for molecular experiments and was obtained from an installed Permulab de-
ionising water system. 
2.l.1.7 General buffers 
All buffers were sterilised by autoclaving for 20 minutes at 15 p.s.i. 
2.1.1.7.1 Phosphate-buffered saline (PBS) buffer 
137 mM NaCI 
2.7 mMKCI 
10 mM Na2HP04 
2mMKH2P04 
Adjusted pH to 7.4 with HCI 
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2.1.1.7.2 10 x Tris-Acetate-EDTA (TAE) buffer 
0.4 M Tris-acetate 
10mMEDTA 
pH 7.6 
2.1.1.7.3 10 x Tris-Borate-EDTA (TBE) buffer 
0.89 M Tris 
0.89 M Boric acid 
20 mM EDTA 
pH 8.3 
2.1.1.7.4 10 x Tris-EDTA (TE) buffer 
0.1 M Tris 
10mMEDTA 
pH 8.0 
2.1.1.7.5 10 x Tris-Glycine-SDS (TGS) buffer 
0.25 M Tris 
2.5 M Glycine 
0.1% w/v SDS 
._----_ .. _-_._._._. __ ._--_._ ...... __ .. _ .. - ... 
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2.1.2 Materials for cell culture 
2.1.2. I Chemical reagents for cell culture 
Chemical Supplier 
(l-MEM Cambrex 
D-MEM Gibco 
HyClone® foetal bovine serum_CFBS) Perbio 
L-glutamine BDH 
Non-essential amino acids (NEAA) Cambrex 
Penicillin Sigma 
Streptomycin sulphate Sigma 
Trypsin Gibco 
Carbon dioxide gas BOC gases 
Nitrogen refrigerated liquid BOC gases 
2.1.2.2 Specific equipment for cell culture 
Item Supplier 
Class II microbiological safety cabinet Walker Safety Cabinets Limited 
C02 incubator Gallenkamp 
-135°C nitrogen freezer Sanyo 
2.1.2.3 Specific buffers for cell culture 
2.1.2.3.1 Versene 
0.02% EDTA in PBS. 
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2.1.3 Materials for pulsed-field gel electrophoresis 
2. 1.3. 1 Chemical reagents for pulsed-field gel electrophoresis 
Chemical Supplier 
Drugs (See 2.2 DRUGS) 
Pulsed-field certified agarose Fisher Biotech 
Agarose for PFGE: sample preparation Sigma 
Proteinase-K Fisher Biotech 
CHEF DNA size standards, S. cerevisiae BioRad 
2. 1.3 .2 Specific equipment for pulsed-field gel electrophoresis 
Item Supplier 
CHEF-DR III power module BioRad 
CHEF-DR III electrophoresis cell BioRad 
Cooling module BioRad 
Variable speed pump BioRad 
Screened caps BioRad 
Plug molds BioRad 
Standard casting stand BioRad 
Wide/long combination casting stand BioRad 
10 well comb (14 cm x 0.75 mm) BioRad 
30 well comb (21 cm x 0.75 mm) BioRad 
Combination comb holder BioRad 
Tygon tubing BioRad 
UV transilluminator UVP Inc. 
DC 290 200M digital camera Kodak 
Power Mac G3 series Apple 
17/200 monitor Pronitron 
Safety mat Kodak 
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2.1.4 Materials for Southern blot 
2.1.4.1 Chemicals for Southern blot 
2. 1.4.1 .1 Chemical reagents for DNA extraction 
Chemical Supplier 
Proteinase K Fisher Biotech 
2. 1.4.1 .2 Chemical reagents for DNA digestion 
Chemical Supplier 
XhoI restriction enzyme New England Biolabs 
HindIII New England Biolabs 
Nco I New England Biolabs 
NEB buffer 2 New England Biolabs 
2. 1.4.1.3 Chemical reagents for preparation of the probe 
Chemical Supplier 
LB-broth Fisher Scientific 
LB-agar Fisher Scientific 
XhoI restriction enzyme New England Biolabs 
BamHI restriction enzyme New England Biolabs 
NEB buffer 2 New England Biolabs 
Hyperladder I Bioline 
QIAquick® gel extraction kit Qiagen 
QIA prep spin mini-prep kit Qiagen 
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2.1.4.1.4 Chemical reagents for radiolabelling 
Chemical Supplier 
Prime-it® 11 random primer labelling kit Stratagene 
9-mer primer 
5 x dCTP buffer 
Exo( -) Klenow enzyme 
Ji-apdCTP MD Biosciences 
DyEx kit Qiagen 
Decon 90 Decon Laboratories Limited 
2.1.4.2 Specific equipment for Southern blot 
Item Supplier 
Hybridisation oven/shaker Stuart Scientific 
DNA thermal cyeler 400 Perkin Elmer 
FLA-300 phospho-imager Fujifilm 
Power Mac G4 Apple 
Visionmaster™ Pro 511 Iiyama 
H5 horizontal gel electrophoresis cell Gibco 
Hybond-N'" Amersham Biosciences 
Whatman paper Scientific Lab Supplies 
Safety glass Nalgene 
Series 900 Geiger counter Mini-monitor 
Glass tubes with screw lid Stuart Scientific 
2. 1.4.2 Computer software for analysis of Southern blot 
Item Supplier 
Image gauge V3.3 Fujifilm 
Image reader V1.8E Fujifilm 
L Process V1.8 Fujifilm 
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2.1.4.4 Specific buffers for Southern blot 
2.1.4.2.1 20 x SSPE 
3 M NaCl 
0.2 M NaH2P04.H20 
20mMEDTA 
pH 7.4 
2.1.4.2.2 20 x SSE 
3 M NaCl 
pH 7.0 
2.1.4.2.3 Denhardt's solution 
1 % w/v Ficoll 400 
1 % w/v Polyvinylpyrolidone 
1% w/v BSA 
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2.1.5 Materials for immunofluorescence 
2.1.5.1 Chemical reagents for immunofluorescence 
Chemical Supplier 
Primary antibody isee 2.3.1 Primary antibodiesl 
Secondary antibody isee 2.3.2 Secondary antibodiesl 
Slowfade® Antifade kit Molecular Probes 
Nail varnish Boots 
2. 1.5.2 Specific equipment for immunofluorescence 
Item Supplier 
TE 300 Eclipse microscope Nikon 
Pentiurn III computer Maple 
Trinitron Multiscan 500 PS Sony 
Microscope (MBB) 
2.1 .5.3 Computer software for analysis of immunofluorescence 
I softWoRx 
Item 
I Delta Vision 
Supplier 
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2.1.6 Materials for recombination assays 
2.1.6.1 Chemical reagents for recombination assays 
Chemical Supplier 
Drugs (see 2.2 DRUGS) 
Hypoxanthine Sigma 
Azaserine Sigma 
Thymidine Sigrna 
6-thioguanine (6-tG) Sigma 
Geneticin (G418) Gibco 
2.1.6.2 Specific buffers for recombination assays 
2.1.6.2.1 Dialysed serum 
Foetal bovine serum (Perbio) was poured into dialysis tubing and left to soak in 1 x PBS 
with agitation at 4°C. The buffer was changed every 4 hours for 16 hours. Removed 
serum from the dialysis tubing and vacuum filtered, before autoc1aving at 15 p.s.i. 
2.1.6.2.2 HAsT medium 
Added hypoxanthine (6.865 mg/ml), azaserine (1.731 mg/ml) and thymidine (12.12 
mg/ml) to DMEM and inverted to mix. 
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2.1.7 Materials for survival assays 
2.1 .7.1 Chemical reagents for survival assays 
I Drugs Chemical I Suppliers 
2. 1.7.2 Specific equipment for survival assays 
I Item Supplier 
I Colony counter Stuart Scientific 
2.1.8 Materials for fluctuation assays 
2. 1.8.1 Chemical reagents for fluctuation assays 
I Chemical 
Geneticin (0418 I Gibco 
Supplier 
2. 1.8.2 Specific equipment for fluctuation assays 
Item Supplier 
Colony counter Stuart Scientific 
2.1.9 Materials for flow cytometry 
2. 1.9.1 Chemical reagents for flow cytometry 
Chemical Supplier 
Drugs (see 2.2 DRUGS) 
Bromodeoxyu_ridine (BrdU) Sigma 
Primary antibody (see 2.3.1 Primary antibodies) 
Secondary antibody (see 2.3.2 Secondary antibodies) 
Propidium iodine Sigma 
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2.1.9.2 Specific equipment for flow cytometry 
Item Supplier 
FACSorter Becton Dickenson 
Computer Mac OS 9.1 
Monitor Formac 
2.1.9.3 Computer software for analysis of flow cytometry 
Item Supplier 
I Cell quest Becton Dickenson 
2.1.10 Materials for Western blot 
2.1.10.1 Chemical reagents for Western blot 
Chemical Supplier 
Protease inhibitor cocktail Roche 
TEMED Sigma 
ECL Western blotting detection reagents Amersham Biosciences 
BioRad protein assay BioRad 
Precision Plus: Dual color standard BioRad 
2.1.10.2 Specific equipment for Western blot 
Item Supplier 
Hoefer mighty small dual cell caster Amersham Biosciences 
Hoefer SE 250 Amersham Biosciences 
Hoefer SE 260 Amersham Biosciences 
Lid with cables Amersham Biosciences 
Lower buffer chamber for SE250 Amersham Biosciences 
Deep lower buffer chamber for SE260 Arnersham Biosciences 
Hoefer glass plates 8 x 10 cm (SE250) Amersham Biosciences 
Hoefer glass plates 10 x 10.5 cm (SE260) Arnersham Biosciences 
Notched alumina plates Amersham Biosciences 
Clamps Arnersham Biosciences 
Spacers 8 cm x 1 mm Amersham Biosciences 
Spaces 10.5 cm x 1 mm Amersham Biosciences 
Trans-blot® SD semi-dry transfer BioRad 
Extra thick blot paper (mini-blot size) Amersham Biosciences 
Hybond-C extra Amersham Biosciences 
HyperfilmTM Arnersham Biosciences 
Super RX Fuji medical x-ray film Fujifilm 
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2.1.10.3 Specific buffers for Western blot 
2.1.10.3.1 5 X RIPA buffer 
5 M NaCl 
1 M Tris 
5% NP-40 
10% DOC 
10% SDS 
2.1. 10.3.2 2 x Protein loading buffer 
1 M Tris 
Glycerol 
10% SDS 
p-mercaptoethanol 
Bromophenol blue 
2.1.10.4 Acrylamide gels for Western blot 
30% acrylamide 
1.5 M Tris (PH 8.8) 
10% SDS 
10% APS 
TEMED 
2. 1.10.5 Computer software for analysis of Southern blot 
Item Supplier 
Kodak ID 3.5.4 USB Kodak Scientific Imaging Systems 
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2.1.11 Materials for transfection 
2.1.11.1 Chemical reagents for transfection 
Chemical Su lier 
2.1.11.5 P cific equipment for transfection 
Item Supplier 
EasyjecT Plus Equibio 
ADP-400 printer Equibio 
Electroporation cuvettes Equibio 
2.1.12 Materials for reverse-transcription PCR (RT-PCR) 
2.1.12.1 hemical reagents for RT-PCR 
Chemical Supplier 
RNeasy@ mini-kit Qiagen 
Reverse-it one step kit Abgene 
. Sense primer (see 7.2 Primers) 
Anti-sense primer (see 7.2 Primers) 
RT-ase Abgene 
2.1.12.2 pecific equipment for RT-PCR 
Item Supplier 
PTC-I00™ programmable thermal cycler MJ Research Ine 
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2.2 Drugs 
2.2.1 P ARP inhibitors 
2.1.1.1 1 5-dihydroxyisoquinoline (ISQ) 
ISQ (also known as 1 5-dihydroxyisoquinolinediol), is a nicotinamide adenine 
dinucleotide (NAD) analogue and is a potent inhibitor of poly (ADP-ribose) polymerase 
(PARP) (ICso = 0.39 /-LM) (Banasik et ai, 1992). It is an aromatic nitrogen compound 
characterised by a double-ring structure, containing a benzene ring and a pyridine ring. 
ISQ (Sigma) is a yellow-brown powder that is made to a stock solution of 100 mM in 
DM 0, and stored at -20°C. ISQ was added to the cell culture medium to a final 
concentration of 0.6 mM (Semionov et ai, 1999). 
OH 
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2.1.1.2 NUI025 
NU I 025 or 8-hydroxy-2-methylquinazoline-4-one, is also a potent P ARP inhibitor 
(I so = 0.4 )lM) (Boulton et ai, 1995). 
o 
o 
It pot ntiates the cytotoxicity of various DNA-active agents, including the DNA strand 
br ak-inducing drug temozolomide, topotecan, bleomycin, and ionising radiation in 
murine L1210 leukaemia cells, Chinese hamster ovary cells, and a variety of human 
tumour cell lines. NUl 025 is an off-white solid (Mw = 176.2) that is made to a stock 
solution of 10 mM in DMSO and is stored at -20°C. 
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2.2.2 bemotberapy drugs 
2.2.2.1 amptothecin (CPT) 
amptothecin is a chemotherapy drug that inhibits topoisomerase I (Top 1), an enzyme 
that relax s DNA supercoiling ahead of replication and transcription complexes. 
o 
Topl induc s a transient break in the DNA, so that the flanking segments of DNA can 
rotate fre ly around it. This break is stabilised by camptothecin, and as replication forks 
mo e towards it they collide and cause the formation of a double strand break, which 
e entually leads to cell death. Camptothecin (Sigma) is a yellow powder (Mw = 348.35) 
that i made up in DMSO as a 100 mM stock solution, and stored at -20°C. 
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2.2.2.2 H droxyurea (HU) 
HU is a replication fork inhibitor that inhibits DNA synthesis by destroying the 
catalyticall essential free tyrosyl radical of ribonucleoside diphosphate reductase 
(RNR) blocking the de novo synthesis of deoxyribonucleotides. 
o 
11 
H N -C-NHOH 2 
HU igma) is a white powder (Mw = 76.05), which is made in DMEM to a stock 
concentration of 10 mM and stored at 4°C. 
2.2.2.3 Thymidine (dT) 
h midine is a nucleoside component of DNA and slows replication forks by limiting 
the d TP supply. 
o 
OH 
Th midine ( igma) is a white powder (Mw = 242.23) that is made up in DMEM at a 
stock concentration of 40 mM, and stored at 4°C. 
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2.2.2.4 -methyl-N-nitro-nitrosoguanidine (MNNG) 
MNNG is an alkylating agent and a very potent mutagen. MNNG forms covalent bonds 
with D A and forms 0 6-methyguanine, causing G-C to A-T transitions. 
NH 
CH3 " 11 
N- C-NHNO / 2 
ON 
MNNG ( igma) is a yellow powder (Mw = 147.09) and is made up in DMSO to a stock 
concentration of 5 mM. 
2.2.2.5 Methylmethanesulfonate (MMS) 
MM ,or methanesulphonic acid methyl ester, is an alkylating agent and is highly 
carcinogenic. This chemical also forms covalent bonds with DNA to form 0 6_ 
meth guanine and causes G-C to A-T transitions. 
o 
11 
CH -S-OCH 3 11 3 
o 
MM ( igma) is a colourless oily liquid (Mw = 110.13) and arrived at a concentration 
of 11.8 moles. Made up a stock solution of 5 mM in DMSO. 
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2.3 Antibodies 
2.3.1 Primary antibodies 
2.3.1.1 Anti-Rad51 
Rabbit pol clonal IgG (Santa Cruz Biotechnology) epitope corresponds to amino acids 
1-92 of human Rad51 but also has cross-reactivity with mouse, rat and hamster Rad51. 
The antibody was used at a concentration of 1: 1 000 in PBS, with 3% BSA. Storage was 
at 4° . 
2.3.1.2 Anti-hXRCC l 
Polyclonal anti-hXRCC l antibody (SeroTec) was raised in rabbit against human 
XR Cl and is not cross-reactive with any other species. The antibody was used at a 
concentration of 1: 1000 in PBS, with 3% BSA. Storage was at 4°C. 
2.3.1.3 Anti-BrdU 
Monoclonal mouse anti-BrdU antibody (Dako) binds to cells that have incorporated 
br modeoxyuridine (BrdU) into their DNA during the S-phase of the cell cycle. Anti-
BrdU was u ed at a concentration of 1: 1000, in PBS-T. Storage was at 4°C. 
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2.3.2 econdary antibodies 
2.3 .2.1 Anti-rabbit Cy-3-conjugate 
CyT 13 Goat anti-Rabbit IgG (H+L) antibody (Zymed) was used at a concentration of 
1 :500 in PB with 3% BSA, and because of the light-sensitive nature of the Cy-3 
conjugate was u d and stored in the dark. Storage was at 4°C. 
2.3.2.2 Anti-rabbit FITC-conjugate 
Anti-Rabbit IgG (whole mo1ecule)-FITC antibody (Sigma) was raised in goat, and used 
at a oncentrat io~ of 1: 1000 in PBS, with 3% BSA. Storage was at 4°C. 
2.3 .2.3 Anti-mouse FITC-conjugate 
Polyclonal goat anti-mouse FITC-conjugated antibody (Dako) was used at a 
concentration of 1 :50000 in PBS-T. Storage was at 4°C. 
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2.4 Method 
2.4.1 11 culture 
P RP-I +/+ ( 19) and P ARP-/- (A 11) cells lines are mouse embryonic fibroblasts which 
ha b n immortalised (Wang et al, 1997). SPD8 are a Chinese hamster lung cell line 
containing a partial duplication in the hprt gene (Helleday et ai, 1998). These cell lines 
er gr wn in Dulbecco's modified Eagle ' s medium (DMEM) with 10% foetal bovine 
erum p nici llin (100 U/ml) and streptomycin sulphate Cl 00 /lg/ml) under an 
atmo ph r containing 5% C0 2. 
he M9-p 02 XH EM9-pcD2EXH5, EM9-pcD2E, EM9-pcXHI-528, EM9-
pcXHW 5D M9-pcXHLI360/361DD were a kind gift from Keith Caldecott, and 
were gr wn in a- M with 10% foetal bovine serum, 2% glutamine, penicillin Cl 00 
/ml) and tr ptomycin sulphate (100 /lg/ml) at 37°C under an atmosphere containing 
5% 2. hes cell lines are all XRCC 1-/- cell lines that have been complimented with 
actor. T h M9-pc0 2EXH and EM9-pcD2EXH5 have been complimented with 
human R 1 (hXR 1). The EM9-pcD2E cell line has been complimented with an 
mpty t r. The M9-pcXHl-528 cell line has been complimented with a short 
f hXR 1 it is missing the BRCT II domain. The EM9-pcXHW385D and 
M -pc H 1360/36 10D cell lines have been complimented with hXRCCl proteins 
th t ha a mutated BRCT I domain. The BRCT I domain in EM9-pcXHW385D has 
th trypt phan r idu at position 385 exchanged for an aspartic acid residue. The 
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BR I domain in EM9-pcXHLI360/361DD has the leucine residue at position 360 and 
th i 01 u in re idue at position 361 exchanged for aspartic acid residues. 
2.4.2 Pul d-field gel electrophoresis 
2.4.2.1 M th d for pulsed-field gel electrophoresis 
2 x 106 ell w r plated onto 100 mm cell culture plates in 10 ml DMEM, and allowed 
to settl 0 might at 37°C. Treatment (Table 1) was for 24 hours. After treatment, 
ell w r w h d x I in phosphate-buffered saline (PBS), trypsinised and resuspended 
int 10 ml OM M in a 15 ml Falcon tube. Cells were then counted and media 
c ntaining 1 x 106 cells was centrifuged at 2000 rpm for S min to form a pellet. The 
p llet w r re u p nd d in 40 III PBS, to which 40 III 1.5% pulsed-field grade agarose 
(igm in PB wa added, and pipetted into a plug mould (BioRad) The agarose was 
boil d t 100° fi rehand to prepare and then kept molten at 40°C while the pellet 
was pr par d. The plug were left to set at 4°C for S min. Set plugs were added to SO 
ml al n tu c ntaining I ml O.SM EDTA, with 1 % N-Iaurylsarcosine and I mg/ml 
pr tein K (Fi h r cientific) and incubated for 48 hrs at SO°C. After 48 hrs, plugs 
w r w h d 4 I hr in cold I x TE buffer, and then embedded into a 0.8% agarose gel. 
Agar d-fi Id c rtified (BioRad) and made in 1 x TBE buffer. The gel was 
pia F-DR III pulsed-field electrophoresis chamber with 3 L O.S x TBE 
bu r. uffi r v a pumped constantly through the chamber by x and kept at 14°C by a 
c ling m dule Bi Rad). Pul ed-field electrophoresis was carried out for 24 hrs at 
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4V/cm. R ri ntation angle was 1200 and switch times were 60-240s. DNA size 
standard . cere i iae (BioRad). 
hapl r 2 Tabl 2.4.2. 1: Drug and concentrations added to each cell line 
Dru Concentration 
Camptothecin 100nM 
Hydroxyurea 0.5 mM 
Thymidine 10mM 
Isoquinoline 0.6 mM 
NUI025 1 mM 
1 +/+) Camptothecin 30nM 
I -/-) Thymidine 10 mM 
MNNG 2JlM 
Isoquinoline 0.6 mM 
NUI025 1 mM 
2.4.2.2 Th ory fpul ed-field gel electrophoresis 
T hniqu fi r m a uring double strand breaks (DSBs) in mammalian cells are used to 
study nurn r of phy iological processes, such as recombination and replication, and 
such as chemotherapeutic drugs and chemical toxicants. 
D ar fi rm d a a re ult of exposure to ionising radiation, clastogenic chemicals, 
re r plication and certain types of repair. The definition of DSBs are 
cl it I placed lesions, in each of the two phospho-diester backbones of 
th dupl D that under denaturing conditions will cause one double helical 
m lecul f t bec me two shorter ones. DSBs are the most deleterious lesion for 
th II in t rm f I thality aberration induction and generation of the transformed 
ph n typ. he m a ur ment of DSBs is crucial to the development of understanding 
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th m chani m underlying these processes, and pulsed-field gel electrophoresis 
FG ) i on of th most popular techniques. 
P ia t hnique fo r resolving chromosome-sized DNA (Schwartz and Cantor, 
1984 ,whi h can b used to measure the amount ofDSB formation. By alternating the 
el tric current b twe n spatially distinct pairs of electrodes, mega-base (mb) sized 
D i abl t r ori nt and move at different speeds through the pores in an agarose 
g I. H re th HEF-DR III system has been used, which uses clamped homogeneous 
I tri fi Id ) ( hu 1986 1990) and programmable autonomously controlled 
le tr de 
Birr n 1 
p t ntial 
) t provide homogenous electric fields within the gel (Cl ark, 1988; 
u ing an array of 24 electrodes, which are clamped to intermediate 
liminat lan distortion. 
B pp ar at th top f the gel as large chromosomal fragments and the amount of 
B indu d i hown a a comparison to control lanes, using Kodak ID3.5.4 USB 
softwar K dak i ntific Imaging Systems). 
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2.4.3 uth ro blotting 
2. 03 .1 th d fi r uthem blotting 
2.4.3.1.1 th d for D A extraction 
tr t d fr m 10 x 106 cells using 1 ml DNA lysis buffer, with 1 00 ~g/ml 
pr t in in ubated overnight at 37C. Added one volume of isoproponol, 
mix d b n and tran ferr d the precipitated DNA into 1 ml water. Dissolved 
th b pi tting and incubating at 37°C. Purified the DNA by phenol-chloroform 
2.4.3 .1.2 th d or DNA digestion 
in appr priat enzymes and buffers (table 2) for 3 hrs at 37°C, and then 
ran n 1 % agar g I t heck digestion. 
hapt r 3 1', I 2.-1.3.1.2: Enzyme and buffers added to each digestion mix 
Enzyme Buffer 
XhoI NEB2 
HindIII NEB2 
XhoI lHindIII NEB2 
XhoIlHindIJIlNcoI NEB2 
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2.4.3 .1.3 thod for DNA transfer 
Ran 35 ).11 of ach dig tion with 5 III of loading dye, on a 1 % gel and ran for 12 hours 
at 32. n light b x cut the gel to size to prevent excess binding of labelled probe to 
o ladd r which wa al 0 removed). Soaked gel in 500 ml of 0.2SM HCI, with 
shaking Cl r 0 min at room temperature (RT). Removed HCL, and rinsed once in 
t r. P ur d I L O.4M NaOH into a large tray and set up transfer equipment 
jigur 2..1.3.1.3 
Figur 2..1.3.1 .3: I-up for outhern blot DNA transfer 
~-------- Balance 
~------- Heavy weight 
Stack of 
Paper towels 
pap r x ~~~~~~~~~~~~~~~~.-- Hybond I~'~ ", membrane 
" ~,Whatman paper 
, x 3 
NaOH 
----- \in film 
PI d n upturne tray into the large tray and placed on top of this, three 
H Whatman paper. The gel was arranged on top of the paper 
in u in from the edges of the gel to the edge of the large tray. 
tid transfer membrane was cut to the size of the gel and 
nt thi w placed three sheets of Whatman paper, also cut to size, a 
t k pprl an upturned tray and a weight. A balance was placed on top of 
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th w ight in rd r to nsur equal pressure. Allowed DNA to transfer to the membrane 
at R er 1 
for 2 min 
2.4.3.1. 
hrs. pparatus v as dismantled, and membrane was incubated in 2 x SSC 
~ r all wing to dry on Whatman paper for 30 min. 
thod ~ r th preparation of the scNEO probe 
T k a m 11 amp\ f bacteria containing a plasmid with the scNEO vector, from a 
pr ad on a LB-ampicillin plate. Incubated the plate overnight at 
37° and th n I ct d ne fthe colonies, and grew up overnight in 5 ml ofLB-broth, 
with ampi illin at 37°. he plasmid was extracted using the QIAprep spin mini-prep 
kit iag n . scN 0 plasmid with restriction enzymes, XhoI and BamHI, 
. Ran 200 ~l of the digested scNEO plasmid, with 20 ~lloading dye, 
g I ~ r hr at I OOV. Extracted the 1.2 kb band from the gel and 
purifi d the fT m th g 1 using a gel extraction kit. 
2 .. 3.1.5 eth d fI r radiolabelling 
m ran \J wr pp d in a gauze (DNA side inwards) and placed into a 20 cm glass 
tu , \J·th this tube was poured 25.5 ml pre-hybridisation buffer: 
10 ,' P 12.5 ml 
solution 1.25 ml 
1.25 ml 
t r 10 ml 
nicat d DNA 0.5 ml 
91 
In tilut· ~ r ',lIl 'r 'wd ic: 
Uni\ cr. il~ 01 Sh 'nicld 
oni at d heat d to 100°C and then chilled, before adding to buffer. Tube 
wa pIa ing heated at 65°C overnight. Radiolabelled the scNEO probe 
by adding 1 ng f th 1.2 kb DNA to 18 III water and 10 III of 9-mer primer 
H t d thi mi fI r 5 min at 100°C and then centrifuged briefly at RT. 
P uffi r In itr gen) and 7 III labelled 32-ap dCTP, and mixed well with 
-) Klenow enzyme (Invitrogen) and mixed thoroughly 
v ith pi tl tip Cl r incubating at 40°C for 10 min. 
f pr -h ridi 
bu r. ure 
th h 
purifi d u ing the Qiagen DyeEx kit and then added to 0.5 ml of 
100° for 5 min, and put on ice. Mix was added to 25 ml 
ntaining 0.1 glml dextran sulphate, to make hybridisation 
th pr -hybridisation buffer from the glass tube, and replaced with 
r. PIa ed into rotating oven at 65°C overnight. Membrane was 
P (with 0.1 % SOS), with shaking, for 10 min, followed by a 
w hing x 1 in 1 x P with 0.1 % D ) with shaking, at 65°C. The membrane was 
th n furth r\ x 1 in 1 x 0.1 PE (with 0.1 % SDS) at 65°C. The membrane 
\J then \ pp in lingfilm and the image was taken using a Fuji phospho-imager. 
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2.4.4 Immun flu r 
2.4 .. 1 
10 
and 
th d r immun fluore cence 
r plat d nt a glas coverslip in 60 mm culture plates in 2 ml DMEM, 
HI fi r 4 hr at 37° . Treatment was for 24 hours. After treatment, 
, 1 in P and fi ed for 20 min at RT in 3% paraformaldehyde in 
.1 % trit n- 100 and 0.15% BSA). Coverslips were rinsed for 15 min x 
4 in - an th n in ub t d in primary antibody for 16 hrs at 4°C. After rinsing 
fi r I min x 4 in P -T co erslips were incubated in secondary antibody for 
1 hr in dark . Rin d r lip for 15 min x 2 in PBS-T, and then for 5 min x 1 
in P r m untin with I wFade® Antifade kit (Molecular probes). 2-3 drops of 
\ re 
tain with 
g nt in PB ) were added to each coverslip and blotted before 
with component C (equilibrium buffer). Coverslips 
ami h and tored at 4°C in a hydrated atmosphere. Images 
a1 mi ro cope and manipulated using SoftWorx. 
immWl flu r nce 
h n ' 
d 
fin d 
th t it ~ ill 
x it ti n li ht 11 flu r scent dyes fade, or photo-bleach. Photo-
inten ity and duration of illumination. The photon output of a 
numb r of cycles of excitation, followed by the emission that 
it i r er ibly photo-bleached. The average photon output 
pr bility that the dye will fluoresce and the probability 
b come a non-fluorescent species. These can be 
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significantl des environment. The main environmental influence on 
phot -bl g n or a fr e radical species. Antifade reagents sustain the dye's 
inhi iling th diffusion of radical oxygen species, therefore decreasing 
th f ph t -bl a hing u ing a compound called 1,4,diazabicyclo[2.2.2]octane, 
r \! hich i a free radical sca enger that extends useful fluorescence emission. 
2.4. R m ination a 
2.4.5 .1 R m in li n ay using the HPRT system 
R m in li n u ing th HPRT system were performed using SPD8 cells, which 
ar hin ham t r lung 11 lin c ntainjng a partial duplication in the hprt gene. 
uunin MP ~ dGMP 
/' t "-
HPR XMP DNA 
t t 
11 p . unthin IMP ---. AMP ---. dAMP 
nth i 
i 
Dc' IlO),() pu rine 
hin.) nthesi. 
r th h p xanthine phosphoribosyltransferase (HPRT) protein, 
f nucleotid s via the salvage pathway C-' ). The 
n 10 P d t inactivation of this gene, and the cells can 
thr u h th d novo pathway C -.). 
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\ re in th pr 
n t 6-thioguanine (6-tO) resistance. 6-tO is a purine 
d y the cell via the sal age pathway, but is toxic if 
nly cells lacking the HPRT protein will survive 
keep PD8 cells in the HPRT - phenotype they 
f 6t (5 Ilglml). 
2. . .1.1. f th Cl r r m inati n a ays using the HPRT system 
PI t l ' 1 
mi ht t ttl 
\) ilh th midin w r 
rin an 
h well f 6-well plates in 2 rn1 DMEM and grew for 4 days 
I x 106 cells onto a 100 mm cell culture plate and left 
tm nt (Table 2.4.5. J. J) was for 24 hours. Cells treated 
wn in M M c ntaining dialysed serum. After treatment, 
and I ft t r cover in lO ml DMEM for 48 hours. From 
d nt two plates (cloning plates), covered with 10 rn1 
t 70 for 7 days. 3 x 10s cells were also seeded from 
ntaining 1 ml HA T medium and 9 ml DMEM 
H m ium ntains 5 x lO's M hypoxanthine, 1 x 10's M 
lh mi in . Hyp xanthine can be converted by HPRT to IMP. 
rin inhi it lh d 1/0\'0 P thway. 
\\' 
me i \\ 
. % in m than I . 
I nin an 
In tilllt 
I ni 
fi r 10 days. After the specified length of time, the 
nn d x 1 with PB ,and stained with methylene blue 
unt d and these data were used to calculate the 
m in ti n frequency. 
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Tabl _..t. 1.1 Dru nd on nlraLion 
DruJ! Concentration 
Camptolhecin 100Nm 
Hydroxyurea 0.5 mM 
Thymidine 10 mM 
ISQ 0.6 Mm 
NU I025 10 IlM 
m in li nays using the HPRT system 
nl'n arti I uplic ti n fthe hprL gene, which gives rise to HPRT-
. Wh n th cells are grown in the presence of HAsT 
m J athway forcing the cells to synthesise 
nu I lid p thw y and therefore undergoes recombination in order to 
n . 
1 k 
SPD8 
e, n 2 3 4 5 6 76 139 
t 6 76 139 
I I • 11 11 • e n 1 2 4 5 6 76 139 
t 
n 4 5 6 139 
hi m hani m u a tit xamine the amount of recombination 
6 
In liIU(' 
t ui 
2.4 . . 2 m in ti n u ing th cNEO system 
nt in l\ d fecti neomycin phosphotransferase genes, 3' neo, 
an col site and is accompanied by the insertion 
II au,x et al., 1988). Homologous 
tw nth l\ neo genes can result in a neo + gene, which is 
drug 418. xpression ofl-Scel allows DSB-
r m l r red p cifically. 
S2neo 
~ 
I-SceI 
h n tran fi t d into a cell line, using electroporation, to 
m n aft r the induction of a DSB. Transfected cells 
f h gr m in (0.5 mg/mJ) to ensure the plasmid is kept. 
in t r using 1- cel. DSBs can also be formed in the 
ri t I f dru , U h a ampt th cin. 
7 
In tilll' r 
2.4 .. _.1 [Ill 
lllin u ~ r thi 
.1 . 
fi rmul : 
in P 
P 8 hinese hamster cells and EM9 (XRCC 1-'-) 
ctor were then labelled S8SN.ll. The EM9 
lab 11 d EM9 N.2 EM9SN.7, EM9SN.ll, 
fi r r suspending in PBS according to the 
:..:..::::=~~==....:..::::~:.!:..:~f~m.!!.e~d=ia = X ml of PBS 
dl JJ I mi \: ith 7 ~I f 11 u pension and left on ice for 10 minutes. 
th 
minute 
r r t 
fl '\\ 1 ni 
4 mm I tr p rati n cu ette and electroporated the cells using 
i at 1 K fern 50. Left on ice for a further 10-
mm ulture plates at three different volumes, in 
ni Incub t d the plates at 37°C for several days 
r tv d s. When colonies could be clearly 
h late and transferred them to separate 25 ml 
with 100mglml G418. 
2.4. ._._ ( th Cl r m in ti n a ays using the scNEO system 
1 x 1 pi ( int h 11 f 6-well plates in 2 ml DMEM and grew for 4 
in (0.5 mg/ml) was added to the medium. From 
100 mm cell culture plate and left overnight to 
..I.5.2. /) wa for 24 hours. Cells treated with 
nt ining dialysed serum. After treatment, cells 
r in 10 ml DMEM for 48 hours. 
r m nt two plates (cloning plates), covered with 
1 ml r \: t 7° fi r 7 days. 2 x 105 cells were also seeded 
r m nt jning 10 ml DMEM (recombination plates) and 
mg/ml ju t d) g neticin (G418) was then added to each 
r m th lat to th incubator for a further 9 days. 
m dia wa pour d off each plate, rinsed x 1 with 
p lu 0.4% in methanol). Colonies were counted and 
ul t th I rung fficiency and the recombination 
Concentration 
100nM 
0.5 mM 
10mM 
3mM 
1-
mi, in thi in tu ith 10 )..1.1 lipofl ctamine2000 in 200)..1.\ serum-
li tu \\ tan {i r 3 minut at r om temperature before 
lieue r 
l ni . 
ddin h 
rumfi tr tm nl. 
J.l1 m and I at 
li 
ml h 
nin m in li 
m in ti n 
ft f in th 
n lh f \ {f. 
lnt m li 
n\ r t n 
nl min 
In 
lat wer prepared by washing the cells in 3 rol 
dd d th mixture to each plate with a further 
7° fI r fi e hours. As a control, added 10 J.lI 
m dia. fter fi e hours removed treatment and 
pi te w r left 0 ernight at 37°C before seeding 
ntinu d a abo 
y u ing the scNEO system 
ct r r combination can occur in one of 
logous ection of the 3' neo gene to remove 
functional neo gene, or a homologous site 
a 
ister chromatid 
pamng 
h rt tr cti~:ne ./ 
ner/" 
Long tract gene 
conversion 
or sister chromatid 
exchange 
I t d fI r by tr ating with neomycin (G418). 
I 0 
Uni it. or h Ili 11 
2.4 . . 
2 .. .1 1 th r urvi 
lal nl 1 0 mm II ultur plates in 10 ml of appropriate media (see 5 
2A.1 all \\ d t r h ur at 37° . Treatments were for continuous for 7 
d r7 
iron \ ' th 
m d I 
2.4. 
d and plates were rinsed x 1 in PBS, before 
lu in 50% m thanol). Colonies bigger than 30 cells 
th per ntage of colonies per treatment plate 
ntr I. 
2 .. 7.1 f th ~rnu tuti n 
PI t 
until 
%m lh 
2.4.1.2 
In 
II in 2 rnl DMEM and left for several days at 37°C 
t d c unt d and approximately 1 x 106 cells 
mm ultur 
ati n l 7° 
unt 
me uring th 
in th presence of a selective agent, G418. 
r tained with 0.4% methylene blue (in 
mbinati n rat in a cell population. The 
rnbinant per total number of cells in the 
1 1 
m in li n r t i th number of recombination events per cell 
di i i n. n \\ h n th fi r t mutation appeared in the population, the 
h \ \arg fl u tuation . Howe er if the cell population is 
appr ximately equal to the number of cells in the 
ul li n lu tu ti n an d t rmine the recombination rate using these 
onul : 
o = ti n f t t 1 cultures with no reversion 
= initi I nurn r of c lIs/culture 
= fin \ nurn r f c lls/culture 
= 11 generations /cell culture = NF-NI / ln2 
> I N = NF/ln2 
= numb r f re ertants per plate = - In Po 
R m in ti n l ' 
- In Po 
11n2 
1i bl _ .7. tit ' I ulalion if the r combination rate 
M N RR 
-0.613 1442695.04 -1.1 8327E-09 
J th r will b a wide fluctuation in revertants from 
In an th t ther will be great variation in the 
h in i idu I lat relati e to the mean number of revertants 
tU f th ntra t if the reversions arise by 
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different plates. In this case, the number of revert ants on each plate is approximately 
equal to the mean number of revertants. 
2.4.8 T-te t 
The Hest assesses whether the data from two groups are statistically different from each 
other. The formula to work out t is: 
variance! + variance2 
sample size sample size 
Once you compute the t-value you have to look it up in a table of significance to test 
whether the ratio is large enough to say that the difference between the groups is not 
likely to have been a chance finding. Usually the significance level is 0.05. This means 
that five times out of a hundred you would find a statistically significant difference 
between the means even if there was none (Le., by "chance"). You also need to 
determine the degrees of freedom (d£) for the test. In the t-test, the degrees of freedom is 
the sample size of both groups minus 2. If the level of significance of the t value is $ 
0.05, then the data is significant. 
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CHAPTER 3: THE ROLE OF PARP-l IN CAMPTOTHECIN-
INDUCED HOMOLOGOUS RECOMBINATION 
3.1 Introduction 
Camptothecin is a topoisomerase I (Topl) inhibitor, and stabilises the transient single-
strand break (SSB) induced in the DNA by Topl (Hsiang, 1985). When this SSB 
encounters an oncoming replication fork, or transcription machinery, a DSB is fonned. 
DSBs are repaired through homologous recombination (HR) (Chadwick & Leenhouts, 
1978) and this mechanism appears to be the major repair pathway for CPT -induced 
DSBs, although non-homologous end joining (NHEJ) also plays an important role 
(Arnaudeau et al., 2001). 
Figure 3.1.1 Top I induces a transient SSB in the DNA. 
CorQ rulxJomaln I 
Core sulxJomain III Carboxy-wmlnaJ clcmah 
Topl is organised into mUltiple subdomains that 'clamp' around the DNA and induce a 
transient SSB in the DNA in order to relax supercoiled DNA. The 3' end of the broken 
DNA strand is covalently linked to the active site tyrosyl group of Top1 (red circle). 
This allows the DNA downstream of the break to rotate, and relaxes the DNA. Topl 
then religates the broken DNA strand. 
From Wang, 2002 
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ePT can stabilise the transient SSB created by Topl by intercalating between upstream 
(-1) and downstream (+1) base pairs, displacing the downstream DNA and preventing 
relegation of the cleaved DNA. This means that the SSB will still be intact when a 
replication fork advances onto it, and cause a DSB to form (CHAPTER 1, Figure 
1.6.1). 
DSBs are lethal to the cell if left unrepaired. Therefore, drugs that inhibit the repair of 
ePT-induced DSBs can enhance the cytotoxicity of camptothecin. This has been shown, 
both in vitro and in vivo, by co-treatment with inhibitors of DNA-dependent protein 
kinase (DNA-PK) or with PARP-1 inhibitors (Bowman et al., 2001), but the mechanism 
is still unknown. 
DNA-PK is involved in the early stages of NHEJ, and is made up of three sub-units, 
DNA-PKcs, Ku70 and Ku80. These three subunits work together to bind the DNA ends 
and recruit other proteins in order to repair the DNA ends by re-alignment, joining and 
re-ligation. DNA-PK inhibitors are likely to enhance the killing of ePT via inhibition of 
NHEJ mediated DSB repair. 
P ARP-1 is a nuclear enzyme that detects single-strand and double-strand breaks in the 
DNA (Neame et al., 1990). Inhibition ofPARP-l affects DNA-PK activity and inhibits 
repair of ionising-radiation (IR) induced DSBs (Veuger et aI., 2004). Thus it is possible 
that P ARP inhibitors affect the NHEJ mediated repair of ePT -induced DSBs. However, 
double knockout mice deficient in both PARP-1 and DNA-PKcs display enhanced 
NHEJ and restored V(D)J recombination, compared to DNA-PKcs knockout mice 
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(Morrison et al., 1997), so this is unlikely. However, inhibition and loss of the protein 
might have different effects. 
PARP-l has been shown to bind to Topl directly (Yung et ai, 2004), and add 
poly(ADP-ribose) polymers to the Topl whilst it is bound to the DNA (Malanga & 
Althaus, 2004). This modifies Topl so that it removes itself from the DNA and religates 
the gap. When the Topl-DNA complex is stabilised by CPT, PARP-l destabilises the 
complex and enhances religation (Park & Cheng, 2005). However, P ARP+1+ cells show 
high sensitivity to CPT, so not all of the complexes can be repaired in this way, leaving 
a lot of SSBs in the DNA. This could explain the increased sensitivity of PARP-/- or 
inhibited cells to CPT. If the Topl-DNA-CPT complex cannot be destabilised by 
PARP-I, this would lead to increased SSBs. Also, tyrosyl-DNA phosphodiesterase I 
(Tdpl) can remove the Topl-DNA-CPT complex from the DNA. However, this leaves 
a SSB, as Tdpl does not enhance religation. In the absence ofPARP-I, Tdpl may try to 
compensate for the lack of PARP-I, but increase the number of SSBs. 
Another possibility is that P ARP inhibitors affect HR mediated repair of CPT -induced 
DSBs. Cell lines deficient in P ARP-l have been shown to have an increase in sister-
chromatid exchange (SCE), which suggests a hyper-recombination phenotype (de 
Murcia et al., 1997; Simbulan-Rosenthal et al., 1999; Wang et al., 1997). Since PARP-l 
can detect DSBs and DSBs are repaired by HR, we were interested to discover the exact 
role of P ARP-l in HR. Here, there are two possibilities; either HR is upregulated by 
loss or inhibition of P ARP-l, or that more DSBs are formed following a defect in SSB 
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repair caused by PARP-l inhibition. However, if HR is upregulated by PARP-l 
inhibition, one would expect resistance to CPT when inhibiting PARP-l. 
3.2 Camptothecin has increased cytotoxicity in PARP-r'- cells 
It has been shown that cells co-treated with CPT and P ARP-l inhibitors have increased 
sensitivity to CPT. When P ARP is inhibited it is suggested that it is irreversibly stuck 
onto DNA strand breaks. Expression of the P ARP-l DNA-binding domain (DBD) acts 
as a dominant negative and results in increased SCE and reduced DNA repair (Masson 
et at., 1995; Molinete et al., 1993). 
PARP-l is a 113 kDa protein that is made up of three domains; the N-terminal DBD (46 
kDa), an automodification domain (22 kDa), and the C-terminal catalytic domain (54 
kDa) (Neame et aI., 1990). The DBD contains two zinc fingers, which bind with high 
affinity to breaks in the DNA. Upon binding, the catalytic domain is stimulated 500-fold 
to produce long polymers of ADP-ribose. These poly(ADP-ribose) polymers can 
modify downstream proteins in the DNA repair pathway, but also bind to P ARP-l, in 
the automodification domain (AMD). Once enough of these ADP-ribose polymers have 
bound to the AMD, P ARP-l leaves the site of the DNA break. This may be because of 
an electrostatic effect; the ADP-ribose polymers are negatively charged, as is the DNA. 
This mechanism is believed to clear a space next to the break for repair enzymes to 
access the break and carry out repair (Lindahl et al., 1995). If only the DBD domain of 
PARP-l binds to the DNA break, the catalytic domain cannot be activated, and no 
poly(ADP-ribose) polymers can form. Therefore, the AMD of PARP-I cannot be 
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automodified, and P ARP-l will not move away from the site of the break, in order for 
repair enzymes to access the break and carry out repair. 
The ability of P ARP to enhance the cytotoxicity of CPT may therefore be because 
PARP-l is bound irreversibly onto CPT-induced SSBs. This prevents the DNA repair 
enzymes from accessing the site of damage, and prevents repair. This unrepaired SSB 
could become a DSB if it collides with an oncoming replication fork, and be lethal to 
the cell. Alternatively, a loss of P ARP-I protein, and therefore its activity, could 
increase sensitivity to CPT. To test this, we treated the PARP-I-1- (All) and PARP-I+1+ 
(AI9) mouse embryonic fibroblast cell line,S continuously with increasing doses of CPT 
for 7 days. 
Figure 3.2 Camptothecin has increased cytotoxicity in PARP-rl- cells 
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PARP-I+1+ (AI9) and PARP-rl- (All) cells were treated in increasing doses ofCPT for 
7 days at 37°C, under an atmosphere containing 5% C02. The effect of CPT on cells is 
expressed as a percentage of controls and the values are the mean ± S.E. of three 
independent experiments. 
We observed that PARP-I-1- cells were more sensitive to CPT than the PARP-I+1+ cell 
line, and showed a 28.7-fold increase in cytotoxicity at a 20 nM dose (figure 3.2), which 
is significant to p < 0.01. This suggests that it is the loss of P ARP-l protein or its 
activity rather than an inability for P ARP-l to be displaced from DNA that is causing 
enhanced CPT sensitivity. 
3.3 Co-treatment of PARP-l+!+ and PARP-1- cells with camptothecin 
and P ARP-l inhibitors increases the killing effect of camptothecin 
The loss of P ARP-I protein and its activity is probably the reason for the increase in 
CPT cytotoxicity. We wondered if the cytotoxicity could be increased further by co-
treating the P ARP-l +1+ and P ARP-l-1- cells with CPT and PARP-l inhibitors, 1,5-
dihydroisoquinoline (ISQ) or 8-hydroxy-2-methylquinazolinone (NUl 025). We treated 
both cells lines continuously in increasing doses of CPT, with 0.6 mM ISQ or 10J..lM 
NUl025. The sensitivity of PARP-l+1+ to CPT is increased by NUl025, 2.2-fold at 10 
nM and 2.9-fold at 20 nM (significant to p < 0.05), but was not significantly increased 
at higher doses, although cells did not survive above 50 nM CPT whilst co-treated with 
lO~M NUI025. PARP-l +1+cells showed increased sensitivity to ISQ, lA-fold at 10 nM 
and 1.5-fold at 20 nM, and did not survive at doses of CPT above 50 nM, whilst co-
treated with 0.6 mM ISQ. However this is not statistically significant. 
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Figure 3.3 Co-treatment of PARP-I+1+ and PARP-rl - cells with camptothecin and 
PARP-I inhibitors increases the killing effect of camptothecin 
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PARP-l +/+ (A19) and PARP-l-/- (All) cells were treated in increasing doses ofCPT 
for 7 days at 37°C, with or without P ARP-l inhibitors, 1,5-dihydroisoquinoline 
(0.6 mM) orNUI025 (10 ~M), under an atmosphere containing 5% C02. The effect of 
CPT and inhibitors on cells is expressed as a percentage of controls and the values are 
the mean ± S.E. of six independent experiments. 
P ARP-I-1- cells did not show a significant increase in sensitivity to CPT whilst co-
treated with NUl025, l.l-fold at 10 nM and l.5-fold at 20 nM, and did not survive at 
110 
------ ._-_._-----------_._--_. 
Institute for Cancer Studies 
lJniversity of Sheffield 
doses above 20 nM CPT when co-treated with 10 ~M NU1025. This lack of survival 
above 20 nM is significant to p < 0.05. Co-treatment with 0.6 mM ISQ had a much 
greater effect on PARP-I-1- cells, with a 4-fold increase in sensitivity at 10 nM and 20-
fold at 20 nM (Figure 3.3). This is statistically significant in t-test to p < 0.01. These 
cells did not survive at doses of CPT above 20 nM whilst co-treated with ISQ 
(statisticaJly significant in t-test, p < 0.05). 
Table 3.3 T-test showing significance of PARP-l +1+ and PARP-rl - cells survival after 
co-treatment with ePT and NUl025 or ISQ. 
CPT 
nM 
0 
10 
20 
30 
50 
60 
80 
100 
A19/NU1025 
0 
0.049255 
0.02105 
0.326214 
0.24318 
0.092639 
0 
0 
A19/1SQ 
0 
0.125528 
0.162976 
0.071714 
0.063262 
0.092639 
0 
0 
A11/NU1025 A11/1SQ 
0 0 
0.386318 0.007428 
0.226132 0.004762 
0.024896 0.024896 
0.029524 0.029524 
0 0 
0 0 
0 0 
These results suggest that the inhibition of PARP-l by ISQ or NUl025 increases the 
cytotoxicity of CPT in P ARP-l +1+ cells, but that cells deficient in PARP-l show a much 
greater sensitivity to ISQ. PARP-I-1- cells do not show increased sensitivity when co-
treated with ePT and NU1025. 
There are several proteins in the PARP family, however PARP-1, PARP-2 and PARP-3 
are thought to have slightly overlapping roles. P ARP-1 is the most abundant of these 
three as P ARP-2 and P ARP-3 are present in the cell at comparatively low levels. 
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Therefore, P ARP-l has the most activity and could be the most important in CPT 
toxicity. However, it could be hypothesised that P ARP-2 and P ARP-3 could 
compensate for the lack ofPARP-l in some way. This increase in cytotoxicity with co-
treatment of CPT and ISQ could be because NUI025 is inhibiting only PARP-l and 
ISQ is inhibiting PARP-2 and PARP-3, as well as PARP-l , and therefore removing any 
compensatory effect. 
The cytotoxicity of CPT is not increased in P ARP-l-/- cells when co-treated with CPT 
and NUI025. This is probably because the PARP-l protein is not present in this cell 
line, so cannot be inhibited. However, an increase in cytotoxicity was observed when 
PARP-l-/- cells were co-treated with CPT and ISQ. This could be because ISQ is 
inhibiting PARP-2 and PARP-3, which of course are present in this cell line, and could 
have a small compensatory effect. This could explain why the cytotoxicity of CPT is 
increased still further in P ARP-l-/- cells. 
3.4 Camptothecin increases the formation of DNA double-stranded 
breaks in P ARP-I-1- cells 
Camptothecin is a topoisomerase I inhibitor (Topl), which stabilises the transient 
single-strand break (SSB) that Topl causes in order to relax the DNA. When this 
stabilised SSB collides with an oncoming replication fork this causes the formation of 
DSBs. It is possible that increased levels of SSBs following inhibition of P ARP-l cause 
more replication forks to collapse, which may result in an increased amount of toxic 
DSBs. 
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Figure 3.4: Camptothecin increases the formation of DNA double strand breaks in 
PARP-rl - cells. 
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PARP-1+1+ (A19) and PARP-I -1- (All) cells were treated with HU (0.5 mM), dT (10 
mM) or CPT (100 nM) for 24 hours at 37°C, under an atmosphere containing 5% C02. 
Cells were then embedded in 0.75% agarose plugs and treated with N-Iaurylsarcosine 
(1 % v/v) and proteinase K (1 mg/ml) for 48 hours at 50°C, to remove cell membranes 
and proteins so that only DNA remains in the plug. Plugs were then embedded in a 
0.8% agarose gel and ran at 4V/cm for 24 hours in a CHEF-DR III pulsed-field gel 
electrophoresis chamber. Switch times were 60-120s and the reorientation angle was 
120°. Double-strand breaks are indicated by the chromosome fragments at 2,200 kb. 
The smears on the PFGE are the result of nucleosomal fragments from apoptosis. 
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To test this we determined the amount of DSBs in P ARP-l +/+ and P ARP-l-/- cell lines 
using a pulsed-field gel electrophoresis (PFGE). Both cell lines were treated with 
0.5 mM hydroxyurea (HU), 10 mM thymidine (dT), or 100 nM camptothecin (CPT) for 
24 hours. HU and dT are both replication inhibitors. HU is a replication fork inhibitor 
that inhibits DNA synthesis by blocking the de novo synthesis of deoxyribonucleotides 
(Thelander & Reichard, 1979), and has previously been shown to cause DSBs (Lundin 
et aI, 2002). dT stalls replication forks by depleting the pool of dCTPs (Bjursell & 
Reichard, 1973), but is not thought to cause DSBs. 
No DSBs were detected in the control or following the dT treatment, and only a small 
increase in the amount of DSB formation was detected following HU treatment of both 
the P ARP-l +/+ and P ARP-l-/- cell lines. However, an increased amount of DSB 
formation was seen in the CPT -treated plug from the P ARP-l-/- cell line, compared to 
the P ARP-l +/+ cell line (Figure 3.4). 
When CPT stabilises the transient SSBs caused by Topl, these SSBs are left unrepaired, 
and can form DSBs if they collide with an oncoming replication fork (CHAPTER 1, 
Figure 1.6.1). These results show that DSBs are formed in both the P ARP-l +/+ and the 
PARP-l-/- cell lines, after treatment with 100 nM CPT, probably due to stabilised SSBs 
colliding with an oncoming replication fork to cause DSBs. There is an increase in 
DSBs caused by CPT in P ARP-l-/- cells. This is probably because there are increased 
levels of SSBs in these cells, because of the lack of PARP-l. Once stabilised, Top 1 
cannot relegate the SSB, leaving an unrepaired SSB in the DNA. In PARP-l+/+ cells, 
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these breaks are detected by PARP-1 and repaired by repair proteins, although this 
repair does not appear to be efficient, as a lot of DSBs are still formed. 
In P ARP-l-I- cells, these SSBs are left undetected and are able to form DSBs when in 
collision with an oncoming replication fork. It seems that any repair of these SSBs, after 
detection by P ARP-1, offers some protection to the cell, and makes sure at least some of 
the SSBs are repaired and do not form DSBs. In the absence of P ARP-I, it could be that 
these SSBs are undetected and that none of the SSBs are detected and therefore lead to 
more DSBs. 
3.5 DNA double-strand breaks are increased in PARP-l+l+ cells co-
treated with camptothecin and PARP-l inhibitors 
CPT causes DSBs in P ARP-I +1+ cells, and this is increased in P ARP-I-I- cells, where the 
P ARP-I protein is absent. We were interested to see if the same effect could be seen if 
PARP-I +/+ cells were co-treated with CPT and ISQ or NUl 025. PARP-1 +1+ and PARP-
}"/-cell lines were treated for 24 hours with 100 nM CPT. PARP-1+1+ cells were also co-
treated with 100 nM CPT and 0.6 mM ISQ or 10 /-lM NU1025 for 24 hours. Cells were 
embedded into plugs and investigated by PFGE. 
CPT -treated plugs from the P ARP-I-I- cells showed an increase in DSBs compared to 
CPT-treated plugs from the PARP-l+l+ cells (Figure 3.5). However, plugs from the 
PARP-I+I+ cells co-treated with CPT and ISQ, or ePT and NUI025 showed an increase 
in DSB formation, to the same level as the breaks detected in plugs from the P ARP-I-1-
cell line. 
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Figure 3.5: DNA double-strand breaks are increased in PARP-]+I+ co-treated with 
camptothecin and PARP-] inhibitors. 
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PARP-l -/- (All) cells were treated with CPT (100 nM) and PARP-1+/+ (A19) were 
treated with CPT (100 nM) with or without 1,5-dihydroisoquinoline (ISQ, 0.6 mM) or 
NU1025 (10 JlM) for 24 hours at 37°C, under an atmosphere containing 5% C02. Cells 
were then embedded in 0.75% agarose plugs and treated with N-Iaurylsarcosine (1 % 
v/v) and proteinase K (1 mg/ml) for 48 hours at 50°C, to remove cell membranes and 
proteins so that only DNA remains in the plug. Plugs were then embedded in a 0.8% 
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agarose gel and ran at 4V/cm for 24 hours in a CHEF-DR III pulsed-field gel 
electrophoresis chamber. Switch times were 60-120s and the reorientation angle was 
1200 • Double-strand breaks are indicated by the chromosome fragments at 2,200 kb. 
The smears on the PFGE are the result of nucleosomal fragments from apoptosis. 
This shows that PARP-1+1+ cells inhibited with ISQ or NU 1025 have the same level of 
DSBs as PARP-I-1- cells when treated with CPT. Therefore, it is the lack of PARP-1 
protein activity that increases the level of SSBs, not the lack of the P ARP-l protein 
itself. This also shows that the inhibition of P ARP-l increases the number of CPT-
induced DSBs formed in P ARP-l +1+ cells, probably due to increased levels of SSBs in 
these cells which cause more replication forks to collapse and result in an increased 
amount of toxic DSBs. 
3.6 Co-treating PARP-r'- cells with camptothecin and PARP-l 
inhibitors increases the amount of DNA double-strand break 
formation 
We have observed an increase in CPT cytotoxicity when PARP-l+1+ cells are co-treated 
with CPT and PARP-l inhibitors. We have also noted an increase in CPT cytotoxicity 
in P ARP-I -1- cells as compared with PARP-I +1+ cells. We have noticed a further increase 
in CPT cytotoxicity when PARP-I-1- cells are co-treated with CPT and ISQ. ISQ is 
known to inhibit several PARP proteins, unlike NUI025, which is specific for PARP-l. 
Therefore it is possible that an increased amount of cytotoxicity could be seen due to 
removal of some compensatory effect from PARP-2 and PARP-3. If this is the case, you 
would expect to see a further increase in DSB formation in P ARP-I-1- cells when co-
treated with CPT and ISQ. 
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Figure 3.6: Co-treating PARP-rl - cells with camptothecin and PARP-l inhibitors 
increases the amount of DNA double-strand break formation. 
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PARP-l +1+ (A19) and PARP-1 -1- (All) were treated with 1,5-dihydroisoquinoline (ISQ, 
0.6 mM) or NUI025 (10 f.!M) with or without CPT (100 nM) for 24 hours at 37°C, 
under an atmosphere containing 5% C02. Cells were then embedded in 0.75% agarose 
plugs and treated with N-laurylsarcosine (1 % v/v) and proteinase K (1 mg/ml) for 48 
hours at 50°C, to remove cell membranes and proteins so that only DNA remains in the 
plug. Plugs were then embedded in a 0.8% agarose gel and ran at 4V /cm for 24 hours 
in a CHEF-DR III pulsed-field gel electrophoresis chamber. Switch times were 60-120s 
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and the reorientation angle was 1200 • Double-strand breaks are indicated by the 
chromosome fragments at 2,200 kb. The smears on the PFGE are the result of 
nucleosomal fragments from apoptosis. 
To investigate this, PARP-l +1+ and PARP-rl- cell lines were treated for 24 hours with 
100 nM CPT, or co-treated with 100 nM CPT and 0.6 mM ISQ or 100 nM CPT and 
10 j.lM NUl025. Both cell lines were also treated for 24 hours with 0.6 mM ISQ or 10 
j.lM NU l 025 alone. Cells were embedded into plugs and analysed using PFGE. 
As already seen, the CPT-treated plug from the PARP-rl - cell line showed an increase 
in DSBs, compared to the PARP-l +1+ cell line (Figure 3.4), and the plugs from the 
PARP-l+/+ cell line co-treated with CPT and ISQ, or CPT and NUI025, showed an 
increase in DSBs compared to being treated with CPT alone (Figure 3.5). However, 
plugs from the P ARP-l -1- cell line that had been co-treated with CPT and ISQ, or CPT 
and NUl 025, did not show a further increase in DSB formation (Figure 3.6). 
These results show an increase in DSBs in P ARP-l +/+ cells when co-treated with CPT 
and PARP-l inhibitors, NUl 025 or ISQ, compared to PARP-l+1+ cells treated with CPT 
alone. The results also show that there is no increase in DSB formation in P ARP-1- cells 
when co-treated with CPT and PARP-l inhibitors, NUI025 or ISQ. This would suggest 
that PARP-2 and PARP-3 do not cause an increase in DSBs and so any increase in CPT 
cytotoxicity caused by co-treatment of cells with CPT and ISQ is not due to an increase 
in DSB formation. 
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3.7 Camptothecin-induced RAD51 foci formation is increased in 
PARP-l-/- cells 
RAD51 foci are small nuclear foci containing all of the proteins involved in 
homologous recombination (HR). These foci form whenever the cell undergoes HR, and 
a measurement of these can be used as an indication of the amount of HR that is taking 
place within a cell. 
Homologous recombination (HR) appears to be the major repair pathway for ePT-
induced DSBs, so to determine if HR is increased in P ARP-l +/+ and P ARP-l-/-cells 
when treated with ePT, we measured the amount of RAD51 foci formed in cells from 
both cell lines when treated with ePT and when no treatment was given. The P ARP-l +/+ 
and P ARP-l-/- cell lines were treated with 100 oM ePT for 24 hours and fixed onto 
coverslips. 
The level of RAD51 foci was examined using immunofluorescence. P ARP-l -/- cells 
have an increased amount of spontaneous RAD51 foci compared to PARP-l +/+ cells 
(Figure 3.7. 1), 10.4% of P ARP-l -/- cells have> 10 RAD51 foci per cell compared to 
3.2% of P ARP-l +/+ cells. This is a 3.3-fold significant difference (p < 0.05). Both 
P ARP-l +/+ and P ARP-l-/-cells have an increased amount of RAD51 foci formation after 
a 24 hour treatment with ePT, 21-fold and 8.8-fold respectively, above their 
spontaneous levels. PARP-l-/-cells, however, have a much higher level of RAD51 foci 
formation, 92% of PARP-l-/- cells compared to 67% of PARP-l +/+ cells. This is a 1.4-
fold significant difference (p < 0.001) (figure 3.7.2). 
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Figure 3. 7. J,' Rad5 J foci in untreated P ARP +/+ and P ARP -/- cells. 
PARP +1+ PARP -1-
PARP-I+1+ (AI9) and PARP-I-1- (All) cells were fixed in 3% paraformaldehyde, and 
incubated with anti-Rad51 primary antibody, and then a Cy3-conjugated antibody. 
Images were obtained with a confocal microscope and manipulated using SoftWorx. 
These results suggest that HR is increased spontaneously in P ARP-1- cells, probably 
because of an increase in SSBs leading to DSB formation when encountered by 
replication machinery, and that HR is the preferred mechanism for the repair of these 
DSB. HR is also shown to be increased in PARP-l+1+ cells when treated with CPT. This 
suggests that HR is the major pathway for the repair of CPT -induced damage. 
In this assay, it was noted that there was an increase in RAD51 foci in P ARP-1- cells 
treated with CPT. This suggests that HR is increased in this cell line when treated with 
CPT. It was also noted that this increase in HR was above the level observed for CPT-
treated P ARP-I +1+ cells. It has already been noted that there is an increased amount of 
RAD51 foci in untreated P ARP-1- cells. This could be accounted for because of the 
hyper-recombination phenotype of this cell line. This further increase in HR when 
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treated with CPT could be due to a synergistic effect. There is already increased HR in 
these cells, but HR is increased further in order to repair an increased number of DSB 
lesions caused by CPT. 
Figure 3. 7. 2: Camptothecin-induced Rad51 foci formation is increased in PARP-rl-
cells. 
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P ARP-1 +/+ (A 19) and P ARP-1-/- (A 11) cells were treated with 100 nM CPT for 24 hours 
at 37°C, under an atmosphere containing 5% C02. Cells were then fixed in 3% 
paraformaldehyde, and incubated with anti-Rad51 primary antibody, and then a Cy3-
conjugated antibody. The effect of CPT on cells is expressed as a percentage of cells 
containing more than 10 Rad51 foci and the values are the mean ± S.E. of three 
independent experiments. 
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3.8 Co-treatment of PARP-l+l+ and PARP-I- cells with camptothecin 
and 1,S-dihydroisoquinoline significantly increases the amount of 
RADSl foci formation in PARP-I-I- cells but not in PARP-l+l+ cells 
We have observed an increased amount of RAD51 foci fonnation in PARP-1-1- cells, 
and in PARP-1+1+ and PARP-l"/- cells treated with ePT. We have also noticed an 
incr ased amount of RAD51 foci fonnation in PARP-1-1- cells treated with ePT, 
compared with P ARP-l +1+ cells. This could be due to an increase in SSB accumulation 
in P ARP-l-/- cells, compared to PARP-1 +1+ cells, leading to an increase in DSBs, which 
are repaired by HR. In fact, we have seen an increase in the amount of DSBs in 
PARP-rl- cells treated with ePT. We have also observed an increase in DSBs In 
P RP_rl- c lI s co-treated with ePT and PARP-I inhibitor, ISQ. 
Therefore we were interested to see if the amount of RAD51 foci is increased in 
P ARP-l +1+ and PARP-I-1- cell lines co-treated with ePT and P ARP-1 inhibitor, ISQ. 
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Figure 3.8: Co-treatment of PARP-1+1+ and PARP-rl - cells with camptothecin and 1,5-
dihydroisoquinline does not significantly increase the amount of Rad51 foci 
formation. 
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PARP-1+1+ (A19) and PARP-1-1- (All) cells were treated with 100 nM camptothecin 
(CPT), 1,5-dihydroisoquinoline (ISQ) (0.6 mM) or a co-treatment of both, for 24 hours 
at 37°C under an atmosphere containing 5% C02. Cells were then fixed in 3% 
paraformaldehyde, and incubated with anti-Rad51 primary antibody, and then a Cy3-
conjugated antibody. The effect of CPT on cells is. expressed as a percentage of cells 
containing more than 10 Rad51 foci and the values are the mean ± S.E. of three 
independent experiments. 
As already seen, P ARP-l-/- cells have an increased amount of spontaneous RAD51 foci 
(Figure 3.7), and RAD51 foci formation is greatly increased in both cell lines after 
treatment with CPT, but significantly higher in PARP-1-1- cells. Treatment with ISQ 
alone slightly increases the amount of RAD51 foci formation (Figure 3.8), 5.8% of 
PARP-l +1+ cells have > 10 RAD51 foci per cell, and 14.5% of PARP-1-1- cells, but this is 
not significant. 
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The amount of RAD51 foci formation in P ARP-l +/+ cells after co-treatment with CPT 
and ISQ was slightly decreased (58.8%), compared to treatment with CPT only 
(66.7%), but not significantly. In contrast, in PARP-l-/-cells, co-treatment with CPT and 
ISQ significantly increased (p < 0.01) the amount ofRAD51 foci (99.7%), compared to 
treatment with CPT only (91.8%). 
These results show that treatment of PARP-l-/- cells with ISQ slightly increases the 
amount of RAD51 foci, and therefore the amount of HR, but this is not significant. 
These results also suggest that there is an increase in RAD51 foci formed in P ARP-l -/-
cells co-treated with CPT and ISQ, compared to P ARP-I-I- cells treated with CPT 
alone. This is not seen in the P ARP-l +/+ cell line, which actually shows a slight decrease 
in the amount of RAD51 foci formation when co-treated with CPT and ISQ, compared 
to P ARP-l +/+ cells treated with CPT alone. 
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3.9 Discussion 
P ARP-I-I- cell lines are hypersensitive to CPT, which suggests that P ARP-l has a role in 
the repair of the damage caused by this drug. We have shown that CPT induces the 
formation ofDSBs in both wildtype and PARP-I-I- cell lines, but that there are a 
greater number of DSBs in the deficient cell line. One hypothesis is that that the repair 
of the DSBs in the PARP-r/- cell line is decreased, leading to an increase in this 
particular lesion. Alternatively, the number ofDSB lesions is increased due to loss of 
some other repair pathway that may result in an increased number of DSBs. 
HR is an important pathway in repair ofCPT-induced DSBs (Amaudeau et al., 2001). 
Although HR deficient cell lines (irsl SF) and NHEJ deficient cell lines (V3-3) are more 
sensitive to CPT than wildtype cells, the HR deficient cell line was more senstitive than 
the NHEJ deficient cell line. We see an increase in the amount of RAD51 foci formation 
in cells that lack P ARP-l, indicating that the level of HR repair has increased .. Thus, it 
appears that there is no general loss of DSB repair by HR in P ARP-I-I- cells, which is 
also supported from the literature. Previously, it was found that the level ofDSB repair 
by HR is not altered in cells with inhibited or lost PARP activity (Schultz et al., 2003; 
Yang et al., 2004). Alternatively, the increased amount ofDSBs may reflect that 
PARP-l inhibits the NHEJ pathway. However, this pathway appears less important in 
repairing CPT-induced DSBs than HR (Arnaudeau et al., 2001). In conclusion, our data 
supports the second hypothesis, that loss of P ARP-l may affect some other repair 
pathway that may result in an increased number of DSBs. 
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We know that CPT stabilises the transient SSB induced by Topl, and that SSBs are 
repaired by base excision repair (BER). P ARP-l has been shown to interact with 
proteins involved in the SSB repair pathway, and binds directly to the SSB repair 
scaffold protein, XRCC 1 (Masson et al., 1998). We also know that P ARP-l can 
recognise SSBs and does this with a very high affinity. Thus, the role ofPARP-l in 
SSB repair may be relevant to explain the increased number of DSBs found when 
inhibiting or losing PARP-l. 
P ARP-l has been shown to bind to Top 1 directly (Yung et al, 2004), and add 
poly(ADP-ribose) polymers to the Topl whilst it is bound to the DNA (Malanga & 
Althaus, 2004). This modifies Topl so that it removes itself from the DNA and religates 
the gap. When the Topl-DNA complex is stabilised by CPT, PARP-l destabilises the 
complex and enhances religation (Park & Cheng, 2005). However, P ARP+1+ cells show 
high sensitivity to CPT, so not all of the complexes can be repaired in this way, leaving 
a lot of SSBs in the DNA. 
We hypothesise that when PARP-l binds to a SSB, it attracts XRCCl via PARP-l 's 
poly(ADP-ribosyl)ation of itself (Caldecott, 2003), to carry out efficient SSB repair. In 
PARP-rl- cells, the Topl-DNA-CPT complex is not destabilised by PARP-l. However, 
the Top! can be removed from the DNA by tyrosyl-DNA phosphodiesterase 1 (Tdpl), 
leaving a SSB in the DNA (Vance & Wilson, 2001). Because of the absence ofPARP-
1 SSB repair proteins are not brought to the site of the break and SSB repair is reduced, 
which results in an increased amount of open SSBs. This may lead to more SSBs 
collapsing at replication forks and thus more DSBs. An increase in collapsed forks will 
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in turn leads to an increase in HR to repair the DSBs. This model would explain the 
increase in RAD51 foci observed in PARP-1- or inhibited cells (Figure 3.1.7 and Figure 
3.1.8). Also, this model explains how P ARP-l inhibitors, for example, ISQ and 
NUI025, increase the cytotoxicity of wild type cells to ePT, and increase the number of 
DSBs in these cells when co-treated with these drugs. 
One important issue is whether PARP-l itself or P ARP activity is important for the 
increased toxicity with P ARP inhibitors. One idea is that inhibited P ARP-l may act as a 
negative regulator ofDNA-PK-dependent NHEJ, while the absence ofPARP-l does not 
show the same inhibitory effect (Veuger, 2004). Here, we find an increased number of 
DSBs and hypersensitivity to ePT in PARP-l-/- cells as well as when inhibiting 
P ARP- l. These data suggest that the activity of P ARP-l is important for survival and to 
avoid forming DSBs at replication forks . 
We did see that inhibition with ISQ has greater effect than NUI025 on production of 
ePT-induced DSBs and cytotoxicity. One reason might be that ISQ is more efficient 
than NUI025 in inhibiting PARP-l. However, the PARP-l enzyme is fully inhibited at 
the doses used here. Rather, we believe that ISQ is less specific for PARP-l and may 
inhibit other PARP-l 's more efficiently that NUI025. In support for this view is that 
P ARP-I-1- cells are further sensitised to ePT with ISQ, while NUl 025 does not sensitise 
PARP-1"/- cells to ePT. 
This can be explained by the presence of other P ARP family proteins in mammalian 
cells. There are a number ofPARP proteins in the PARP family, two of which can be 
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found in the mammalian nucleus, P ARP-l and P ARP-2. P ARP-l is the most abundant, 
but these other P ARP proteins may also be affected by the P ARP inhibitors and 
contribute to the increased amount of DSBs. Thus, the additional killing effect with ISQ 
could be related to that both P ARP-l and PARP-2 are inhibited, which may be 
additionally lethal since P ARP-l and P ARP-2 double knockout mice die in utero 
(deMurcia, 2000). Alternatively, ISQ may have additional effects, such as being a 
topoisomerase inhibitor. If this is the case one may expect additional killing with ISQ 
that is unrelated to P ARP inhibition. P ARP-I-I- cells also show an increase in RAD51 
foci after co-treatment with CPT and the PARP-l inhibitor, ISQ, probably as a result of 
the increased number ofDSBs, possibly due to additional effects with ISQ. 
This rise in RAD51 foci after co-treatment of CPT and ISQ, is not seen in PARP-l +1+ 
cells, in fact the percentage of cells displaying RAD51 foci is slightly decreased, but not 
to a significant level. This may be because PARP-l inhibitors do not completely deplete 
the cell of P ARP activity, whereas the activity of this protein is completely diminished 
in the PARP-I-1- cells. Therefore, there is still some background activity in P ARP-I after 
treatment with the P ARP inhibitors, but in the P ARP-I-I- cells, there is none. Therefore 
there is more of an effect if the other two proteins are inhibited. 
If as we predict from the hyper-recombination phenotype, HR repair is increased 
following inhibition of P ARP, and CPT causes DSBs that can be repaired by HR then 
one would imagine that inhibition of P ARP would in fact decrease sensitivity to CPT 
rather than enhance it. However, we have seen that this is not the case. The inhibition of 
PARP-l increases the sensitivity ofCPT. 
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In conclusion, we suggest that the role of PARP-I in SSB repair of ePT lesions most 
likely explains the results found. The inhibition of P ARP-l may slow the repair of ePT-
induced SSBs, which in turn would lead to more SSBs collapsing at replication forks 
and thus more DSBs. This is a plausible mechanism although it is not clear whether 
P ARP- l binds the SSB within the ePT stabilised Topo I cleavage complex. 
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CHAPTER 4: THE ROLE OF XRCCl IN CPT-INDUCED 
HOMOLOGOUS RECOMBINATION 
4.1 Introduction 
In the previous chapter, we showed that camptothecin (CPT) has increased cytotoxicity 
in P ARP-I-I- cells due to an increased amount of DNA double strand breaks (DSBs) 
formed. We also showed that RAD51 foci formation is increased in camptothecin (CPT) 
treated PARP-I-1- cells, indicating that homologous recombination (HR) is increased in 
these cells. We saw an increase in DSBs whether PARP-l was absent or inhibited, 
demonstrating that it is the activity of the enzyme that is important for protection 
against CPT toxicity. 
CPT stabilises the transient single strand break (SSB) induced by topoisomerase I 
(Top 1) (Hsiang, 1985), which increases the number of unrepaired SSBs in the cell. 
PARP-l binds to Top! (Yung et ai, 2004) and adds poly(ADP-ribose) polymers to the 
protein, which allows it to destabilise from the Topl-DNA-CPT complex (Malanga & 
Althaus, 2004; Park & Chung, 2004 ). P ARP-l also recognises SSBs with a very high 
affinity and is required for efficient repair of SSBs (Trucco et ai, 1998). When PARP-l 
is absent or inhibited, it cannot destabilise the Topl-DNA-CPT complex. This leads to 
Topl being removed from the DNA by Tdpl, leaving a SSB. IfSSBs are not repaired 
they collapse into replication forks which leads to DSB formation. Thus, the role of 
PARP-l in SSB repair may explain the increased number ofDSBs found when 
inhibiting or losing P ARP-l. Further, an increase in collapsed forks would in turn lead 
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to an increase in HR to repair the DSBs, which would explain the increase in RAD51 
foci observed in P ARP deficient or inhibited cells. 
PARP-l 's role in SSB repair may be due to its interaction with the BER scaffold 
protein, x-ray repair cross-complementing 1 (XRCCl) (Masson et al., 1998). Following 
oxidative damage in the absence of P ARP-l , XRCC 1 does not form foci at the sites of 
damage and it is thought that following SSB formation, P ARP-1 binds to the break, is 
activated, and autoribosylates itself, as XRCCl preferentially interacts with modified 
P ARP-l it is then attracted to the site of damage. Therefore we hypothesis that in 
P ARP-I -I- cells, it is this inability or reduced ability for XRCC 1 to sense CPT -induced 
SSBs which is responsible for reduced SSB repair and hence increase DSB formation 
and HR we observe. 
4.2 Increased cytotoxicity to camptothecin in XRCCl defective cells 
CPT stabilises the transient SSB created by Topl by binding and intercalating between 
upstream (-1) and downstream (+1) base pairs, displacing the downstream DNA and 
preventing relegation of the cleaved DNA, which in turn leaves Top1 covalently bound 
to the DNA (Beidler & Cheng, 1995). This leaves an unrepaired SSB in the DNA which 
must be repaired before it collides with the oncoming replication machinery, and results 
in a DSB. 
PARP-l is a 113 kDa protein that is made up of three domains; the N-terminal DNA-
binding domain (DBD) (46 kDa), an automodification domain (AMD) (22 kDa), and 
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the C-terminal catalytic domain (CTD) (54 kDa) (Neame et al., 1990). The DBD 
contains two zinc fingers, which binds with high affinity to breaks in the DNA. Upon 
binding, the CTD is stimulated SOO-fold to produce long polymers of ADP-ribose. 
These polymers are added to several downstream proteins, but are predominantly added 
to the auto-modification domain ofPARP-l. 
Figure 4.2.1 XRCCl binds PARP-1 and DNA ligase III through BRCT motifs. 
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Adapted from Masson et al., 1998 
XRCC1 has been shown to bind preferentially to automodified PARP-l, indicating that 
PARP-l may function to recruit SSB repair proteins to the site of damage (Masson et 
al. , 1998). When PARP-1 detects a SSB, it binds to it, triggering automodification. 
XRCC 1 binds to the automodified P ARP-1, bringing with it proteins involved in SSB 
repair. XRCC1 has no demonstrated catalytic activity, and is thought to be a scaffold 
protein interacting directly with DNA ligase III and DNA polymerase P (Caldecott, 
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2003) (Figure 4.2.1). XRCCl binds DNA ligase III through a breast cancer protein 1 
carboxyl terminus (BRCT) motif. These are folding units of about 90-100 amino acids, 
and so called because they were first identified in breast cancer cells. These BRCT 
motifs consist of four p-strands forming a core sheet structure and two a-helices, and 
are important in specific protein-protein interactions (CHAPTER 1, Figure 1.5). In 
fact BRCT motifs have been found in many DNA-damage responsive and cell cycle 
check-point proteins. DNA ligase III contains a BRCT motif in its C-terminal domain, 
amino acids 841 to 922, and XRCC 1 contains two BRCT motifs, one at amino acids 
314 to 402, and another in the C-terminal at amino acids 538 to 622. XRCCl binds 
DNA ligase III through its C-terminal BRCT motif. 
XRCCl binds DNA polymerase p through its N-terminal domain, amino acids 1 to183. 
This section of the XRCCl protein also binds to SSBs in the DNA (Marintchev et al., 
2000). The three-dimensional structure of the N-terminal domain of XRCC 1 has been 
reported, and has been shown to be well-suited to the inside curvature of 90° bent DNA 
(Marintchev et al., 1999). When P ARP-I binds to SSBs in the DNA, it induces a V-
shape bend in the DNA. P ARP-I eventually moves away from the DNA, leaving room 
for the repair proteins to access the break. It may be that XRCC 1 then binds the site 
recently vacated by PARP-l , bringing DNA polymerase p and DNA ligase III to the 
site. XRCCI binds DNA polymerase p via its N-terminal region, but this domain has a 
much higher affinity for SSBs in the DNA, approximately 100 times greater. It could be 
that XRCCI binds DNA polymerase p via the N-terminal, which is then possibly 
released upon binding to a SSB. 
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XRCC 1 binds P ARP-l through its central BRCT motif which binds directly with a 
BRCT motif within PARP-l 's automodification domain (AMD). This is the domain 
where P ARP-l automodifies itself by adding ADP-ribose polymers and XRCC 1 
preferentially binds to automodified PARP-l. PARP-1 binds XRCCl through its BRCT 
motif, and also with the zinc-fingers found within the N-terminal region. The 
XRCC 1 defective cell line (EM9) contains XRCC 1 that has a frameshift mutation at codon 
22 1. This results in a truncated protein (Figure 4.2.2) that is missing two thirds of the 
normal sequence (Shen et al., 1998). Therefore EM9 is effectively a null mutant, whose 
properties can be compared to cell lines carrying a knock-out mutation (Tebbs et al., 
1999). 
Figure 4.2.2 Structure ojXRCCl in EM9 cells compared tojulllengthXRCC1. 
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We observed that XRCCl defective EM9 cells were more sensitive to CPT than the 
wildtype cell line (AA8), and showed a 1.7-fold increase in cytotoxicity at a 40 nM dose 
(figure 4.2.4), which is statistically significant to p < 0.05 in t-test. The sensitivity of 
EM9 cells to CPT increased to 2.5-fold at 50 nM, 4.4-fold at 75 nM (p < 0.01), and 8.2-
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fold at 100 nM (p 0.001). This suggests that in the absence ofXRCCl, SSBs cannot be 
repaired, or are repaired more slowly, because the SSB repair proteins cannot reach the 
site of damage. Whether there is no repair, or whether it is slower repair is unclear. 
Figure 4.2.3: Camptothecin has increased cytotoxicity inXRCCldejeclive cells 
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XRCCl wt (AA8) and XRCCI defective (EM9) cells were treated in increasing doses of 
CPT for 7 days at 37°C, under an atmosphere containing 5% C02. The effect of CPT 
on cells is expressed as a percentage of controls and the values are the mean ± S.E. of 
three independent experiments. 
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4.3 Co-treatment of XRCCl wt and XRCCl defective cells with 
camptothecin and PARP-l inhibitors increases the killing effect of 
camptothecin 
We know that XRCC 1 binds to automodified P ARP-1, and brings the SSB repair 
proteins, DNA ligase III and DNA polymerase p to the site of SSBs. We have seen that 
the absence ofPARP-1 increases the cytotoxicity ofCPT to the cell (figure 3.2), and 
that inhibiting PARP-1 with ISQ or NUI025 has the same effect (figure 3.3). We have 
also seen that the absence of XRCC 1 increases the cytotoxicity of ePT to the cell 
(figure 4.2.3). 
Our hypothesis is that this increase in sensitivity to CPT is because P ARP-1 detects the 
SSBs stabilised by CPT, and that PARP-1 signals to XRCCl to come to the site of the 
l?reak. In the absence of either of these proteins, SSB repair would be slower, or 
completely impaired. Consequently, more SSBs would become DSBs after being 
encountered by the replication machinery. To test ifPARP-l and XRCC1 act in the 
same pathway, we co-treated XRCC 1 defective EM9 cells with increasing doses of CPT 
and PARP-1 inhibitors, NU1025 (10 j..lM) or 1,5-dihydroisoquinoline (ISQ) (0.6 mM). 
We observed that wildtype cells are sensitive to higher doses of CPT; there was 35% 
survival at 80 nM CPT, and 17% survival at 100 nM CPT (figures 4 .. 3.2 and 4.3). 
When this cell line was co-treated with NU1025, survival decreased 1.7-fold at 80 nM 
CPT and 2-fold at 100 nM CPT (statistically significant in t-test, p < 0.01). When 
XRCC1wt cells were co-treated with CPT and 0.6 mM ISQ, survival was decreased still 
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further. Survival was decreased 4-fold at 50 nM CPT, 7-fold at 60 nM CPT, 44-fold at 
80 nM CPT and 66-fold at 100 nM CPT (statistically significant to p < 0.001). 
Figure 4.3: Co-treatment of XRCCr
' 
and XRCClde/eclive cells with camptothecin and 
PARP-I inhibitors increases the killing effect of camptothecin. 
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XRCC1'vt (AAS) and XRCC1defective (EM9) cells were treated in increasing doses of 
CPT for 7 days at 37°C, under an atmosphere containing 5% C02. Some cells were co-
treated with 10 j..lm NUl 025 or 0.6 mM ISQ. The effect of CPT on cells is expressed as 
a percentage of controls and the values are the mean ± S.E. of three independent 
experiments. 
In addition, we observed that XRCC1 defective EM9 cells are even more sensitive to CPT, 
as shown infigure 4.2.3, and that this sensitivity is also increased when co-treated with 
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CPT and 10~M NUI025 or 0.6 mM ISQ (figure 4.3). Survival was decreased 2-fold at 
50 nM CPT when treated with CPT alone (statistically significant in t-test, p < 0.01), 
and decreased further by 3-fold at 60 nM CPT, 6-fold at 80 nM CPT, and 12-fold at 100 
nM CPT (statistically significant in Hest, p < 0.001). When co-treated with CPT and 
10 ~M NUI025, survival at 50 nM, 60 nM, 80 nM, and 100 nM CPT, was 3-fold, 4-
fold, 20-fold and 50 fold respectively (statistically significant in Hest, p < 0.001), 
compared to survival of wild type cells. 
XRCCl defective cells showed even greater sensitivity to CPT when co-treated with 0.6 
mM ISQ. Survival was decreased 3 I-fold at 50 nM CPT, and lOO-fold at 60 nM CPT. 
No cells survived at higher concentrations of CPT (statistically significant in Hest, 
p < 0.001). This data suggests that both XRCCl and PARP-l are required for survival 
following CPT treatment. 
4.4 Increased formation of DNA double strand breaks following 
camptothecin treatment in XRCCl defective cells 
Our hypothesis is that the absence ofXRCCI in the cell increases the amount of 
unrepaired SSBs, as DNA ligase III and DNA polymerase ~ are not brought to the site 
of the SSB. These two proteins are usually bound to the scaffold protein, XRCCl, and 
carried to the site of damage. In the absence of XRCC 1, this is not likely to happen, and 
this would explain slower SSB repair, as the proteins need to find SSBs independently 
of XRCC 1. If this is indeed the case, you would expect to find an increased amount of 
DSBs in the cell, as the SSBs are encountered by oncoming replication forks. 
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Figure 4.4: Camptothecin increases the formation of DNA double strand breaks in 
XRCCldejec'ive cells. 
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XRCC l wt (AA8) and XRCC 1 defective (EM9) cells were treated with HU (0.5 mM), dT 
(l 0 mM) or CPT (lOO nM) for 24 hours at 37°C, under an atmosphere containing 5% 
C0 2. Cells were then embedded in 0.75% agarose plugs and treated with N-
laurylsarcosine (1 % v/v) and proteinase K (1 mg/ml) for 48 hours at 50°C, to remove 
cell membranes and proteins so that only DNA remains in the plug. Plugs were then 
embedded in a 0.8% agarose gel and ran at 4V/cm for 24 hours in a CHEF-DR III 
pulsed-field gel electrophoresis chamber. Switch times were 60-120s and the 
reorientation angle was 120°. Double-strand breaks are indicated by the chromosome 
fragments at 2,200 kb. 
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dT is a replication inhibitor that stalls replication forks by depleting the pool of dCTPs 
(Bjursell & Reichard, 1973), but is not thought to cause DSBs (Lundin et al., 2002). 
MNNG is a monofunctional alkylating agent that is extremely mutagenic. This agent 
methylates the N3 position of adenine and N7 and 0 6 position of guanine, however it is 
thought that the 0 6MeG lesion is the most mutagenic (Goldmacher et al., 1986; Karran 
and Bignami, 1992). The N3MeA and N7MeG are efficiently repaired by SSB repair, 
but the 0 6MeG lesion is not. After DNA replication, the 0 6MeG lesion is recognised as 
an adenine instead of a guanine and is mismatched in the new DNA strand with 
thymidine. This is primarily repaired via direct demethylation by methylguanine-DNA 
methlytransferase (MGMT) (Lindahl et al., 1982) but is also recognised and repaired by 
mismatch repair (MMR) (Griffin et al., 1994; Duckett et al., 1996). 
No DSBs were detected in the control or following the dT treatment and in the 
XRCCl \\1 cell line after CPT or MNNG treatment. However, an increased amount of 
DNA fragmentation was seen in the MNNG-treated and CPT-treated plugs from the 
XRCC 1 defective cell line, compared to the XRCC 1 M cell line (Figure 4.4). It is unlikely 
that the DNA fragmentation following MNNG treatment represents real DSBs as 
methylated DNA is heat-labile and converts to SSBs, which when close to another SSB 
will resulting a DSB (Lundin et al., 2005). The increase in DSBs seen supports our 
hypothesis that lack of XRCC 1 decreases SSB repair following CPT induced DNA 
damage. 
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4.5 Camptothecin-induced RAD51 foci formation is increased in 
XRCCl defective cells 
RAD5l foci are small nuclear foci containing all of the proteins involved in 
homologous recombination (HR). These foci form whenever the cell undergoes HR, and 
a measurement of these can be used as an indication of the amount of HR that is taking 
place within a cell. 
HR appears to be the major repair pathway for CPT -induced DSBs, so to determine if 
HR is increased in XRCCl wt and XRCCldefective cells when treated with CPT, we 
measured the amount of RAD5l foci formed in cells from both cell lines when treated 
with or without 100 nM CPT for 24 hours. 
The level of RAD51 foci in XRCC 1 wt and XRCC 1 defective cells was examined using 
. fl XRCCldefective 11 h . d f Immuno uorescence. ce save an Increase amount 0 spontaneous 
RAD51 foci compared to XRCCl wt cells (Figure 4.5),42% ofXRCCldefcctivc cells have 
> 10 RAD51 foci per cell compared to 2.4% of XRCCl wt cells. This is a 17-fold 
significant difference (statistically significant in t-test, p < 0.001). Both XRCCl wt and 
XRCC 1 defective cells have an increased amount of RAD5l foci formation after a 24 hour 
treatment with CPT, l4-fold (p < 0.05) and 3-fold (p < 0.001) above their spontaneous 
lev Is) respectively. XRCCl defective cells however, have a much higher level of RAD5l 
foci formation, 95% of XRCCl defective cells compared to 33% of XRCCl wt cells. This is 
a 2.9-fold significant difference (p < 0.01). 
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Figure 4.5: Camptothecin-induced RAD51 foci formation is increased in 
XRCClde/ective cells. 
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XRCC 1 wt (AAS) and XRCC 1 defective (EM9) cells were treated with 100 nM CPT for 24 
hours at 37°C, under an atmosphere containing 5% C02. Cells were then fixed in 3% 
paraformaldehyde, and incubated with anti-Rad51 primary antibody, and then a Cy3-
conjugated antibody. The effect of CPT on cells is expressed as a percentage of cells 
containing more than 10 Rad51 foci and the values are the mean ± S.E. of three 
independent experiments. 
In this assay it was noted that there was an increase in RAD51 foci in XRCC1defective 
cells treated with CPT. This suggests that HR is increased in this cell line when treated 
with CPT. It was also noted that this increase in HR was above the level observed for 
P -treated XRCC1 wt cells. It has already been noted that there is an increased amount 
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of RAD51 foci in untreated XRCC 1 defective cells (Figure 4.5) i.e. there is already 
increased spontaneous HR in these cells, but these data suggest that HR is increased 
further in order to repair an increased number ofDSB lesions caused by CPT. 
4.6 Camptothecin-induced RAD51 foci formation is significantly 
increased in XRCCl defective cells, when co-treated with 1,5-
dihydroisoquinoline. 
To determine if HR is increased in XRCC 1 wt and XRCC 1 defective cells when P ARP-l is 
inhibited, we co-treated both cell lines with CPT and ISQ. XRCCl defective and XRCCl wt 
cells were treated with either 100 nM CPT or 0.6 mM ISQ, or co-treated them with 
both. We also examined the level of RAD51 foci in untreated cells. These cell lines 
were treated for 24 hours and then fixed onto coverslips. The level of RAD51 foci was 
examined using immunofluorescence. 
As we have already noted, XRCC 1 defective cells have an increased amount of 
spontaneous RAD51 foci compared to XRCC 1 \vt cells (Figure 4. 5), and both XRCC 1 wt 
and XRCC 1 defective cells have an increased amount of RAD51 foci formation after a 24 
hour treatment with CPT. XRCCl defective cells however, have a much higher level of 
CPT -induced RAD51 foci formation that XRCC 1 wt cells. 
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Figure 4.6: Camptothecin-induced RAD51 foci formation is significantly increased 
in XRCCldejective cells, when co-treated with 1,5-dihydroisoquinoline. 
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XRccrvt (AA8) and XRCCldefective (EM9) cells were treated with 100 nM CPT or 
0.6 mM ISQ for 24 hours at 37°C, under an atmosphere containing 5% C02. Some 
cells were co-treated with 100 nM CPT and 0.6 mM ISQ. Cells were then fixed in 3% 
paraformaldehyde, and incubated with anti-Rad51 primary antibody, and then a Cy3-
conjugated antibody. The effect of CPT on cells is expressed as a percentage of cells 
containing more than 10 Rad51 foci and the values are the mean ± S.E. of three 
independent experiments. 
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Here we observed that the amount of RAD51 foci fonnation is also increased in both 
cell lines when treated with ISQ alone (Figure 4.6). 13% of XRCC1 wt cells showed> 
10 RAD51 foci per cell, whereas XRCCldefective cells showed 97.5%. This is a 5.5-fold 
(statistically significant in !-test, p < 0.01) and a 2.3-fold (p < 0.001) increase above 
their spontaneous levels, respectively. 
The percentage of ISQ-treated XRCC 1 defective cells with> 10 RAD51 foci per cell was 
7-fold higher than the percentage of ISQ-treated XRCCl wt cells (statistically significant 
in t-test, p < 0.001). When XRCC1defective cells were co-treated with CPT and ISQ, the 
percentage of cells showing> 10 RAD51 foci per cell was 100%, a 2.4-fold increase 
above spontaneous levels, statistically significant in !-test p < 0.001, but not 
significantly higher than the percentage of cells containing > 10 RAD51 foci in 
XRCC1 defective cells treated with CPT or ISQ alone. 
When XRCC 1 \Vt cells were co-treated with CPT and ISQ, 40% of the cells showed < 10 
RAD51 foci per cell. This is a 17-fold increase above spontaneous levels (p < 0.001), a 
3-fold increase above the level (13%) when treated only with ISQ (P < 0.01), but not 
significantly more than when XRCC1 wt cells are treated with CPT alone. As with the 
survival data this data suggests that both XRCCl and PARP-l are important for repair 
of both spontaneous and CPT induced SSBs, as we propose that a failure of SSB repair 
will result in increased HR to repair the resultant DSBs which fonn at replication forks. 
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4.7 Expression of a mutated BRCT I motif increases sensitivity to 
camptothecin in XRCCl defective cells. 
The XRCC 1 protein has been implicated to be involved in a DNA ligase III dependent 
and independent SSB repair (Taylor, 2002). The DNA ligase III dependent SSB repair 
appears to be active throughout the cell cycle and involves the BRCT I motif ofthe 
XRCC l protein, whilst DNA ligase III independent XRCCl repair appears to be active 
at replication forks and involves the BRCT Il motif of the XRCC 1 protein. Here, we 
wanted to test which repair pathway was implicated in the repair of CPT -induced DNA 
damage. To do this we used XRCCI mutant cell lines that had one or both of the BRCT 
motifs removed. 
XR Cl is thought to be a scaffold protein in SSB repair that transports DNA ligase III 
and DNA polymerase ~ to the site of SSBs in the DNA. It is also known to bind to 
automodified PARP- l. XRCCl binds DNA ligase III by the BRCT Il motif. To test 
whether it is lack ofXRCCl or the inability to bring DNA ligase III to the site of 
damag which is responsible for the increase in HR, we used an XRCC 1 defective cell line, 
M9 which had been complemented with a short XRCCl (XH-ST). This protein was 
mi ing th last 95 amino acids, the part that comprises the BRCT II motif, and 
ther for could not bind DNA ligase Ill. 
XR 1 bind PARP- l by the BRCT I motif. IfXRCCl cannot bind PARP-l , it cannot 
bring D A ligase III and DNA polymerase ~ to the SSB. To see ifit is XRCCl's ability 
tint r t with PARP- l that s responsible for the increase in HR, we used the 
RId re live M9 cell line, which had been complemented with one of two different 
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mutated XRCCl proteins. The EM9-pcD2EXH and EM9-pcD2EXH5 have been 
complimented with human XRCC1 (hXRCC1). The EM9-pcD2E cell line has been 
complimented with an empty vector. The EM9-pcXHl-528 cell line has been 
complimented with a short version of hXRCC1 , it is missing the BRCT II domain. The 
EM9-pcXHW385D and EM9-pcXHLI360/361DD cell lines have been complimented 
with hXRCCl proteins that have a mutated BRCT I domain. The BRCT I domain in 
EM9-pcXHW385D has the tryptophan residue at position 385 exchanged for an aspartic 
acid residue. The BRCT I domain in EM9-pcXHLI360/361DD has the leucine residue 
at position 360 and the isoleucine residue at position 361 exchanged for aspartic acid 
residues. This disrupted the folding of p-sheet three ofthe BRCT I motif and so could 
not bind P ARP-l (Caldecott, 1992). 
We tr ated all of these cell lines, as well as the XRCC 1 wt cell line and the 
uncomplemented EM9 cell line, with increasing concentrations of CPT. To be sure any 
effects were due to the mutated XRCCl proteins, and not due to the vector containing 
the XRC 1 mutants, we also tested the XRCC 1 defective EM9 cell line, which had been 
complemented with the full XRCC1 protein (XH and XH5), and the same cell line 
complemented with an empty vector (EM9-V). In line with our previous results, we 
fi d th XRCC l defective 11 . . wt oun at ce s were more senSItive to CPT than XRCC 1 cells, 
h wing a 1.7-fold increase in sensitivity at 10 nM CPT (statistically significant in t-
test p >0.01) increasing to a 59-fold increase at 40 nM CPT (statistically significant in 
t-te t p> 0.001). XRCC l defective cells complemented with an empty vector (EM9-V) 
wer imilarly sensitive, showing a 1.9-fold increase in sensitivity at 10 nM CPT, 
incr a ing to 33-fold at 40 nM CPT (statistically significant in t-test, p > 0.001). This 
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sensitivity was reversed when EM9 cells were complemented with human XRCC1 (XH 
and XH5) (Figure 4.7). Both XH and XH5 showed similar levels of sensitivity to CPT 
as the XRCC 1 wl cell line. 
Figure 4.7: Camptothecin has increased cytotoxicity in XRCCl defective cells 
complemented with XRCCl that is missing the BRCT I motif. 
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All cell lines were treated in increasing doses of CPT for 7 days at 37°C, under an 
atmosphere containing 5% C02. The effect of CPT on cells is expressed as a 
percentage of controls and the values are the mean ± S.E. of three independent 
exp riments. 
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XR I defecti e c lis complemented with short XRCCl (XH-ST) had a similar level of 
sen ili ity to PT as EM9 and EM9-V. Compared to XRCCl wt cells, XH-ST cells 
how d a 1.6-fold increase in sensitivity at 10 nM CPT (statistically significant in Hest, 
p > 0.01) which increased to a 27.7-fold increase at 40 nM CPT (statistically significant 
in He t p > 0.001) suggesting that it was the lack of DNA ligase III which was 
r pon ible for the increased cytotoxicity seen in EM9 cells. 
XR I defccti e cells complemented with XRCCl missing the BRCT I motif (XH-a3 or 
XH-P3) ha e en further increased sensitivity to CPT. Compared to the EM9 cell line, 
XH-a3 1I ha ea S-fold increase in sensitivity at 10 nM CPT, and a 24-fold increase 
at 20 nM PT (stati tically significant in t-test, p > 0.01). XH-P3 cells show a similar 
n iti ity t XH-a3 cells, which is not significantly different when subjected to the t-
c lIs ha ea 4.4-fold increase in sensitivity at 10 nM CPT, and a 46.2-fold 
incr at 20 nM PT (statistically significant in Hest, p > 0.01). Compared to the 
XR H-a3 cells have a 8.8-fold increase in sensitivity to 10 nM CPT, and a 
47.S-CI 1 incr as at 20 nM (statistically significant in t-test, p > 0.001 and p > 0.01 
ly . XH-P3 cells showed a 7.4-fold increase in sensitivity at 10 nM CPT, 
mpar d t XR I wt cells, and a 90.7-fold increase at 20 nM CPT (statistically 
ignifi ant in He t p > 0.001 and p> 0.01 respectively). Both XH-a3 and XH-P3 cells 
did n t urvi ab 20 nM CPT. These data suggest that mutation of the PARP-l 
int ra ti n d main f RCC1 has a dominant negative effect on CPT sensitivity but the 
\ in v hi h thi ur is unknown. 
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4.8 Camptothecin-induced RAD51 foci formation is increased in 
XRCCl defective cells complemented with XRCCl that is missing 
the BRCT I motif 
To armn if HR was also increased in these cell lines, we examined the level of 
RAD51 foci formation in each cell line after treatment for 24 hours with or without 
100 nM PT. We have already seen that XRCCl defective cells have an increased amount 
f p ntan ous RAD5 1 foci compared to XRCCl wt cells (Figure 4. 5), and both 
1 wl and XRCC 1 defective cells have an increased amount of RAD51 foci formation 
aft r a 24 hour treatm nt with CPT. We have also observed that the amount ofRAD51 
fo i fI rmation is increased in both cell lines when treated with ISQ alone. 
W Cl und that pontaneous and CPT -induced RAD51 foci formation was similar in 
RId fi co e C 11 lines complemented with XRCCl, XH and XH5, as in the XRCCl wt 
11 \in Figur -I. ). 2.6% of XH and XH5 cells showed spontaneous RAD51 foci, 
compar d t XR 1 wt cells, and 41 % of XH cells had > 10 RAD51 foci per cell in 
r p ns to treatment with 100 nM CPT, compared to 39% of XH5 cells and 33% of 
R 1 \ \1 11 (Figure 4. ). These results were not significantly different from each 
th r \! h n ubjected to the t-test. 
h p r nt g f cell with spontaneous and CPT -induced RAD51 foci in 
1 d fe live C lIs c mplemented with an empty vector (EM9-V) was similar to 
1 d fe live M9 ells. 50% of untreated EM9-V cells showed > 10 RAD51 foci , 
mp r t 42% f M9 cells, and 98.5% of EM9-V cells showed > 10 RAD51 foci 
aft r tr atm nt with PT compared to 95% of EM9 cells. The amount of RAD51 foci 
~ . . R 1 defective cells I d·th I~ rmatt n 10 comp emente W1 short XRCCl (XH-ST) was 
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lightly increased compared to EM9 cells, but not significantly. 51 % of untreated XH-
T cells had> 10 RAD5l foci, compared to 42% of EM9 cells, and 96% of XH-ST 
cell how d > 10 RAD5l foci after CPT treatment, compared to 95% of EM9 cells. 
Figure.J. : amptothecin-induced RAD51 foci formation is increased in 
XRCCldefective cells complemented with XRCCI that is missing the 
BRCT J motif. 
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11 II lin w r tr ated with 100 nM CPT for 24 hours at 37°C, under an atmosphere 
nt ining 5% 2. Cells were then fixed in 3% paraformaldehyde, and incubated 
with anti- d51 rimary antibody, and then a Cy3-conjugated antibody. The effect of 
n ell ' pre ed as a percentage of cells containing more than 10 Rad5l foci 
and th mean ± S.E. of three independent experiments. 
152 
In:tilut· or '.U1' 'f • 'ludks 
t fni' 'f. it} of 'hcfJic\ i 
1 d fe live C lIs complemented with XRCCl which had the BRCT I motif removed 
H-o. and XH-P3) had a dramatically increased amount of both spontaneous and 
P -induc d RAD51 foci. 89% of untreated XH-0.3 cells and 90% of XH-p3 cells 
ho\) d > 1 0 RAD51 foci compared to 2.4% of XRCCl wt cells (statistically significant 
in t-t t P > 0.001) and 42% of EM9 cells (statistically significant in t-test, p > 0.01). 
100% of -0.3 and XHP3 cells had > 1 0 RAD51 foci when treated with CPT, 
mpar d to 33% ofXRCCl wt cells (statistically significant in t-test, p>O.OI) and 95% 
f 9 lls ( tatistically significant in t-test, p > 0.05). Like the toxicity data this data 
thi data ugg t that mutation of the PARP interacting domain of XRCCl has a 
d minant n gati effect over repair of CPT induced SSBs. 
RC 1 defective cells, complemented with XRCCl that is missing 
th BR T I motif, have increased sensitivity to camptothecin 
~ h n co-treated with 1,5-dihydroisoquinoline. 
pr i u I fI und that RCC 1 defective cell lines complemented with XRCC 1 which 
h the R T I motif r mo ed, XH-0.3 and XH-p3, had increased sensitivity to CPT, 
mpar d 1 th R 1 \Vt cell line, the XRCC 1 defective EM9 cell line, the XRCC 1 defective 
lllin mplem nt d with an empty vector, and the XRCCl defective cell line 
mpl m nt with human XRCCI. They were also more sensitive to CPT than 
RId fccllve llline ompiemented with short XRCCl(XH-ST), which had the 
R Il m tifmi ing (figure 4. 7).We also found that the XH-a3 and XH-P3 cell lines 
h ntan u and PT-induced RAD51 foci formation, compared to those 
lh f lllin (fi If ./. ). We next examined the sensitivity of these cell lines to CPT 
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when co-treated with PARP-1 inhibitors, NUl 025 or ISQ. We treated XH-a3 and XH-
p3 with incr asing doses ofCPT and 10 ~M NU1025 or 0.6 mM ISQ. 
Figure 4.1.9: XRCC 1 defective cells, complemented with XRCC 1 that is missing the 
BRCT I motif, have increased sensitivity to camptothecin when co-
treated with 1,5-dihydroisoquinoline. 
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m r 100 nM PT and 10 f.l.M NU1025. The effect ofCPT on cells is expressed 
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W found that as before both XH-a3 and XH-~3 cell lines were more sensitive to CPT 
treatment alone compared to XRCCl defective EM9 cells. XH-a3 cells showed a 1.7-fold 
increase in sensitivity to 10 nM CPT, a 3.8-fold increase at 15 nM CPT, and a 16-fold 
incr a at 20 nM CPT. XH-~3 cells showed a similar increase in sensitivity, with a 1.8-
fold incr ase at 10 nM CPT, a 4.3-fold increase at 15 nM CPT, and a 21-fold increase at 
20 nM PT (all statistically significant in Hest, p>O.OOI). This sensitivity was not 
in r ased further when these cell lines were co-treated with NUI025, except at 20 nM 
P wh n both cell lines no longer survived (statistically significant in Hest, p>0.05). 
B th H-a3 and XH-P3 cell lines showed a large increase in sensitivity to CPT when 
-tr at d with I Q (figure 4.9). XH-a3 showed a 2.6-fold increase in sensitivity at 5 
nM P and a 9-fold increase at 7.5 nM CPT, compared to EM9 cells treated with ISQ 
tati ti all ignificant in Hest, p>O.OOI). No XH-a3 cells survived at more than 20 
n P \! h n co-treated with ISQ. XH-a3 showed a similar fold increase in sensitivity 
wh n mpar d to XH-a3 cells co-treated with CPT and NUl 025 (statistically 
ignifi ant in t-te t p > 0.01). XH-~3 showed a 5.2-fold increase in sensitivity at 5 nM 
P and a 2 1-fo ld incr ase at 7.5 nM CPT, compared to EM9 cells treated with ISQ 
tati ti ally ignificant in t-test, p>O.OOI). No XH-a3 cells survived at more than 20 
nM P wh n e-treated with ISQ. XH-~3 showed a similar fold increase in sensitivity 
" h n mpar d t XH-~3 cell s co-treated with CPT and NU 1025 (statistically 
ignifi ant in t-t t p>O.OOI). Interestingly, XH-p3 cells seem to be more sensitive to 
P than -a3 there is a 2-fold increase in sensitivity in XH-P3 cells at 15 nM CPT 
an 20 nM PT ( tatistically significant in Hest, p > 0.05). This data indicate that what 
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e r the effect mutating the BRCT I domain has it is mimicked but inhibition of 
PARP-l b UI025. 
4.10 Chinese hamster cell line, SPD8 has decreased homologous 
recombination when co-treated with camptothecin and PARP-1 
inhibitor, 1,5-dihydroisoquinoline. 
W had already examined the level of HR in XRCCl wt and XRCCldefective cell lines, 
aft r tr atm nt with CPT and ISQ, or after a co-treatment with CPT and ISQ, by 
'amining the le el of RAD5l foci in the cell. These foci form whenever the cell 
und rg e HR and a measurement of these can be used as an indication of the amount 
of HR that i taking place within a cell. However, it is possible that the RAD5l foci 
ft rm but that HR does not continue from this point. To be certain that HR does take 
pia aft r PT or I Q treatment we used the HPRT gene system in the SPD8 cell line 
H PT R 2.4.5.1). 
W fi un th t PD8 cells are sensitive to high doses of CPT (Figure 4.10), when 
tr t d with increa ing doses of CPT. 86% of cells survived at 20 nM CPT, which 
d t 13% at 50 nM PT, 3% at 100 nM CPT and 1.5% at 200 nM CPT. 
100 nM PT was chosen as a suitable dose for this cell line, as it was toxic 
ut 11 w d nough urvival for us to examine HR. 
un th t PD8 c lIs had a spontaneous reversion frequency of 5.9 cells per 
PD8 cell treated with ISQ alone did not increase recombination above 
1 ha ing a frequency of 6.5 cells per 100,000 cells. However, cells 
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co-treated with CPT and ISQ had a reduced level of recombination, compared to 
treatment with CPT alone (figure 4.10.3). Cells treated with CPT alone had a reversion 
frequenc of 38 cells per 100,000 cells, but cells co-treated with CPT and ISQ had a 
re ersion fr quency of 6.8 cells per 100,000 cells. 
Figur -1.10: hinese hamster cell line, SPD8 has decreased homologous 
recombination when co-treated with camptothecin and PARP-l inhibitor, 
1,5-dihydroisoquinoline. 
a) 
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P w r tr atcd in increasing doses of CPT for 7 days at 37°C, under an 
alm ph r c ntaining 5% C02. The effect of CPT on cells is expressed as a percentage 
ntr 1 an th alues are the mean ± S.E. of three independent experiments. 
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PO c 11 wer tr ated with 100 nM CPT, 0.6 mM ISQ or both for 24 hours at 37°C, 
und r an tmo pher containing 5% C02. Cells were then plated out cloning and 
r mbinati n plates and allowed to grow at 37°C for 7 or 10 days respectively. 
R mbination plat s were grown in HAsT medium. Colonies were counted and these 
data w rued to calculate the cloning efficiency and the recombination frequency. 
in th level of recombination was equivalent to the amount seen 
u I in the cell or when SPD8 cells were treated with ISQ alone. This 
ugg t th t at I ast in this reporter system, while increased SSB formation by CPT 
treatm nt d r suit in an increase in HR, presumably because of the increase in DSBs 
ti n forks inhibition of P ARP does not produce the same increase. 
Thi i t the effect seen when measuring HR by Rad5 1 foci formation. In 
d ili n gain in ntlict with the RAD51 foci results, co-treatment of cells with CPT 
and P rases HR. Either the reporter system cannot pick up these HR 
en r lh Cl i ar n n-functional for HR. 
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4.11 S8SN.ll cells show increased homologous recombination when 
treated with camptothecin. 
We v anted to examine the level of HR inside the XRCCl wt and XRCC I defective cell lines 
dir ctl so we used the SCneo vector transfected into XRCCI de~ective cell lines, using 
PD8 tran fected with SCneo (S8SN.ll) as the wildtype cell line (CHAPTER 2.4.5.2). 
We u d outhem blotting to ensure the vector was inside the cell line. 
Figure -1.11: 
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N.11 cells show increased homologous recombination when 
treated with camptothecin. 
o +-~----~~~~~--~~-
ontro l HU dT CPT MNNG 
.11 11 were treated with 1 mM HU, 10 mM dT, 100 nM CPT or 10 J.tM MNNG 
fi r 2 h ur under an atmosphere containing 5% C02. Cells were then plated out 
nin and r combination plates, and allowed to grow at 37°C for 7 or 10 days 
r p ti Jy. R combination plates were grown in HAsT medium. Colonies were 
and th data were used to calculate the cloning efficiency and the 
re In inati n fr u ncy. 
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.11 is sensitive to 100 nM CPT, so is a good control cell line for our experiments 
(Figure -I. J J) .In order to examine HR in S8SN.Il cells after treatments with a variety of 
drugs we tr ated these cells with 1 mM hydroxyurea (HU), 10 mM thymidine (dT), 10 
~M G and 100 nM CPT for 24 hours. They were then grown in media containing 
100 mg/m1 geneticin. Cells that have not undergone HR wit.! not survive in this media. 
4.12 Reel defective cells show homologous recombination when DSBs 
are induced using Sce-I endonuclease. 
w ~ und that 8 N.1 1 cells had a spontaneous recombination frequency of 0.23 cells 
r 100000 cell. These cells show recombination above spontaneous levels when 
tr at d with HU (0.75 c lls per 100,000 cells), dT (lA cells per 100,000 cells), MNNG 
1. c 11 p r 100000 cells) and CPT (3.7 cells per 100,000 cells) (Figure 4. 11) . 
. 1 1 cells show the most recombination when treated with CPT, 
mpar d t the contro l HU (statistically significant in t-test, p>O.OOl), dT and MNNG 
tati tic lly ignificant in t-test p> 0.01). 
I f HR in the XRCC 1 defective EM9 cells, five different clones which had been 
tran t d with th n 0 vector were used (EM9SN .2, EM9SN. 7, EM9SN .11 , 
M9 N. t 3). Each clone was treated with Sce! endonuclease and we 
xamm 
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Figllr -1.12: XR Cl defective cells show homologous recombination when DNA 
double trand breaks are induced using Sce-! endonuclease. 
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11 lllin w r treated with Sce-I, with no treatment as a control. Cells were then 
ut I ning and recombination plates, and allowed to grow at 37°C for 7 or 10 
ti ely. R c mbination plates were grown in medium containing G418. 
unted and these data were used to calculate the cloning efficiency and 
mbinati n fT quency. 
rv that ft 11 wing ce-I treatment four out of the five clones showed an 
dam unt fr mbination compared to S8SN.ll. EM9SN.7 showed only a 
mbination (Figure 4.12). S8SN.l1 had a recombination frequency 
f 00 cell. M9SN.2, EM9SN.l1, EM9SN.l2 and EM9SN.13 had a 
m in ti nfr u ncy f49837 1,340and347cellsper100,000cellsrespectively .. 
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p ntane u HR however was not any different to that seen in wildtype cells. This 
h v that lack ofXRCCl increases the amount ofDSB induced HR but does not alter 
p ntan u HR rates . 
. 1 Cl defective cells are hypersensitive to treatment with CPT or 
G. 
ant d 1 amine the level of sensitivity of the transfected XRCC 1 defective cell line, 
.2 t a numb f of toxic agents. We treated S8SN.ll and EM9SN.2 with 1 mM 
H 10 m d 100 oM PT or 10 ~M MNNG. 
th .1 1 and M9 N.2 showed 100% survival when untreated (Figure 4.13) . 
. 2 h \i d a decrease in survival compared to S8SN.ll when treated with HU, 
3 % mpar d t 61 % ( tatistically significant in t-test, p>0.05), and a smaller 
di n b tween the two cell lines when treated with dT (50% in EM9SN.2, 
60% in 8 N.lI) which was statistically significant in t-test, p>0.05 . 
. 2 howed a huge decrease in survival when treated with CPT, 
.11 howing only 0.6% survival, compared to 52% in S8SN.l1 cells 
ignificant in t-test p > 0.001). EM9SN.2 did not survive when treated 
\! ith t ti ti lly significant in t-test, p > 0.01). Thus XRCCl appears to be 
imp rt nt 1 n t nly to PT induced damage as we have seen previously but also 
t H th mi in and MNNG induced DNA damage. 
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Fi ure -1.13: XR Cl defective cells are hypersensitive to treatment with camptothecin or 
-l1'let hyl-N-n i tro-N-nitroso guanidine 
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11 l1lin w r tr at d with 1 mM HU, 10 mM dT, 100 nM CPT or 10 IlM MNNG 
und r n tmo phere containing 5% C02. The effect of each drug on cells is 
pre p r nt g of controls and the values are the mean ± S.E. of three 
prim nt . 
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4.14 CCI defective cells do not undergo homologous recombination 
, hen treated with CPT 
V ha aIr ad en that that the XRCC 1 defective EM9 cell line, and the same cell line 
Cneo vector, EM9SN.2, are sensitive to CPT (Figure 4.2 and 
Figur -1.13). We ha also seen that the level of RAD51 foci is increased 
p ntan u ly in M9 cells and after treatment with CPT (Figure 4.5 and Figure 4.6). 
Thi indicat that the level of HR in these cells is also increased. 
I amine the I vel of HR in the transfected XRCC 1 defective cell lines after 
tr atm nt with P . To do this we treated two of the XRCCl defective cell lines 
with ne M9SN.2 and EM9SN.7, with 100 nM CPT, and examined the 
am unt fr mbination compared to S8SN.ll cells. 
und that unlik fi Howing Sce-I induced DSB formation, EM9SN.7and EM9SN.2 
id nth w any r c mbination when treated with CPT (both statistically 
i nifi ant in t-le t p>O.OOl), while in wildtype cells, recombination was induced 20-
previously seen, EM9SN.7 showed 0 spontaneous recombination 
but .11 h w d a small amount of spontaneous recombination, 0.025 cells per 
10000 r this was still lower than the amount see in S8SN.ll, which 
r combination frequency of 0.04 cells per 100,000 cells, and was 
nt in th t-t t. This experiment shows that while EM9 cells can undergo 
HR P d n t indu e HR in our reporter construct in the absence of XRCC 1. 
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Fi Ir -1.1.1 -I: R 1 defective cells do not undergo homologous recombination when 
treated with camptothecin. 
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11 lllin \ r tr ated with 10 nM, 30 nM, or 50 nM CPT, with no treatment as a 
ntt 1. f; r 7 day under an atmosphere containing 5% C02 Cells were then plated out 
ning mbinati n plates and allowed to grow at 37°C for 7 or 10 days 
ination plates were grown in medium containing 6-tG. Colonies 
unl d and th data were used to calculate the cloning efficiency and the 
r m in ti n r qu ncy. 
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4.15 XRCCl defective cells do not undergo spontaneous homologous 
recombination 
We have seen increased spontaneous and CPT-induced RAD51 foci in the 
XRCC 1 defective cell line (Figure 4. 5 and Figure 4. 6), but no spontaneous HR in the 
XRCC 1 defective EM9 cell line transfected with the SCneo vector. We hypothesised that 
the XRCC 1 defective cell line may have a very low spontaneous recombination rate so we 
plated out more cell s in order to examine the spontaneous recombination level. 
We examined the spontaneous level of HR in both EM9SN.2 and EM9SN.ll , compared 
to the 8SN .11 cell line (Figure 4. 15). We plated out 1,000,000 cells from 1,000 cells 
and grew them in 100 mg/ml Geneticin to determine the number of revertants per 
1 000 000 cells. 
Figure 4.15: XRCC1de/eclive cells do not undergo spontaneous homologous 
recombination. 
Cell line Spontaneous recombination frequency 
S8SN.l 1 6.4 x 10-7 
M9SN.2 0 
EM9SN.7 0 
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We observed that S8SN.ll underwent a low level of spontaneous recombination, with 
only 6.4 cells per 1,000,000 undergoing recombination. No recombination was observed 
in EM9SN.2 and EM9SN.7 cells so we can conclude that the spontaneous 
recombination rate in these cells is less than 1 in 1,000,000 (statistically significant in t-
test p> 0.01). 
4.16 Discussion 
XRCC 1 d fective cells are more sensitive to CPT than XRCC 1 wt cells, which suggests that 
XRCC 1 has a role in the repair of SSBs. XRCCl is believed to be a scaffold protein that 
is invol ed in the SSB repair pathway. In the defective cell lines, XRCCl cannot bring 
the Br pair proteins, DNA ligase III and DNA polymerase p to the site of the SSB, 
so it is likely that repair is slower. We have shown that CPT induces the formation of 
D Bs in both XRCC 1 defective and XRCC 1 wt cell lines, but that there are a greater number 
ofDSBs in the deficient cell line. Our hypothesis is that as the repair of the SSBs in the 
XRCC 1 d fective cell line is slower SSBs encounter the replication machinery, at which 
point they are converted to DSBs, this is supported by the fact that if you inhibit 
r plication CPT-induced DSBs and HR is decreased (Saleh-Gohari et al. ,2005) . 
We see an increase in the amount of RAD51 foci formation in XRCCl defective cells, 
suggesting that the level of HR repair is increased. This is not unexpected as we also see 
that 0 B formation is increased and HR is the preferred mechanism for the repair of 
these D B. HR is also shown to be increased in XRCCl wt cells when treated with CPT. 
This suggest that HR is a major pathway for the repair of CPT -induced damage. The 
167 
-------------- ._----------_._--------
In. titull,; fI r Cane 'r Stud ic ' 
Unh ersit} of Sheftield 
increased spontaneous levels of RAD51 foci in SSB repair defective cells, suggests that 
a S B is an important endogenous lesion for HR. This is supported by the fact that the 
spectrum of spontaneous recombinant products formed is highly similar to the CPT-
induced spectrum of recombinants (Saleh-Gohari et aI., 2005). 
Co-treating XRCC 1 wt cells with CPT and P ARP inhibitors, NU 1025 or ISQ, increased 
the sensitivity to CPT. This is probably because when PARP-l is inhibited by NUI025, 
or I Q it cannot catalyse the production ofpoly(ADP-ribose) polymers. This may have 
two effects firstly XRCCI may not be as strongly attracted to SSBs and secondly if 
PARP is not automodified it will not eventually be displaced and may block the access 
of other repair enzymes to the site of damage. It has been shown that when PARP-l is 
inhibited by 3-aminobenzamine (3-AB), PARP-l blocks access for BER proteins to the 
B (parsons et ai, 2005). 
Another explanation could be that proteins involved in SSB repair, other than XRCC I 
might b attracted to SSBs by PARP. In this scenario, additional inhibition of P ARP, in 
XRC 1 defective cells, would result in further sensitivity to CPT. When we inhibited 
P ARP in XRCCl defective cells we saw that sensitivity was in deed further increased 
adding weight to this idea. 
We observ d that XRCCl wt cells and XRCCl defective cells were more sensitive to a co-
treatment with CPT and ISQ, than CPT and NUI025. This may be explained by the 
diffl r nt potencies of the two inhibitors. 
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In XRCC 1 defective cells there is an increased amount of spontaneous HR. As discussed 
previously this may be because the lack ofXRCCl results in slower SSB repair, so any 
endogenous SSBs in the DNA are repaired at a slower rate and can become DSBs when 
encountered by a replication fork. When XRCC 1 defective cells are treated with ISQ, the 
amount cells with > 10 RAD5l foci (an indicator of~) further increases to 97.5%. 
This is a drastic increase in the amount of HR, and could be because when there is no 
XRCC 1 and P ARP-l is inhibited, SSB repair becomes even slower, or does not occur at 
all. In this case, all of the endogenous SSBs in the cell would become DSBs and result 
in a dramatically increased amount of HR. 
We ha e seen how lack of XRCCl in cells results in an increase in DSBs and 
homologous recombination, presumttbly as a reflection of less SSB repair occurring, we 
have also seen that inhibiting P ARP in these deficient cells further enhances this effect, 
and ha e hypothesised that this is because SSB repair is even less efficient. In addition 
co-treatment of wt cells with either CPT or P ARP inhibitors also increases Rad51 foci 
formation compared to none treated cells. When XRCCl wt cells are treated with CPT, 
this drug stabilises the SSBs induced by Top 1, so there will be more SSBs in the cell. 
Inhibition of P ARP will also increase the number of SSBs in the cell by decreasing the 
efficiency of endogenous SSB repair. However, SSB repair is active in the cell and the 
Bs can be repaired so why do we see an increase in HR? It may be that there are too 
many Bs for SSB repair to fix them all before they are encountered by the replication 
machin ry and become DSBs, they then require HR for repair. When XRCC 1 wt cells are 
co-tr ated with PT and ISQ, there is still an increase in the number of SSBs due to the 
effect of PT but PARP-l is also being inhibited by ISQ. This means that SSB repair is 
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likel to b slower, so there are both more SSBs formed and more left unrepaired. This 
further increases the number ofSSBs becomes an increased number ofDSBs when they 
encounter replication forks and so result in the further increase in HR, which we see. 
When XRCC 1 defective cells are treated with CPT there is a similar level of HR to when 
they are treated with ISQ alone, 95% of cells contain> 10 RAD51 foci. This is the same 
as we observed previously, and is probably due to the increased amount of SSBs in the 
cell cau ed by CPT, and SSB repair being slower due the lack ofXRCCl or inhibition 
of P ARP. When XRCC 1 defective cells are co-treated with CPT and ISQ, 100% of cells 
contain> 1 0 RAD51 foci. This is probably because SSB repair is very slow, or does not 
happen at all when both XRCC 1 and P ARP-l are not active in the cell. At the same 
time CPT is causing lots of SSBs, which are not being repaired by SSB repair. This 
leads to Bs becoming DSBs in the cell, and an increase in HR to repair them. If there 
ar lots of SBs due to the action of CPT, and no SSB repair this would increase the 
numb r of D Bs and would explain the dramatic increase in the amount of HR, as 
indicated by the increased number of cells containing> 10 RAD51 foci. The effect of 
inhibiting both PARP and XRCCl together may be more detrimental than is reflected in 
the increase in foci as the damage response pathways may be saturated, once 100% of 
cells are seen to be containing foci we cannot record any more increase in HR. In the 
future further Rad51 foci assays will be needed to ascertain whether there is an additive 
effect for PT and ISQ in the PARP-1- cells. This could be dome by decreasing the dose 
of the PT 0 that the assay does not max out, or by treating the cells for less time. 
The XR protein has been implicated in a DNA ligase III dependent and 
indep ndent B repair (Taylor, 2002). The DNA ligase III dependent SSB repair 
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appears to be active throughout the cell cycle and involves the BRCT I motif of the 
XRCCl protein whilst DNA ligase III independent XRCCl repair appears to be active 
at replication forks and involves the BRCT II motif of the XRCCl protein. To test 
which repair pathway was involved in the repair of CPT -induced DNA damage, we 
used XRCC 1 mutant cell lines that had one or both of the BRCT motifs removed. 
When the XRCCl defective cell line was complemented with an empty vector, it had no 
effect on the sensitivity of the cell line to CPT. However, when the same cell line was 
complemented with the full XRCC 1 protein, sensitivity was reverted back to the same 
levels as the wildtype cell line. Confirming that it is mutation of XRCC 1 which is 
responsible for the sensitivity of the EM9 cells. 
Both of th XRCC 1 defective cell lines complemented with short XRCC 1 had the same 
le el of sensiti ity to CPT as the deficient cell line. Therefore it seems that it is the lack 
ofDN ligase III at the site of the SSB that slows SSB repair. Short XRCCl still 
carries ON p lymerase p to the site of the SSB, so it is not likely that this protein is 
the rate limiting step. The XRCC l defective cell line complemented with XHa3 or XHP3 
showed e en greater sensitivity to CPT. than EM9, thus the defect seems to have a 
dominant negative effect in cells. These cells lines have the BRCT I motif disrupted, 
XH-a3 ha th third a-helix of the BRCT motif disrupted, and XH-P3 has the third p-
heet of the BR T motif disrupted. The BRCT I motif is known to bind to the BRCT 
motif in the automodification domain of P ARP-l , but we do not know what effect the 
disrupt d XR 1 BRCT I motif could have on the P ARP-l protein. 
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In th cell lin s that have the XRCCl BRCTI motif disrupted, we observed increased 
sensiti ity to CPT, compared to XRCCl defective cells, an increased number of cells 
displaying pontaneous and CPT - induced RAD51 foci and a further increase in 
s nsiti ity to CPT when co-treated with ISQ. However, no significant increase in 
sensiti ity to CPT was observed when these cell lines were co-treated with CPT and 
U 1 025. This may be explained by the different potencies of the two inhibitors. 
We can conclude that disruption of the BRCT I domain in XRCCl has the same effect 
as inhibiting P ARP-I in XRCC 1 defective cells. It is likely then that disrupting the 
BR TI domain inhibits PARP activity in some way. It could be that the BRCT I motif 
bind PARP-l a normal, but then PARP-l cannot break away from XRCCl, inhibiting 
its acti itie . In this scenario P ARP-l would be unable to bind to further SSBs and 
other B repair protein may be unable to access the site of damage. 
p ntaneou and CPT-induced RAD51 foci formation is increased in both XH-a3 and 
XHP3 celllin compared to XRCCldefective cells. This could again be because PARP-l 
is inhibit d by the disrupted BRCT I motif, causing SSB repair to be slower. This in 
turn would lead t more SSBs in the cells, which could encounter the replication 
machinery to b come D Bs. Therefore, there would be more DSBs in the cell to be 
r paired. HR appear to be the major repair pathway for these single-ended DSBs, so 
the increa in c 11 containing RAD51 foci , could be an indication of a rise in HR 
repair. It may al be that HR repair is deficient in the absence ofPARP-l and XRCCl. 
hi i upp rted b th fact that PARP-l inhibitors reduce the number of CPT -induced 
r mbinant. 
172 
In lilUl' fl r 'anc 'r :tudics 
l Ini\ er. it) of 'heftield 
Whil the RAD51 foci results suggest that that both spontaneous and CPT induced HR 
increase in XRCCl defective and PARP inhibited cells, and that this level further 
incr ase if both are defective/inhibited, direct analysis of HR at the hprt loci or in the 
Cneo reporter a ay did not agree. SPD8 cells show increased HR following treatment 
with 100 nM CPT but no increase following P ARP inhibition and in fact have 
decreas d R when co-treated with CPT and ISQ. One possible explanation could be 
that the HR event studied in SPD8 cells requires a recombination tract longer than 5 kb. 
Pre iou Iy it was found that recombination induced at replication forks is likely to 
in I e short recombination tracts and will not be detected in the HR assay in the SPD8 
cells (Lundin et al., 2003). This could indicate that another recombination event is 
trigger d in pr sence of an inhibitor ofP ARP. An alternative explanation could be that 
I treatment may arrest cells in the G2 phase of the cell cycle (Schultz and Helleday, 
per onal ommunication), which would result in fewer cells reaching the S phase of the 
cell cycle' the pha HR normally occurs (Saleh Gohari et al., 2004) . 
. 11 cells ar P08 cells transfected with the SCneo vector. These cells show 
incr ased HR wh n treated with CPT, compared to treatments with HU, dT or MNNG. 
his indicates that PT is a strong inducer of HR repair. XRCCl defective cells, that have 
al n tran fected with the SCneo vector, show HR when treated with Sce-I and are 
hyp r nsiti e to PT and MNNG. However they do not undergo HR when treated with 
P . am cells undergo de creased spontaneous recombination. We see increased 
D51 fi i in the e cells but the SCneo assay shows that HR does not take place. It 
ul b that RAD51 foci form but cannot complete HR or that the HR event occurring 
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following PT treatment in EM9 cells involves very short recombination tracts not 
d t table in the HR assay. 
In conclusion we suggest that the role of P ARP-l and XRCC 1 in 88B repair of CPT 
lesions is likely to xplain the results found. The inhibition of XRCCl may slow the 
repair of PT-induced Bs, which in turn would lead to more 88Bs collapsing at 
r plication forks and thus more D8Bs. This in turn would increase the amount of 
RADS 1-foci forming fo r repair. When PARP-l and XRCCl were both inhibited or 
defecti e in the cell sensitivity to CPT increases. This may be because there are two 
B rep ir pathways in the cell, one involving XRCC 1 and P ARP-l , the other 
in 01 ing PARP-l. When XRCC l is defective in the cell, 88B repair is slower, but can 
be ontinu d ia the PARP- l dependent pathway. When XRCCl is defective and 
PARP-l i inhibited neither pathways are viable, and no 8SB repair takes place. This 
r inforced by observations that sensitivity to CPT increases when both 
pr t ins ar de£ ti e or inhibited in the cell. 
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P R 5: DI CUSSION 
5.1 h r le of PARP-l in CPT-induced damage 
-tr atm nt f P ARP-I +1+ and P ARP-I -1- cells with camptothecin (ePT) and P ARP-l 
th killing effect ofePT. This is probably because when PARP-l is 
inhibit d 1025 r 1,5-dihydroisoquinoline (ISQ), these drugs bind to the 
catal main pr enting P ARP-l from catalysing the production of poly(ADP-
n p I m r . P RP-I can till bind to the single-strand break (SSB), but because it 
ann t aut m if it If PARP-l remains bound to the SSB. Also, if PARP-l is not 
aut m difi R 1 wi ll not bind to it, and bring the SSB repair proteins to the site of 
It ha b n h wn that wh n P ARP-l is inhibited by 3-aminobenzamine (3-AB), 
P RP- I 
h 
it i 
di pI d r m 
H\.\.\J;);) fo r B repair proteins to the SSB (Parsons et aI, 2005). 
n hown that the presence of the P ARP-l protein in the cell 
[ the B from cellular nucleases. 
increased cytotoxicity in P ARP-I-1- cells. This suggests that 
RP- I pr t in or its activity rather than an inability for PARP-l to be 
lh t i cau ing enhanced ePT sensitivity. 
th f P RP- I fr m the c 11 increases the cytotoxicity of ePT, it must be the 
P RP- I r th r than its pres nce at the SSB that is protecting the SSB from 
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becoming a double-strand break (DSB). This may happen when the SSB encounters the 
replication machinery. The activity of P ARP-l would recruit the SSB repair proteins to 
the site of DNA damage. Without this, the cell is more sensitive to CPT, probably 
because the repair of the SSB is slower. However, P ARP-I-I- cells co-treated with CPT 
and PARP inhibitors also showed an increase in sensitivity to CPT. This is likely to be 
because the pres nce of the P ARP-l protein, even though inhibited, does offer some 
protection and could explain why P ARP-I-1- cells show more sensitivity to CPT than 
P ARP-l +1+ cells co-treated with CPT and PARP-l inhibitors. 
We observed that PARP+1+ cells were more sensitive to a co-treatment with CPT and 
ISQ than CPT and NU I025. This could be explained by the fact that NUI025 is active 
at a much lower concentration than ISQ, which likely increase substrate specificity. 
Also treatm nts with ISQ alone arrests cells in the G21M phase of the cell cycle 
(Schultz Bryant and Helleday, personal communication), which is likely due to 
inhibition of also tankylase 1, which has a role in spindle assembly during mitosis 
( hang et al. 2005' Dynek & Smith, 2004). Treatments with NUl 025 does not arrest 
cells in the G21M phase of the cell cycle suggesting it is more specific inhibitor of 
PARP-I ( chultz Bryant and HeUeday, personal communication). 
PARP-like proteins have been discovered in humans, with 40% (p ARP-2) and 31 % 
(PARP-3) homology to PARP-l. Both of these proteins lack DNA-binding domains and 
automodification domains but show strong homology with the catalytic domain 
(Johan n 1999' Ame et al., 2001). These proteins were discovered when it was 
observed that P ARP knockout mice still showed residual PARP activity (Shall & de 
Murcia 2000). PARP-2 and PARP-3 were able to synthesise pADPr polymers in 
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response to DNA damage, although these polymers were much shorter in length. 
Therefore it seems that these proteins are catalytically active, and may have an 
important role to play in some of the same pathways as PARP-l. Therefore, it would be 
beneficial to further our knowledge and define their exact roles. This however is a 
further study. 
CPT incr ases the formation of DSBs in P ARP-I-1- cells. The likely explanation for an 
increas in D Bs in these cells is that in the absence ofPARP-l, the SSB repair proteins 
are not recruited to the site of the SSB via the interaction of P ARP-l with XRCC 1. 
Therefor B repair is slower. Since there are more unrepaired SSBs in the cell , it is 
more likely that they will encounter the replication machinery and form DSBs. This is 
probably why we see an increase in DSBs in these cells after treatment with CPT. DSBs 
are also increased in P ARP-l +1+ cells co-treated with CPT and P ARP-l inhibitors, 
NU 1025 or I Q. In this case, it is likely that inhibited P ARP-l may bind the SSB, even 
though it cannot recruit XRCCl to the site by auto-ADP-ribosylating itself. Even 
thought the presence of P ARP-l in the cell may protect'the SSBs from degradation from 
cellular nucleases, it may not protect them from becoming DSBs on encountering the 
replication machinery. 
HR app ar to be the major repair pathway for CPT-induced DSBs (Arnaudeau et al., 
200 I). A measurement of the number of cells containing> 10 RAD51 foci per cells can 
be used as an indication of the amount of HR taking place within a cell. RADS 1 foci 
are small nucl ar foc i containing all of the proteins involved HR. These foci form 
whene r th 11 undergoes HR. 
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Spontaneous and CPT -induced RAD51 foci formation is increased in P ARP-I -1- cells. 
These results suggest that HR is increased spontaneously in P ARP-1- cells, probably 
because of an increase in SSBs leading to DSB formation when encountered by 
replication machinery, and that HR is the preferred mechanism for the repair of these 
DSB. HR is also shown to be increased in PARP-l+l+ cells when treated with CPT. This 
suggests that HR is the major pathway for the repair of CPT -induced damage. 
There is an increase in RAD51 foci in P ARP-1- cells treated with CPT. This suggests that 
HR is increased in this cell line when treated with CPT. This increase in HR is above 
the le el observed for CPT -treated P ARP-l +1+ cells. It has already been noted that there 
is an iner ased amount of spontaneous RAD51 foci in P ARP-1- cells. 
Co-treatment of P ARP-l +1+ and P ARP-1- cells with CPT and ISQ significantly increases 
the amount of RAD51 foci formation in P ARP-I-1- cells but not in PARP-l +1+ cells. In 
the abs nee of P RP-I, there is an increase in CPT -induced DSBs, and a consequent 
increase in HR. When PARP-l is inhibited by ISQ and treated with CPT, we seem to 
see the same effect. In P ARP-I-1- cells, we already see an increase in CPT -induced 
DSBs and an increase in HR. When P ARP-I-1- cells are co-treated with ISQ, there is a 
further increase in spontaneous and CPT-induced HR. This may because of the 
possibility that J Q may inhibit P ARP-2 and P ARP-3 as well. These two other PARPs 
are part of the P ARP fam ily but are less abundant in the cell. Their roles are still no well 
known, but they may offer some compensatory effect in cells where P ARP-I is 
inhibited. his may explain the further increase in HR. 
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5.2 The role of XRCCl in CPT -induced damage 
We have already showed that CPT has increased cytotoxicity in PARP-r/- cells and 
that this is due to an increased amount ofDSBs. We have also showed that RAD51 foci 
formation was increased in PARP-l-/- cells treated with CPT. This may indicate that HR 
is increased in these cells. It may also be that the high level of Rad51 foci is an 
indication of decreased HR repair in these cells. We see an increase in DSBs whether 
PARP-l is absent or inhibited, so it is clear that it is the activity of the enzyme that is 
important for protection against CPT toxicity. In P ARP-l-/- cells, there is no P ARP-I to 
bind to the SSBs and signal XRCCl to the site of damage. Therefore, the inhibition of 
P ARP-I may decrease the repair of CPT -induced SSBs, which in turn leads to more 
SSBs collapsing at replication forks and more DSBs. An increase in collapsed forks 
would in turn lead to an increase in HR to repair the DSBs, which would explain the 
increase in RAD51 foci observed in PARP deficient or inhibited cells. 
PARP-l can bind the scaffold protein, XRCCl, and bring the SSB repair proteins to the 
site of the SSB. Here, we hypothesise that the role of XRCCl in HR is linked to the 
affinity of XRCCI to PARP-l that has bound a SSB. XRCCl can then bring other 
proteins to the site of the damage, and carry out repair. In the absence of P ARP-l, 
XRCC I cannot so easily relocate to the SSBs, and repair of CPT lesions is decreased. 
There is an increased cytotoxicity to CPT in XRCC 1 defective cells. This is likely to be 
because e en though PARP-l can bind to the SSB and attract XRCCl to the site of the 
damage the XRCCl in this cell line is defective, and cannot bring DNA ligase III and 
DNA polymeras ~ to the site of damage. Therefore, SSB repair will be slower, which 
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as in the case of P ARP-l inhibition, results in collapsed replication forks and an 
increase in toxicity. This hypothesis is supported by the increase in DSBs that we 
observe in EM9 cells. 
Co-treatment of XRCC 1 wt and XRCC 1 defective cells with camptothecin and P ARP-l 
inhibitors increases the killing effect of camptothecin. In the XRCC 1 wt cell line, if 
P ARP-l is inhibited, it may be binding to the site of the SSB, but cannot recruit 
XRCC 1. In this case, SSB repair will be slower. In the XRCC 1 defective cells, PARP- l 
cannot recruit XRCCl, but there is no XRCCl to recruit. Thus, one would not expect 
any further effect of inhibition of PARP-l in these cells. The fact, there is a further 
synergistic effect suggests that either PARP-l or XRCCl has some other role in the cell 
that causes increased sensitivity to CPT when it is removed. We know that PARP-l has 
many roles within the cell besides its role in SSB repair. It may be that there are two 
pathways for repair of SSBs; one involving XRCCl and PARP-l, and the other 
involving PARP-l. In the absence ofXRCCl , the other PARP-l pathway can repair the 
SSB perhaps by recruiting the SSB proteins itself. In the absence of PARP-l , XRCC 1 
can still recruit the SSB repair proteins to the site of the SSB, however more slowly. 
Howe er in the absence of both proteins, SSB repair cannot be carried out, or is carried 
out e en mor slowly. XRCC l defective cells showed greater sensitivity to CPT when co-
treated with ISQ, rather than NUl025. This is possibly explained by that NUI025 is an 
inhibitor specific for PARP-l, whereas ISQ inhibits PARP-2 and PARP-3 as well and 
remo es any possible compensatory effects. There is an increased amount of DSB 
formation fo llowing CPT treatment in XRCCl defective cells. This could be explained by 
th fact that th XRCC 1 wl cell line has efficient SSB repair, and can repair methylated 
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adenine and guanine bases in the cell. It can also repair any SSBs stabilised by CPT. dT 
is not known to cause DSBs and does not form them in either cell line. In the 
XRCCl d fective cell line, SSB repair is slower because DNA ligase III and DNA 
polymerase p are not transported to the site of the SSB by XRCC 1. The observation that 
CPT causes an increased amount of DSBs in the XRCCI defective cells, could also be due 
to SSB repair being slower, leaving more unrepaired SSBs in the cell, which could 
potentially become DSBs. 
Camptothecin-induced RAD51 foci formation is increased in XRCC 1 defective cells. These 
results suggest that HR is spontaneously increased in XRCCI defective cells, probably 
because of an increase in SSBs leading to DSB formation when encountered by the 
replication machinery, and that HR is the preferred mechanism for the repair of these 
DSB. HR is also shown to be increased in XRCCl wt cells when treated with CPT. This 
suggests that HR is the major pathway for the repair of CPT-induced damage. Also, 
increased spontaneous levels of RAD5I foci in SSB repair defective cells, suggests that 
a SSB is an important endogenous lesion for HR. This is supported by that the spectrum 
of spontaneous recombinants is highly similar to the CPT -induced spectrum of 
recombinants, caused by SSBs (Saleh-Gohari et aI., 2005). Camptothecin-induced 
RAD51 foci formation is significantly increased in XRCC 1 defective cells, when co-treated 
with ISQ. This may be because in XRCCI wt cells, there is an intact P ARP-I protein. 
When this is inhibited by ISQ, SSB repair still occurs, but at a slower rate, increasing 
the number of unrepaired SSBs. It could also be that the inhibited P ARP-I cannot 
destabilise the Top I-DNA-CPT complex, and remove Top! from the DNA. PARP-l 
also enhances religation of the DNA so that no SSB forms. If P ARP-I is inhibited, this 
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means that Tdpl must remove Topl from the DNA, leading to many SSBs. This 
increase in SBs eventually results in an increase in DSBs, and hence an increase in HR 
to repair these. 
Figure 5.2 Model ofDSBformation in the presence and absence ofPARP-l. 
XRCC I 
DNAJiglse III 
-+=== 
en 
....:::J 
In the presenc ofCPT Topl-DNA complexes are stabilised. When PARP-l is present, 
it binds to Top l and adds poly (ADP-ribose) polymers to it. This destabilises the Topl-
DNA- PT complex removes Topl and enhances DNA religation. Also, PARP-l brings 
XR 1 and the BER proteins to the site of the SSB. When P ARP-l is absent, the 
Top l - PT complex is not destabilised or the Topl protein is removed by Tdpl. ither 
way this lea s a B to be repaired. When P ARP-l is not present, the BER repair 
proteins are not brought to the site of damage. On oncoming replication fork can then 
collide with the B to form a DSB. 
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When XRC 1 ,y\ cells are treated with CPT, this drug stabilises the SSBs induced by 
Top I so there are more of these in the cell. However, SSB repair is active in the cell 
and they can b repaired. It may be there are too many SSBs to repair them all before 
they are encounter d by replication machinery and become DSBs. This may be why we 
see an increase in HR in thi s instance. When XRCCl\vt cells are co-treated with CPT 
and ISQ there is still an increase in the number of SSBs due to the effect of CPT, but 
PARP-l is also b ing inhibited by ISQ. This means that SSB repair is probably slower, 
so there ar even more SBs becoming DSBs, resulting in an increase in HR, which we 
ha e seen. 
In XR C l defi ti e cells there is an increased amount of spontaneous HR. This may be 
because the lack of XRCC 1 results in slower SSB repair, so any SSBs in the DNA are 
repaired at a slower rate and can become DSBs when encountered by a replication fork. 
When XR C l defi ctive cells are treated with ISQ, the amount cells with > 10 RAD51 foci 
(an indicator f HR) increases to 97.5%. This is a drastic increase in the amount of HR, 
and could b because when there is no XRCCl and PARP-I is inhibited, SSB repair 
becomes e en slower or does not occur at all. In this case, all of the SSBs in the cell 
would become D Bs and result in a dramatically increased amount of HR. 
When XR 1 d fcctivc C lls are treated with CPT there is a similar level of HR to when 
they are treated with I Q alone, 95% of cells contain> 10 RAD51 foci. This is the same 
as we ob erved pr iously and is probably due to the increased amount of SSBs in the 
cell cau d by and S B repair being slower due the lack of XRCC 1. When 
XR I defe ti c C II are co-tr ated with CPT and ISQ, 100% of cells contain > 10 
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RADSl foc i. This further increase m HR when treated with CPT is probably a 
synergistic effect. There are more cells containing RADS1 foci in the XRCC 1 defective cell 
line then would be expected from adding the effect of CPT in XRCC1 wl cells to the 
background level of RADSl foci seen in the XRCC 1 defective cells. 
This is probably because SSB repair is very slow, or does not happen at all when both 
XRCC 1 and P ARP-l are not active in the cell. At the same time, CPT is causing lots of 
SSBs, which are not being repaired by SSB repair. This leads to SSBs becoming DSBs 
in the cell, and an increase in HR to repair them. If there are lots of SSBs due to the 
action of CPT, and no SSB repair this would increase the number repair of DSBs and 
would explain the dramatic increase in the amount of HR, as indicated by the increased 
number of cells containing> 10 RADSl foci. 
5.3 The role of the XRCCl BRCT motifs in CPT -induced damage 
The XRCC I protein has been implicated to be involved in a DNA ligase III dependent 
and independent SSB repair (Taylor, 2002). The DNA ligase III dependent SSB repair 
appears to be active throughout the cell cycle and involves the BRCT 11 motif of the 
XRCC1 protein, whilst DNA ligase III independent XRCC1 repair appears to be active 
at replication forks and involves the BRCT I motif of the XRCC 1 protein. Here, we 
wanted to test which repair pathway was implicated in the repair of CPT -induced DNA 
damage. To do this we used XRCCl mutant cell lines that had one or both of the BRCT 
motifs removed. 
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Expression of a mutated BRCT I motif increases sensitivity to camptothecin in 
XR Id r. tive C 11 . When the XRCC 1 defective cell line was complemented with an empty 
ctor it had no effect on the sensitivity of the cell line to CPT. However, when the 
same elllin was c mplem nted with the full XRCCl protein, sensitivity was reverted 
back to th am I el a the wi ldtype cell line. Therefore it seems like complementing 
the XR Id re tiv ell line with full XRCC l reverses the increased sensitivity seen in 
the d ficient ell lin . Both of the XRCC 1 defective cell lines complemented with short 
XR I had the am le el of sensitivity to CPT as the deficient cell line. Therefore it 
seems that it i the lack fDNA ligase III at the site of the SSB that slows SSB repair. 
hort XR Cl till carrie DNA polymerase ~ to the site of the SSB, so it is not likely 
that thi pr t in i the rate limiting step. The XRCCI defective cell line complemented with 
XHa3 r H~3 sh w d highest sensitivity to CPT. 
It is lik ly that the di ruption of the BRCT I domain in XRCCI has some effect on 
P ARP- l 81th ugh th nature of this effect is unknown. It could be that the BRCT I 
motif bind P RP-I normal but then PARP-l cannot break away from XRCCI , 
inhibiting it a ti iti . In this cenario PARP-I would be unable to bind to further 
Bs and attra t 
were inhibit d. 
repair proteins to the site of the damage. It would be as if PARP-l 
p ntan u and P -induc d RAD51 foci formation is increased in both XH-a3 and 
XH~ lllin mpar d t XRC 1 defective cells. This could be because PARP-l is 
inhibit db th di rupted BR T I motif, causing SSB repair to be slower. This in turn, 
w uld 1 ad t m re in th cell which could encounter the replication machinery 
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to become DSBs. Therefore, there would be more DSBs in the cell to be repaired. HR 
appears to be the major repair pathway for these single-ended DSBs, so we see an 
increase in cells containing RAD51 foci, indicating a rise in HR repair. 
XRCC 1 defective cells, complemented with XRCC 1 that is missing the BRCT I motif, have 
increased sensitivity to camptothecin when co-treated with 1,5-dihydroisoquinoline, but 
not when co-treated with NUI025. This could be because of the different potencies of 
these two inhibitors. 
5.4 The role ofPARP-l in CPT-induced HR 
The Chinese hamster cell line, SPD8, was transfected with the SCneo vector (S8SN.lI), 
in order to measure the amount of HR taking place within the cell. S8SN.II cells show 
increased homologous recombination when treated with camptothecin. This indicates 
that CPT is a strong inducer of HR, probably through its stabilisation of Top I-induced 
SSBs, which then can become DSBs. This can then trigger HR repair. 
SPD8 contains a partial duplication of the hprt gene, which creates a non-functional 
HPRT protein. A functional HPRT gene can be reverted to via HR, and this can also be 
used to measure the amount of HR occurring in the cell. SPD8 undergoes a large 
amount of HR after treatment with CPT, but has decreased homologous recombination 
when co-treated with camptothecin and PARP-I inhibitor, ISQ. This contradicts the 
RAD5I foci data, which indicated that the amount of HR was increased in cells after 
treatment with CPT, and when co-treated with CPT and ISQ. 
186 
Institute for Cancer Studies 
University of Sheffield 
-_ .. __ .--_. __ .. __ ._._ .. _ .. _. __ ._--_._----_._-_ .. _----_._-
One possible explanation could be that the RAD51 foci do form, but that HR does not 
get past this stage. An alternative explanation could be the HR events studied in SPD8 
cells require a recombination tract longer than 5 kb and that the CPT -induced 
recombination in PARP-l inhibited cells trigger short tract recombination. Previously, it 
was found that overexpression ofRAD51 results in an increase in RA51 foci, but a 
decrease in thymidine, etoposide or hydroxyurea-induced recombination (Lundin, 2003 
JMB) which was explained by that recombination induced at replication forks is likely 
to involve short recombination tracts and will not be detected in the HR assay in the 
SPD8 cells. This could indicate that another recombination event is triggered in 
presence of an inhibitor ofPARP. 
An alternative explanation could be that ISQ treatment may arrest cells in the G2 phase 
of the cell cycle (Schultz, Bryant and Helleday, personal communication), which would 
result in fewer cells reaching the S phase of the cell cycle; the phase HR normally 
occurs (Saleh Gohari et al., 2004). 
5.5 The role of XRCCl in CPT -induced HR 
The XRCCl defective EM9 cell line was transfected with the SCneo vector, and several 
clones were made (EM9SN.2, EM9SN.7, EM9SN.ll, EM9SN.l2 and EM9SN.13), in 
order to measure the amount of HR taking place within the cell. The transfected cell 
lines were treated with Sce-I endonuclease to test if they were capable of undergoing 
HR. They all show HR when DSBs are induced using Sce-I endonuclease. This 
endonuclease creates a double-ended DSB in the DNA Therefore, on encountering a 
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double-ended DSB in the DNA, XRCCl defective cells are capable of repairing them 
via HR. 
XRCCl defective cells are hypersensitive to treatment with CPT or MNNG. This is 
probably because both of these compounds create SSBs in the DNA, and SSB repair 
appears to be slow in these cells. However, XRCC 1 defective cells do not undergo HR 
when treated with CPT. These results on HR contrast the results on RAD51 foci 
formation. This could be explained either by RAD51 foci form but cannot complete HR 
or the HR event occurring following CPT treatment in EM9 cells involves very short 
recombination tracts not detectable in the HR assay. 
XRCC 1 defective cells do not undergo spontaneous homologous recombination. This 
indicates that it is not just the response to CPT that cannot be repaired by HR in these 
cells, but also any spontaneous SSBs arising in the cell. CPT -induced and spontaneous 
SSBs cause a similar lesion in the DNA; that is during replication, the SSB causes the 
replication fork to collapse. This is mainly repaired through sister chromatid exchange 
(SCE) (Saleh-Gohari et al. , 2005). Different DSBs are repaired through different kinds 
of HR, short tract gene conversion (STGE), long tract gene conversion (L TGC) or SCE. 
Double-ended DSBs, the type caused by Sce-I, is mostly repaired through STGC. In 
order for spontaneous and CPT -induced SSBs to collapse replication forks, the SSB 
must collide with DNA polymerase during replication. Since this takes place during the 
S-phase of the cell-cycle, it may be that these cells are arrested in S-phase and cannot 
undergo HR, because they cannot move through this phase ofthe cell cycle. Again, it is 
highly interesting to find lower HR events in XRCCl defective cells. This is in line with 
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decreased CPT -induced HR in P ARP defective cells and could be explained by the 
inability of the recombination reporter to pick up the recombination events occurring in 
the cells, as discussed earlier. However, it is also possible that both P ARP-l and 
XRCC 1 plays a separate unique role in homologous recombination, maybe in a more 
downstream event following RAD51 foci formation. It is possible that the short-patch 
BER pathway is involved in recombination. Further support for such suggestion is that 
DNA polymerase ~ overexpressing cells show a general increase in homologous 
recombination levels and RAD51 foci formation (Cazaux, 2004). 
5.6 Future perspectives 
In the future, I would like to know if the disrupted BRCT I domain ofXH-a3 and XH-
~3 binds PARP-I, and if the level ofPARP-l activity changes in these cell lines. I 
would like to see the spontaneous levels ofPARP-l activity in both cell lines, and the 
activity after CPT treatment. I would also like to see if PARP-l is capable of 
automodification, or the modification of other proteins via poly(ADP-ribosyl)ation. 
Both XH-a3 and XH-~3 cells are sensitive to CPT, which collapses replication forks. It 
. would also be interesting to find out ifXH-a3 and XH-~3 are sensitive to agents that 
stall replication forks, such as thymidine, or agents that inhibit replication fork 
progression, such as hydroxyurea. In cell lines lacking PARP-l, or where PARP-l was 
inhibited, we have seen increased sensitivity to CPT, and an increase in DSBs. 
Therefore another future plan would be to find out if there is an increased amount of 
DSBs in the XH-a3 and XH-~3 cell lines. Also, it would be interesting to see if they 
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have also got an increased amount ofRAD51 foci, or if like the XRCCl defective cells, 
they do not seem to undergo HR. 
5.7 Clinical applications 
CPT is a very toxic chemotherapy drug, whose use was discontinued in the 1970s due to 
the severity of the side effects. Since then several less toxic analogues, such as 
irinotecan and topotecan, have been created and are in clinical use today. However, 
these drugs still have some strong side effects in some patients. For example, irinotecan 
can cause nausea, vomiting and diarrhoea, and in some cases has also caused colonic 
ulceration with gastro-intestinal bleeding. Also irinotecan commonly causes neutropenia 
(abnormally low number ofneutrophils), leukopenia (abnormally low number of white 
blood cells), anaemia, asthenia (feeling of weakness), fever, abdominal pain and 
alopecia. Side effects to topotecan seem less severe, but still include nausea, loss of 
appetite, alopecia, asthenia and diarrhoea. P ARP-l inhibitors potentiate the cytotoxicity 
of several CPT -derivatives, including irinotecan and topotecan. This means that when 
PARP-l inhibitors are applied clinically in conjunction with these drugs, the dose of the 
CPT-derived drugs may be lower, and will reduce the side-effects. Also, in 
understanding better, how the P ARP-inhibitors are working in the cell, it may be 
possible to develop drugs against new targets within the cell that potentiate these drugs 
even further and improve their ability to kill cancer cells. 
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APPENDI 1: Addres e of companies 
3M 
3M United Kingdom PL ,3M Centre, Cain Road, Bracknell, RG 12 8HT, UK 
T I: 08705 360036 Web: www.3m.com 
Adam Healthcarc 
Lotherton Wa arforth Leed , West Yorkshir , Unit d Kingdom, LS25 2N, UK 
T I: (0113)2320066 Fax: (0113)2871317 Web: www.adams-healthcare.co.uk 
Amer ham Bio cience 
Amersham Bio ciences UK Limited Amersham Place, Little Chalfont, 
Buckinghamshir HP7 9N 
Tel: 0870606 1921 Fax: 01494544350 Web: www.amershambiosciences.com 
Amity U.K. Limited 
Amity UK Ltd Friendship House, Dodworth Business Park 
Barnsley South Yorkshire S753SP 
Tel: (01226) 770787 Fax: (01226) 770757 Email: sales@amityintemational.com 
Web: wwwamityintemational.com 
Apple 
Apple (UK), 2 Furzeground Way, Stockley Park East, Uxbridge Middlesex, UB11 
1BB, UK 
Tel: 0800039 1010 Web: www.apple.comJuk 
Azlon 
RealLabware, Unit 33, Moor Park Industrial Centre, Tolpits Lane, Watford Herts, WDl 
8SP, UK 
Tel: (019230249492 Fax: (01923) 249751 Email: info@reallabware.com 
Web: reallabware.com 
BDH 
Merck House, PooIe, Dorset, BH15 1 TD, England 
Tel: +44 1202660444 Fax: +44 1202 666856 Email: pat.simrnons@uk.vwr.com. 
Web: www.bdh.com 
BDUKLtd 
Medical Pharmaceutical Systems, 21 Between Towns Road, Cowley, Oxford OX4 3L Y, 
UK 
Tel: (01865) 781555 Fax: (01865) 781596 Email: bdpharma@eurpe.bd.com 
Web: www.bdphanna.com 
Becton Dickenson Immunocytometry Systems 
2350 Qume Drive, San Jose, CA 95131, USA 
Tel: 408-223-8226 
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Bibby Sterilin 
Bibby Sterilin Ltd. Tilling Drive Stone, Staffordshire, United Kingdom. ST15 OSA, UK 
Tel: (01785) 812121 Fax: (01785) 815066 bsl@bibby-sterilin.com 
Web: www.bibby-sterilin.co.uk 
BioRad 
Bio-Rad Laboratories Ltd, Bio-Rad House, Maylands Avenue, Hemel Hempstead, 
Hertfordshire HP2 7TD, United Kingdom 
Tel: 020 8328 2000 Fax: 020 8328 2550 E-mail: uk.lsg.marketing@bio-rad.com 
Web: www.bio-rad.com 
BOC gases 
The Priestly Centre, 10 Priestly Road, Surrey Research Park, Guildford, Surry, GU2 
7XY, UK 
Tel: (01483) 579857 Web: www.boc.com 
Bodyguards 
Medisavers, Harrier Park, Southgate Way, Orton Southgate, Peterborough, Cambs, PE2 
6YQ, UK 
Tel: (01733) 361414 Fax: (01733) 361121 Email: sales@medisavers.co.uk 
Web: www.medisavers.co.uk 
Cambrex 
Cambrex Bio Science Wokingham, Ltd., 1 Ashville Way, Wokingham, Berkshire, 
RG41 2PL, England 
Tel: 0118 979 5234 Fax: 01189795231 Email: sales.uk@cambrex.com 
Web: www.cambrex.com 
Catenvrap 
Chefs Trolley Ltd, Hillcroft Business Park, Whisby Road, Lincoln LN6 3QT 
Tel: (01522) 888188 Fax: (01522) 888190 Email: enquiries@chefs-trolley.co.uk 
Web: www.chefs-trolley.co.uk 
Chemlab 
Chemlab Scientific Products Ltd, Construction House, Grenfall Avenue, Hornchurch, 
Essex, RM12 4EH, United Kingdom 
Tel: (01708) 476162 
Continental Lab Products 
CLP, 4 Carousel Way, Riverside Business Park East, Northampton NN3 9VV, UK 
Tel : (01604) 417900 Fax: (01604) 417909 Email: mail@c1pdirect.com 
Web: www.clpdirect.com 
ConTaFree Liquids 
Quest Biomedical, The Exchange, 24 Haslucks Green Road, Shirley, Solihull, West 
Midlands, UK 
B902EL 
Tel: 0044 (0)121 7447674 Fax: 0044 (0)121 7440775 Email: 
sales@questbiomedical.com Web: www.questbiomedical.com 
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Corning Incorporated 
Coming Limited , The Guildway, Old Portsmouth Road, Artington, Surrey GU3 1 LR 
TeI: (01483) 526520 Fax: (01483) 526798 
Web: www.coming.com 
Denver Instruments 
Denver House, Sovereign Way, Trafalgar Business Park, Downham Market, Norfolk. 
PE389SW 
Tel: 0044 1366386242 Fax: 0044 1366386204 
Email: sales@denverinstrurnent.co.uk 
Drummond Scientific 
Alpha Laboratories Ltd. 
TeI: 44 23 80483000 Email: alpha@alphalabs.co.uk 
Web: www.alphalabs.co.uk 
ENMCompany 
5 617 Northwest Highway Chicago, IL 60646-6135 
Tel: 773 775-8400 Fax: 773 775-5968 Email: support@enmco.com 
Web: www.enmco.com 
Eppendorf 
EppendorfUK Limited Endurance House Chivers Way Histon Cambridge 
CB49ZR 
Tel: (01223) 200 440 Fax (01223) 200 441 
Web: www.eppendorf.com.uk 
Equihio Limited 
The Wheelwrights The Green Boughton Maidstone Kent, ME174LT 
Web site: http://www.eguibio.com 
Fisher Scientific . 
Fisher Scientific UK Ltd Bishop Meadow Road, Loughborough, 
Leicestershire LE 11 5RG 
Tel: 01509231166 Fax: 01509231893 
Web: www.fisher.co.uk 
FMC BioProducts Europe 
Risingevej 1, DK-2665, Vallensbaek Strand, Denmark 
Tel: 42 73 11 22 Fax: 42 73 56 92 
Web: www.bioproducts.com/ 
Fujifilm 
PO Box 015, Leamington Spa, Warwickshire, CV 31 YA, England 
Tel: 01926335537 Fax: 01926 887793 
Web: www.fujifilm-europe.com/ 
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Gilson 
3000 W. Beltline Hwy., PO Box 620027, Middleton, WI 53562 
Tel : 608 836 1551 , 800445 7661 Fax: 608 831 4451 
Web: www.gilson.com 
Grant 
Barrington, Cambridge, CB2 5QZ, England 
TeI: 01763 260811 Fax: 0176326241 EmaiI: Marketing@grantinst.co.uk 
Web: www.grant.co.uk 
Greiner Bio-One 
Greiner Bio-One, Inc, 1205 Sarah St, Longwood, FL 32750, USA 
TeI: 407.333.2800 Fax: 407.333.3001 EmaiI: INFO@greinerbiooneinc.com 
Web: www.greinerbioone.com 
Harvard Instruments 
22 Pleasant St. , South Natick, MA 01760 
TeI; 508 655 7000, 800 272 2775 Fax: 508 655 6029 
Iiyama 
First Floor, Unit 9 Meadway Court Meadway Technology Park Rutherford Close 
Stevenage Herts SG 1 2EF 
TeI: (01438) 745482 Fax: (01438) 745483 
Web: www.iiyama.co.uk/ 
IKA 
Janke & Kunkel-Str. 10 D-79219 Staufen Germany / Deutschland 
TeI: +49-7633-831-0 Fax: +49-7633-831-98 Email: sales@ika.de 
Web: www.ika.netlika/home.htmI 
Invitrogen 
1600 Faraday Avenue, Carlsbad, CA 92008 
Tel: 800-955-6288 Fax: 750-603-7201 Email: tech_service@invitrogen.com 
Web: www.invitrogen.com 
Jobnson & Jobnson Medical Limited 
Coronation Road, Ascot, Berks. SL5 9EY, England 
Tel: 01344 871 000 Fax: 01344 872 599 
Kimberley Clark 
1 Tower View Kings Hill West Mailing, Kent ME 19 4HA England, U.K. 
TeI: (0800) 626008 Fax: (01732)594910 
E-mail: consumeruk@kcc.com Web: www.kimberly-clark.com 
Labcold 
Unit F The Loddon Centre Wade Road Basinstoke Hampshire RG248FL 
Tel : (0870) 300 1010 Fax: (0870) 300 1004 Email:website@Iabcold.com 
Web: www. labcold.co.uk 
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Lotus Professional 
Sovereign Publications Limited Meridien House 42 Upper Berkeley Street 
London WIH 5QJ 
Tel: +44 (0)20 7616 0800 Fax: +44 (0)20 7724 1444 
Email: webmaster@sovereign-publications.com 
Web: www.sovereign-publications.com 
LTE Scientific Ltd. 
Address: Greenbridge Lane, Greenfield, Oldham, OL3 7EN, England 
Tel: 01457 876221 Fax: 01457870131 Email: mktg@lte.u.net.com 
Maple 
2414 Major Mackenzie Dr. W. P.O. Box 645 Maple, Ontario L6A 1 W5 
Tel: 416.410-3128 E-mail: sales@maplecomputers.com 
Web: www.mapiecomputers.com 
Marvel 
Nestle UK 
Tel: 00800 63785385 
Web: www.nestle.co.uk 
MD Biosciences 
Tel: 08000197200 Email: info@mdbiosciences.com 
Web: www.mdbiosciences.com 
Mettler 
Mettler-Toledo Ltd., 64 Boston Road, Beaumont Leys Leicester, LE4 1 A W 
Tel: (0116) 2357070 Email: enguire.mtuk@mt.com 
Web: www.mt.comfmthomepage 
MSE 
97 Avenue Road Beckenham Kent BR3 4RX United Kingdom 
Tel: +44 (0)2084024426 Fax: +44 (0)20 8778 7571 Email: info@mseuk.co.uk 
Web: www.mseuk.co.uk 
New Brunswick Scientific (UK) Ltd. 
Edison House, 163 Dixons Hill Road, North Mimms, Hatfield AL9 7JE, England 
Tel: 01707 75733 Fax: 0170767859 
Web: www.nbsc.com 
New England Biolabs 
Knowl Piece, Wilbury Way, Hitchin, Herts SG4 OTY, England 
Tel: (01462) 420 616, 0800 318486 Fax: (01462) 421 057,0800435682 
Email: info@uk.neb.com Web: www.uk.neb.com 
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Nikon UK Ltd. 
Nikon House, 380 Richmond Road, Kingston upon Thames, Surrey KTI 5PR, England 
Tel: 0181 541 4440 Fax: 01815414584 
Web: www.nikon.co.uk 
Nunc 
Nalge Nunc Intemational2000 N. Aurora Rd., Naperville, IL 60563-1796 
Tel : 6309835700,8002886862,8004166862 Fax: 6304162556,6304162519 
Web: www.nalgenunc.com 
Olympus 
8 Honduras Street, London, EC 1 Y OTX, England 
Tel: 0171 2504069 Fax: 0171 2504677 Email: SimonShelley@compuserve.com 
Web: www.olympus.europa.com 
Panasonic 
Panasonic House Willoughby Road Bracknell Berkshire RG 12 8FP 
United Kingdom 
Web: www.panasonic.co.uk 
Pechioey Plastic Packaging 
Email: contactpharmaeurope@alcan.com 
Web: www.pechineyplasticpackagingcom 
Perbio 
Medical Supply Co. Ltd Damastown Mulhuddart Dublin 15 Ireland 
Tel: +35318224222 Fax: +35318224100 Email: info@medicalsupply.ie 
Web: www.pewrbio.com 
Perkin Elmer 
549 Albany Street Boston, MA 02118, USA 
Tel: 617-482-9595 Email: ProductInfo@perkinelmer.com 
Web: www.perkinelmer.com 
Pierce 
Perbio Science UK Ltd. Century House, High Street, Tattenhall, Cheshire CH3 9RJ, 
United Kingdom 
Tel: (01829) 771 744 Fax: (01829) 771 644 Email: uk.info@perbio.com 
Web: www.piercenet.com 
Plastibrand 
BiocomDirect,6 Lomond Crescent, Bridge of Weir, PAll 3HJ, United Kingdom 
Tel: +44 1505615973 Fax: +44 1505615976 Email: info@biocomdirect.com 
Qiagen 
Qiagen House Fleming Way Crawley West Sussex RHI0 9NQ 
Tel: 01293-422-922 Email: customercare-uk@giagen.com 
Web: wwwl.quigen.com 
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Rodwell Scientific Instruments 
Rodwell Scientific Instruments Bentalls Pipps Hill Industrial Estate Basildon Essex 
SS14 3SD England 
Tel: +44 (0)1268 286646 Fax: +44 (0)1268 287799 
Email: sales@rodwelI-autoclave.com Web: www.rodwell-autoclave.com 
Sanyo Gallenkamp PLC 
Park House, Meridian East, Meridian Business Park, Leicester LE3 2UZ, England 
Tel: 01162630530 Fax: 01162630353 Emai1: 100633.127@compuserv.com 
Sarstedt 
68 Boston Road Beaumont Leys Leicester LE4 lAW United Kingdom 
Tel.: +44 1162359023 Fax: +44 1162366099 E-mail: info@sarstedt.com 
Web: www.sarstedt.com 
Scbott Duran 
Schott Corp. 3 Odell Plaza, Y onkers, NY 10701 
Tel: 914968 8900, 8006334505 Fax: 914968 8585 
Scientific Industries 
Jencons-PLS Unit 6, Forest Row Business Park Station Road Forest Row 
East Sussex RH18 5DW UK 
Tel: (01342) 826836 Fax: (01342) 826771 Email: uksales@iencons.co.uk 
Web: http://www.scientificindustries.com 
Scientific Laboratory Supplies 
Wilford Industrial Estate Ruddington Lane Wilford Nottingham NG 11 7EP 
Tel: +44 (0)115 982 1111 Fax: +44 (0)1159825275 
Web: http://www.scientific-Iabs.net 
Scotsman 
Frimont S.p.a. - Via Puccini, 22 20010 Bettolino di Pogliano - Milan - Italy 
Tel: +39-02-939601 Fax: +39-02-93550500 Emai1: scotsman.europe@frimontit 
Web: http://www.scotsman-ice.com 
Seiko Instruments Inc 
Micro Printer Division 2990 West Lomita Blvd. Torrance CA 90505 
Tel: (800) 553-6570 Fax: (310) 517-8154 E-mail: siumpd.id@salessupport.com 
Web: www.seikoinstruments.com 
Sigma 
Sigma-Aldrich Company Ltd., The Old Brickyard, New Road, Gillingham, 
Dorset, SP8 4XT 
Tel: 0800717181 Fax: 0800378785 E-mail: ukorders@eurnotes.sial.com 
Web: www.sigma-aldrich.com 
Sony 
Email: sales.gb@sonystyle-europe.com 
Web: www.sony.co.uk 
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Starlab 
4 Tanners Drive Blakelands Milton Keynes MK14 5NA Great Britain 
Tel: (01908) 283800 Fax: (01908) 283802 E-mail: info@starlab.co.uk 
Web: www.starlab.de/ukJcorp 
Stuart Scientific 
Beacon Road Stone Staffordshire ST15 OSA UK 
Tel: +44 (0) 1785 - 812121 Fax: +44 (0) 1785 - 813748 
E-mail: bsl@barloworld-scientific.com Web: www.barloworld-scientific.com 
Swann-Morton 
Owlerton Green Sheffield S6 2BJ 
Tel: +44 (0)114 234 4231 Fax: +44 (0)114231 4966 Email: info@swann-morton.com 
Web: www.swannmorton.com 
Techne 
Barloworld Scientific Ltd Beacon Road Stone Staffordshire ST15 OSA UK 
Tel: +44 (0)1785812121 Fax: +44 (0)1785813748 
Web: www.techne.com 
Terinex 
Terinex Limited Harnmond Road Elms Estate Bedford MK41 OND England 
Tel: +44 (0) 1234364411 Fax: +44 (0) 1234271486 Email: info@terinex.co.uk 
Web: http://www.terinex.co.uk 
Walker Safety Cabinets Limited 
Unit 1, Howard Town Mills Mill Street Glossop Derbyshire SK13 8PT 
Tel: (001457) 864936 Fax: (01457) 857377 Email: sales@walkersafetycabinets.co.uk 
Web: www.walkersafetycabinets.co.uk 
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